Delaware
|
001-37955
|
62-1493316
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
1A Burton Hills Boulevard
|
|
|
Nashville, Tennessee
|
|
37215
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Yes [X]
|
No [ ]
|
Yes [ ]
|
No [X]
|
Yes [X]
|
No [ ]
|
Yes [X]
|
No [ ]
|
Large accelerated filer [X]
|
Accelerated filer [ ]
|
Non-accelerated filer [ ]
|
Smaller reporting company [ ]
|
(Do not check if a smaller reporting company)
|
Emerging growth company [ ]
|
Yes [ ]
|
No [X]
|
i
|
1
|
Item 1. Business - (continued)
|
2
|
Item 1. Business - (continued)
|
|
Revenue Mix
|
||||
|
2017
|
|
2016
|
||
Emergency department and hospitalist services
|
54
|
%
|
|
55
|
%
|
Anesthesiology services
|
28
|
|
|
27
|
|
Radiology services
|
8
|
|
|
5
|
|
Children's services
|
2
|
|
|
2
|
|
Office based, surgery and other
|
8
|
|
|
11
|
|
Total
|
100
|
%
|
|
100
|
%
|
3
|
Item 1. Business - (continued)
|
4
|
Item 1. Business - (continued)
|
5
|
Item 1. Business - (continued)
|
•
|
expand our national physician services capabilities through management expertise, enhancements in our internal physician recruiting, credentialing and onboarding organizations, further development of our provider quality metrics capabilities and investment in reimbursement technologies;
|
•
|
provide our health system clients with a compelling and diverse suite of clinical solutions to deliver on our customers' mandate for increased clinical quality, patient satisfaction and coordination of care;
|
•
|
work with our clients to develop increased efficiencies through the application of best practice information regarding physician staffing and procedural turnaround;
|
•
|
further advance our relationships with national managed care companies to facilitate favorable contract terms and more efficient revenue cycle management;
|
•
|
collaborate with hospitals, ASCs and other healthcare facilities to improve their operations by leveraging the clinical leadership of our physicians at clients’ facilities; and
|
•
|
recruit and retain high quality physicians and healthcare professionals by providing clinical resources, comprehensive administrative practice support, competitive compensation and career opportunities.
|
6
|
Item 1. Business - (continued)
|
•
|
disputes between payors as to which party is responsible for payment;
|
•
|
the difficulty of adherence to specific compliance requirements, diagnosis coding and various other procedures mandated by the government; and
|
•
|
failure to obtain proper physician credentialing and documentation in order to bill governmental payors.
|
7
|
Item 1. Business - (continued)
|
•
|
we bill patients and third-party payors directly for physician fees,
|
•
|
we bill patients and third-party payors directly for physician fees, with the hospital paying us an additional pre-arranged fee for our services, or
|
•
|
we bill the hospitals directly for the physicians fees.
|
|
Percentage of Net Revenue
|
|
Percentage of Total Volume
|
||||||||||||||
|
Year Ended December 31,
|
|
Year Ended December 31,
|
||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2017
|
|
2016
|
|
2015
|
||||||
Medicare
|
20
|
%
|
|
20
|
%
|
|
13
|
%
|
|
33
|
%
|
|
32
|
%
|
|
36
|
%
|
Medicaid
|
8
|
|
|
8
|
|
|
5
|
|
|
23
|
|
|
25
|
|
|
22
|
|
Commercial and managed care
|
55
|
|
|
54
|
|
|
71
|
|
|
31
|
|
|
30
|
|
|
33
|
|
Self-pay
|
2
|
|
|
1
|
|
|
1
|
|
|
13
|
|
|
13
|
|
|
9
|
|
Net fee for service revenue
|
85
|
%
|
|
83
|
%
|
|
90
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Contract and other revenue
|
15
|
|
|
17
|
|
|
10
|
|
|
|
|
|
|
|
|||
Net revenue for physician services
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
8
|
Item 1. Business - (continued)
|
•
|
gastroenterology - colonoscopy and other endoscopy procedures;
|
•
|
ophthalmology - cataracts and retinal laser surgery; and
|
•
|
orthopaedic -
knee and shoulder arthroscopy and carpal tunnel repair.
|
|
|
Specialty Count
|
|
Net Revenue Mix
|
||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
2017
|
|
2016
|
|
2015
|
||||||
Gastroenterology
|
|
162
|
|
|
155
|
|
|
151
|
|
|
51
|
%
|
|
51
|
%
|
|
52
|
%
|
Multispecialty
|
|
55
|
|
|
57
|
|
|
58
|
|
|
29
|
|
|
30
|
|
|
29
|
|
Ophthalmology
|
|
37
|
|
|
38
|
|
|
39
|
|
|
15
|
|
|
14
|
|
|
14
|
|
Orthopaedic
|
|
10
|
|
|
10
|
|
|
9
|
|
|
5
|
|
|
5
|
|
|
5
|
|
Total
|
|
264
|
|
|
260
|
|
|
257
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
9
|
Item 1. Business - (continued)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Procedures performed during the period at consolidated centers
|
1,715,595
|
|
|
1,721,399
|
|
|
1,729,262
|
|
|||
Centers in operation, end of period (consolidated)
|
234
|
|
|
238
|
|
|
236
|
|
|||
Centers in operation, end of period (unconsolidated)
|
30
|
|
|
22
|
|
|
21
|
|
|||
Average number of continuing centers in operation (consolidated)
|
237
|
|
|
237
|
|
|
238
|
|
|||
New centers added, during period
|
10
|
|
|
8
|
|
|
11
|
|
|||
Centers merged into existing centers, during period
|
—
|
|
|
1
|
|
|
—
|
|
|||
Centers disposed, during period
|
6
|
|
|
4
|
|
|
—
|
|
|||
Surgical hospitals in operation, end of period (unconsolidated)
|
1
|
|
|
1
|
|
|
1
|
|
|||
Centers under letter of intent, end of period
|
2
|
|
|
3
|
|
|
5
|
|
|||
Average revenue per consolidated center (in thousands)
|
$
|
5,392
|
|
|
$
|
5,352
|
|
|
$
|
5,168
|
|
Same center revenues increase, day adjusted (consolidated)
|
1.8
|
%
|
|
4.3
|
%
|
|
6.0
|
%
|
•
|
attract and retain physicians that are leaders in their specialty and community;
|
•
|
increase same-center revenues and profitability at our existing surgery centers;
|
•
|
expand our national network of ASCs by selectively acquiring both single-specialty ASCs and multispecialty ASCs, and developing new ASCs in partnership with physicians and health systems; and
|
•
|
pursue the acquisition of companies that own and operate multiple ASCs.
|
10
|
Item 1. Business - (continued)
|
•
|
the physicians affiliated with the ASCs recruiting new physicians to their practices;
|
•
|
identifying additional physicians to join the partnerships that own the ASCs; and
|
•
|
recruiting non-partner physicians in the same or other specialties to use the ASCs.
|
•
|
physician scheduling enhancements;
|
•
|
improved patient flow; and
|
•
|
improved operating room turnover.
|
•
|
Diversified physician group:
ASCs that have eight to ten (or more) physicians. In order to manage succession planning, we look to acquire ASCs where physicians vary in age in order to limit the risk of several physicians exiting the practice in a short period of time.
|
•
|
Market leader:
ASCs that are market leaders for the procedures performed in that facility.
|
•
|
Contracts with payors:
ASCs that contract with all or most of the major commercial payors in their market.
|
•
|
History of growth:
ASCs with a track record of consistent case and revenue growth.
|
11
|
Item 1. Business - (continued)
|
12
|
Item 1. Business - (continued)
|
13
|
Item 1. Business - (continued)
|
14
|
Item 1. Business - (continued)
|
•
|
federal and state governments, primarily under the Medicare and Medicaid programs;
|
•
|
HMOs and private insurers;
|
•
|
individual patients;
|
•
|
fees for stand-by and event driven coverage, including from its national contract with FEMA; and
|
•
|
community subsidies.
|
•
|
the ability to improve customer service, such as on-time performance and efficient call intake;
|
•
|
the ability to provide comprehensive clinical care;
|
•
|
the ability to recruit, train and motivate employees, particularly ambulance crews who have direct contact with patients and healthcare personnel; and
|
•
|
pricing, billing and reimbursement expertise.
|
15
|
Item 1. Business - (continued)
|
16
|
Item 1. Business - (continued)
|
•
|
the limited partnerships and limited liability companies exist to effect legitimate business purposes, including the provision of high quality, cost-effective and efficient services to the patients served;
|
17
|
Item 1. Business - (continued)
|
•
|
the limited partnerships and limited liability companies function as an extension of the practices of physicians who are affiliated with the surgery centers and the surgical procedures are performed personally by these physicians without referring the patients outside of their practice;
|
•
|
our physician partners have a substantial investment at risk in the limited partnerships and limited liability companies;
|
•
|
terms of the investment do not take into account the volume of the physician partners’ past or anticipated future services provided to patients of the surgery centers;
|
•
|
the physician partners are not required or encouraged as a condition of the investment to treat Medicare or Medicaid patients at the surgery centers or to influence others to refer such patients to the surgery centers for treatment;
|
•
|
the limited partnerships, the limited liability companies, our subsidiaries and our affiliates do not loan any funds to or guarantee any debt on behalf of the physician partners with respect to their investment; and
|
•
|
distributions by the limited partnerships and limited liability companies are allocated uniformly in proportion to ownership interests.
|
18
|
Item 1. Business - (continued)
|
19
|
Item 1. Business - (continued)
|
20
|
Item 1. Business - (continued)
|
21
|
Item 1. Business - (continued)
|
•
|
non-clinical operation management;
|
•
|
physician and allied care recruiting;
|
•
|
revenue cycle management;
|
•
|
compliance, education and oversight;
|
•
|
managed care contracting with third-party payors;
|
•
|
information technology;
|
•
|
human resources;
|
•
|
risk management;
|
•
|
quality improvement; and
|
•
|
credentialing.
|
•
|
Billing services -
Billing systems that perform facilities-based revenue cycle management for each of the specialties in which we provide physician services, as well as for many of our ASCs.
|
•
|
Enterprise management -
Enterprise-wide reporting systems that are used for all essential accounting and finance functions, which include both integrated human resource and payroll functions.
|
•
|
Recruitment and business development -
A third-party database used by our business development departments and our physician recruitment subsidiary. This application is primarily used to develop a database of medical professionals that can be targeted in the recruitment process and also to manage other aspects of the recruitment and hiring process.
|
•
|
Web-based applications -
Our web-based comprehensive neonatal clinical electronic health record system, which is used in each of the facilities where we provide NICU and newborn nursery services to gather all pertinent clinical data from our patients to determine outcomes. Our web-based portal providing physician partners with access to financial information, financial and quality benchmarking reports along with best practices from the ambulatory services segment community of surgery centers and peer, physician-to-physician, insights on latest technologies and therapies.
|
22
|
Item 1. Business - (continued)
|
•
|
providing guidance, education and proper controls based on the regulatory risks associated with our business model and strategic plan,
|
•
|
conducting internal audits and reviews to identify any improper practices that may be occurring,
|
•
|
resolving regulatory matters, and
|
•
|
enhancing the ethical culture and leadership of the organization.
|
•
|
formal policies and written procedures,
|
•
|
designation of a Compliance Officer,
|
•
|
education and training programs,
|
•
|
internal monitoring and reviews,
|
•
|
responding appropriately to detected misconduct,
|
•
|
open lines of communication, and
|
•
|
discipline and accountability.
|
23
|
Item 1. Business - (continued)
|
24
|
Item 1. Business - (continued)
|
25
|
Name
|
|
Age
|
|
Experience
|
|
|
|
|
|
|
|
|
|
|
Christopher A. Holden
|
|
53
|
|
President and Chief Executive Officer and Director of the Company. Prior to the Merger, Mr. Holden served from October 2007 through November 2016 as President and Chief Executive Officer and a director of AmSurg. Prior to October 2007, Mr. Holden served for over ten years in various capacities, including Division President, with Columbia/HCA Healthcare Corporation, now known as HCA, and Triad Hospitals, Inc.
|
|
|
|
|
|
Karey L. Witty
|
|
53
|
|
Executive Vice President & Chief Operating Officer since October 2017. Previously, Mr. Witty served as Chief Executive Officer of Corizon Health, Inc., a leading provider of correctional healthcare services in the United States, from October 2015 through September 2017. Mr. Witty served as Chief Financial Officer of naviHealth from January 2014 until October 2015, and as Chief Financial Officer of HealthSpring from 2009 until 2012.
|
|
|
|
|
|
Randel G. Owen
|
|
58
|
|
Executive Vice President and President - Ambulatory Services Group. Prior to the Merger, Mr. Owen served as Chief Financial Officer and Executive Vice President of EHH from May 2011 through November 2016 and as Chief Operating Officer of EHH from September 2012 through November 2016. Prior to May 2011, Mr. Owen served for over ten years as Executive Vice President and Chief Financial Officer of predecessor and affiliated entities of EHH.
|
|
|
|
|
|
Kevin D. Eastridge
|
|
52
|
|
Executive Vice President and Chief Financial Officer since October 2017 and Senior Vice President and Chief Accounting Officer from December 2016 until October 2, 2017. Prior to the Merger, Mr. Eastridge served as Senior Vice President of Finance of AmSurg from July 2008 through November 2016 and as Chief Accounting Officer from July 2004 through November 2016. Mr. Eastridge served in various capacities with AmSurg from March 1997 through July 2004, including Vice President of Finance and Controller.
|
|
|
|
|
|
Patrick B. Solomon
|
|
48
|
|
Senior Vice President and Chief Strategy Officer. Prior to the Merger, Mr. Solomon served as Senior Vice President and Chief Strategy Officer of AmSurg from 2015 through November 2016. Mr. Solomon joined Sheridan, which AmSurg acquired in July 2014, in 2003, and served as Executive Vice President and Chief Development Officer of Sheridan from 2012 to 2015 and as Executive Vice President of Operations from 2003 to 2012.
|
|
|
|
|
|
Craig A. Wilson
|
|
49
|
|
Senior Vice President, General Counsel and Secretary. Prior to the Merger, Mr. Wilson served as Senior Vice President, General Counsel and Secretary of EHH from May 2011 through November 2016. Mr. Wilson has served in various capacities with EHH and its predecessors and affiliates since March 2000.
|
|
|
|
|
|
Kenneth E. Zongor
|
|
42
|
|
Senior Vice President and Chief Accounting Officer since October 2017. Mr. Zongor has served as Chief Accounting Officer since October 2017. Previously, Mr. Zongor served as Senior Vice President of Financial Reporting, a post he held from July 2017 to October 2017. Prior to that, Mr. Zongor served as Vice President of Financial Reporting of AmSurg from September 2010 until December 2016 and in the same position with the Company from December 2016 until July 2017.
|
26
|
Item 1A. Risk Factors
|
27
|
Item 1A. Risk Factors - (continued)
|
28
|
Item 1A. Risk Factors - (continued)
|
29
|
Item 1A. Risk Factors - (continued)
|
30
|
Item 1A. Risk Factors - (continued)
|
31
|
Item 1A. Risk Factors - (continued)
|
32
|
Item 1A. Risk Factors - (continued)
|
33
|
Item 1A. Risk Factors - (continued)
|
34
|
Item 1A. Risk Factors - (continued)
|
•
|
disputes between payors as to which party is responsible for payment;
|
•
|
failure of information systems and processes to submit and collect claims in a timely manner;
|
•
|
variation in coverage for similar services among various payors;
|
•
|
our reliance on third-parties to provide billing services for certain of our service lines;
|
•
|
the difficulty of adherence to specific compliance requirements, diagnosis coding and other procedures mandated by various payors; and
|
•
|
in connection with billing for physician services, failure to obtain proper physician credentialing and documentation in order to bill various payors.
|
35
|
Item 1A. Risk Factors - (continued)
|
•
|
make it more difficult for us to make payments on our indebtedness;
|
•
|
increase our vulnerability to general economic and sector conditions, including recessions and periods of significant inflation and financial market volatility;
|
•
|
expose us to the risk of increased interest rates because any borrowings we make under the ABL Facility, and our borrowings under the Term Loan Facility under certain circumstances, will bear interest at variable rates;
|
•
|
require us to use a substantial portion of our cash flow from operations to service our indebtedness, thereby reducing our ability to fund working capital, capital expenditures and other expenses;
|
•
|
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
|
•
|
place us at a competitive disadvantage compared to competitors that have less indebtedness; and
|
•
|
limit our ability to borrow additional funds that may be needed to operate and expand our business.
|
36
|
Item 1A. Risk Factors - (continued)
|
•
|
incur additional indebtedness or issue certain preferred shares;
|
•
|
pay dividends on, redeem or repurchase stock or make other distributions in respect of the Company's capital stock;
|
•
|
make investments;
|
•
|
repurchase, prepay or redeem subordinated indebtedness;
|
•
|
incur additional liens;
|
•
|
transfer or sell assets;
|
•
|
consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;
|
•
|
enter into certain transactions with our affiliates; and
|
•
|
designate any of our subsidiaries as unrestricted subsidiaries.
|
•
|
incur additional indebtedness or issue certain preferred shares;
|
•
|
pay dividends on, redeem or repurchase stock or make other distributions in respect of the Company's capital stock;
|
•
|
make investments;
|
•
|
repurchase, prepay or redeem junior indebtedness;
|
•
|
agree to payment restrictions affecting the ability of our restricted subsidiaries to pay dividends to us or make other intercompany transfers;
|
•
|
incur additional liens;
|
•
|
transfer or sell assets;
|
•
|
consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;
|
•
|
enter into certain transactions with affiliates;
|
•
|
make negative pledges; and
|
•
|
designate any of our subsidiaries as unrestricted subsidiaries.
|
37
|
Item 1A. Risk Factors - (continued)
|
•
|
authorize the issuance of “blank check” preferred stock that could be issued by our Board of Directors to thwart a takeover attempt;
|
•
|
provide for the Company to be governed by Section 203 of the General Corporation Law of the State of Delaware (the “DGCL”), which affords the Company certain antitakeover protections;
|
•
|
currently provide for a classified Board of Directors, which divides our Board of Directors into three classes, with members of each class serving staggered three-year terms, which prevents stockholders from electing an entirely new Board of Directors at an annual meeting;
|
•
|
limit the ability of stockholders to remove directors;
|
•
|
prohibit stockholders from calling special meetings of stockholders;
|
•
|
prohibit stockholder action by written consent, thereby requiring all actions to be taken at a meeting of the stockholders; and
|
•
|
establish advance notice requirements for nominations of candidates for election as directors or to bring other business before an annual meeting of our stockholders.
|
•
|
billing and coding for services, including documentation of care, appropriate treatment of overpayments and credit balances, and the submission of false statements or claims;
|
•
|
relationships and arrangements with physicians, hospitals, vendors and other referral sources and referral recipients, including self-referral restrictions, prohibitions on kickbacks and other non-permitted forms of remuneration and prohibitions on the payment of inducements to Medicare and Medicaid beneficiaries in order to influence their selection of a provider;
|
•
|
licensure, certification, enrollment in government programs and CON approval, including requirements affecting the operation, establishment and addition of services and facilities;
|
•
|
the necessity, appropriateness, and adequacy of medical care, equipment, and personnel and conditions of coverage and payment for services;
|
38
|
Item 1A. Risk Factors - (continued)
|
•
|
quality of care and data reporting;
|
•
|
ownership of surgery centers;
|
•
|
operating policies and procedures;
|
•
|
qualifications, training and supervision of medical and support personnel;
|
•
|
fee-splitting and the corporate practice of medicine;
|
•
|
screening, stabilization and transfer of individuals who have emergency medical conditions;
|
•
|
workplace health and safety;
|
•
|
debt collection practices;
|
•
|
communications with patients and consumers;
|
•
|
anti-competitive conduct;
|
•
|
confidentiality, maintenance, data breach, identity theft and security issues associated with health-related and other personal information and medical records; and
|
•
|
environmental protection.
|
39
|
Item 1A. Risk Factors - (continued)
|
40
|
Item 1A. Risk Factors - (continued)
|
41
|
Item 1A. Risk Factors - (continued)
|
42
|
43
|
|
|
1
st
|
|
2
nd
|
|
3
rd
|
|
4
th
|
||||||||
|
|
Quarter
|
|
Quarter
|
|
Quarter
|
|
Quarter
|
||||||||
2016:
|
|
|
|
|
|
|
|
|
||||||||
High
|
|
$
|
78.88
|
|
|
$
|
83.27
|
|
|
$
|
81.34
|
|
|
$
|
74.75
|
|
Low
|
|
$
|
60.01
|
|
|
$
|
72.03
|
|
|
$
|
61.20
|
|
|
$
|
57.32
|
|
2017:
|
|
|
|
|
|
|
|
|
||||||||
High
|
|
$
|
73.00
|
|
|
$
|
64.00
|
|
|
$
|
63.31
|
|
|
$
|
45.97
|
|
Low
|
|
$
|
60.96
|
|
|
$
|
53.12
|
|
|
$
|
42.50
|
|
|
$
|
23.77
|
|
44
|
Issuer Purchases of Equity Securities
|
||||||||||||||
|
|
|
|
|
|
|
|
(d) Maximum
|
||||||
|
|
|
|
|
|
|
|
Number (or
|
||||||
|
|
|
|
|
|
|
|
Approximate Dollar
|
||||||
|
|
(a) Total
|
|
|
|
(c) Total Number of
|
|
Value) of Shares (or
|
||||||
|
|
Number of
|
|
(b) Average
|
|
Shares (or Units)
|
|
Units) That May Yet
|
||||||
|
|
Shares
|
|
Price Paid
|
|
Purchased as Part of
|
|
Be Purchased Under
|
||||||
|
|
(or Units)
|
|
per Share
|
|
Publicly Announced
|
|
the Plans or
|
||||||
Period
|
|
Purchased (1)
|
|
(or Unit)
|
|
Plans or Programs
|
|
Programs (2)
|
||||||
October 1, 2017 through
|
|
|
|
|
|
|
|
|
|
|
|
|
||
October 31, 2017
|
|
258
|
|
|
$
|
43.60
|
|
|
—
|
|
|
$
|
—
|
|
November 1, 2017 through
|
|
|
|
|
|
|
|
|
|
|
|
|
||
November 30, 2017
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
December 1, 2017 through
|
|
|
|
|
|
|
|
|
|
|
|
|
||
December 31, 2017
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
Total
|
|
258
|
|
|
$
|
43.60
|
|
|
—
|
|
|
$
|
—
|
|
|
(1)
|
During the three months ended December 31, 2017, we repurchased 258 shares with a value of approximately $10 thousand dollars to cover payroll withholding taxes in connection with the vesting of restricted stock awards under the Envision Healthcare Corporation 2014 Equity and Incentive Plan.
|
(2)
|
On September 17, 2017, the Board authorized a stock repurchase program that authorizes the Company to repurchase up to $250 million of its common stock. See “Management's Discussion & Analysis - Liquidity and Capital Resources” for further discussion of this authorization.
|
45
|
Item 6. Selected Financial Data
|
|
Year Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
|
(Dollars in millions, except per share amounts)
|
||||||||||||||||||
Consolidated Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net revenue
(1)
|
$
|
7,819.3
|
|
|
$
|
3,497.9
|
|
|
$
|
2,566.9
|
|
|
$
|
1,621.9
|
|
|
$
|
1,057.2
|
|
Operating expenses
|
7,649.9
|
|
|
3,157.4
|
|
|
2,002.3
|
|
|
1,238.0
|
|
|
730.0
|
|
|||||
Net gain (loss) on disposals and deconsolidations
(2)
|
(2.4
|
)
|
|
5.7
|
|
|
36.7
|
|
|
3.4
|
|
|
2.2
|
|
|||||
Equity in earnings of unconsolidated affiliates
|
22.2
|
|
|
23.7
|
|
|
16.2
|
|
|
7.1
|
|
|
3.2
|
|
|||||
Operating income
|
189.2
|
|
|
369.9
|
|
|
617.5
|
|
|
394.4
|
|
|
332.6
|
|
|||||
Interest expense, net
|
231.1
|
|
|
142.4
|
|
|
121.5
|
|
|
83.3
|
|
|
29.5
|
|
|||||
Debt extinguishment costs
|
—
|
|
|
30.3
|
|
|
—
|
|
|
16.9
|
|
|
—
|
|
|||||
Other income, net
|
11.0
|
|
|
1.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Earnings (loss) from continuing operations before income taxes
|
(30.9
|
)
|
|
198.2
|
|
|
496.0
|
|
|
294.2
|
|
|
303.1
|
|
|||||
Income tax expense (benefit)
(3)
|
(496.8
|
)
|
|
(3.3
|
)
|
|
113.8
|
|
|
48.1
|
|
|
48.7
|
|
|||||
Net earnings from continuing operations
|
465.9
|
|
|
201.5
|
|
|
382.2
|
|
|
246.1
|
|
|
254.4
|
|
|||||
Net earnings (loss) from discontinued operations
(4)
|
(491.9
|
)
|
|
4.0
|
|
|
(1.0
|
)
|
|
(1.3
|
)
|
|
7.1
|
|
|||||
Net earnings (loss)
|
(26.0
|
)
|
|
205.5
|
|
|
381.2
|
|
|
244.8
|
|
|
261.5
|
|
|||||
Less net earnings attributable to noncontrolling interests
|
202.0
|
|
|
224.1
|
|
|
218.2
|
|
|
191.1
|
|
|
188.8
|
|
|||||
Net earnings (loss) attributable to Envision Healthcare Corporation stockholders
|
(228.0
|
)
|
|
(18.6
|
)
|
|
163.0
|
|
|
53.7
|
|
|
72.7
|
|
|||||
Preferred stock dividends
|
(4.5
|
)
|
|
(9.1
|
)
|
|
(9.1
|
)
|
|
(4.5
|
)
|
|
—
|
|
|||||
Net earnings (loss) attributable to Envision Healthcare Corporation common stockholders
|
$
|
(232.5
|
)
|
|
$
|
(27.7
|
)
|
|
$
|
153.9
|
|
|
$
|
49.2
|
|
|
$
|
72.7
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Amounts attributable to Envision Healthcare Corporation common stockholders:
|
|
|
|
|
|
|
|
|
|
||||||||||
Earnings (loss) from continuing operations, net of tax
|
$
|
259.4
|
|
|
$
|
(31.7
|
)
|
|
$
|
154.9
|
|
|
$
|
50.8
|
|
|
$
|
71.0
|
|
Earnings (loss) from discontinued operations, net of tax
|
(491.9
|
)
|
|
4.0
|
|
|
(1.0
|
)
|
|
(1.6
|
)
|
|
1.7
|
|
|||||
Net earnings (loss) attributable to Envision Healthcare Corporation common stockholders
|
$
|
(232.5
|
)
|
|
$
|
(27.7
|
)
|
|
$
|
153.9
|
|
|
$
|
49.2
|
|
|
$
|
72.7
|
|
Basic earnings (loss) per share attributable to Envision Healthcare Corporation common stockholders:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net earnings (loss) from continuing operations
|
$
|
2.19
|
|
|
$
|
(0.54
|
)
|
|
$
|
3.22
|
|
|
$
|
1.29
|
|
|
$
|
2.27
|
|
Net earnings (loss)
|
$
|
(1.96
|
)
|
|
$
|
(0.47
|
)
|
|
$
|
3.20
|
|
|
$
|
1.25
|
|
|
$
|
2.32
|
|
Diluted earnings (loss) per share attributable to Envision Healthcare Corporation common stockholders
(5)
:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net earnings (loss) from continuing operations
|
$
|
2.14
|
|
|
$
|
(0.54
|
)
|
|
$
|
3.18
|
|
|
$
|
1.28
|
|
|
$
|
2.22
|
|
Net earnings (loss)
|
$
|
(1.93
|
)
|
|
$
|
(0.47
|
)
|
|
$
|
3.16
|
|
|
$
|
1.24
|
|
|
$
|
2.28
|
|
Weighted average number of shares and share equivalents outstanding (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Basic
|
118,397
|
|
|
59,002
|
|
|
48,058
|
|
|
39,311
|
|
|
31,338
|
|
|||||
Diluted
(5)
|
120,943
|
|
|
59,002
|
|
|
51,612
|
|
|
39,625
|
|
|
31,954
|
|
46
|
Item 6. Selected Financial Data - (continued)
|
|
Year Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
|
(In millions)
|
||||||||||||||||||
Consolidated Balance Sheet and Cash Flow Data:
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
(6)
|
$
|
312.2
|
|
|
$
|
316.9
|
|
|
$
|
106.7
|
|
|
$
|
208.1
|
|
|
$
|
50.8
|
|
Working capital
(6)
|
996.5
|
|
|
955.3
|
|
|
151.8
|
|
|
278.1
|
|
|
121.2
|
|
|||||
Total assets
(7)
|
16,572.6
|
|
|
16,708.9
|
|
|
6,499.3
|
|
|
5,446.6
|
|
|
2,167.1
|
|
|||||
Long-term debt and other long-term liabilities, net of deferred financing costs
|
6,413.2
|
|
|
5,892.6
|
|
|
2,405.6
|
|
|
2,267.2
|
|
|
597.9
|
|
|||||
Non-redeemable and redeemable noncontrolling interests
(8)
|
829.4
|
|
|
839.7
|
|
|
647.0
|
|
|
602.8
|
|
|
539.1
|
|
|||||
Envision Healthcare Corporation stockholders’ equity
|
6,527.1
|
|
|
6,731.1
|
|
|
2,293.4
|
|
|
1,679.5
|
|
|
764.2
|
|
|||||
Cash flows provided by operating activities
(9)
|
797.4
|
|
|
419.8
|
|
|
538.0
|
|
|
424.8
|
|
|
332.8
|
|
|||||
Cash flows used in investing activities
|
(982.1
|
)
|
|
(303.7
|
)
|
|
(1,016.8
|
)
|
|
(2,225.1
|
)
|
|
(98.7
|
)
|
|||||
Cash flows provided by (used in) financing activities
|
205.3
|
|
|
108.8
|
|
|
377.4
|
|
|
1,957.6
|
|
|
(229.6
|
)
|
|
(1)
|
Comparability of revenue is impacted by the Merger completed December 1, 2016, the acquisition of Sheridan completed July 16, 2014 and other acquisitions. See Note
4
to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K for the impact of acquisitions on net revenue.
|
(2)
|
The net gain on disposals and deconsolidations primarily results from transactions in which we have sold or contributed all or a portion of our equity interests into new unconsolidated investments, primarily in our ambulatory services segment. See Note
9
to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K.
|
(3)
|
Includes a benefit of
$596.6 million
related to tax reform in 2017.
|
(4)
|
Amounts have been restated in 2016 for the medical transportation business and discontinued operations.
|
(5)
|
See Note
20
to the “Consolidated Financial Statements” included in Item 8 of this Form 10-K for a reconciliation of amounts used in diluted earnings per share for the years ended
2017
, 2016 and 2015.
|
(6)
|
Excludes amounts related to discontinued operations.
|
(7)
|
Amount includes
$2.75 billion
and
$3.04 billion
related to assets held for sale as of December 31, 2017 and 2016, respectively.
|
(8)
|
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies.”
|
(9)
|
Amounts from cash flows include the operations related to the discontinued operations business for 2017 and 2016.
|
47
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
48
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
49
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
50
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
51
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
52
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
53
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
54
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
55
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
2017
|
|
2016
|
|
2015
|
|||
Net revenue
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
Operating expenses:
|
|
|
|
|
|
|||
Salaries and benefits
|
72.0
|
|
|
58.9
|
|
|
52.4
|
|
Supply cost
|
2.8
|
|
|
5.7
|
|
|
7.2
|
|
Insurance expense
|
1.8
|
|
|
1.3
|
|
|
1.2
|
|
Other operating expenses
|
9.9
|
|
|
11.9
|
|
|
13.1
|
|
Transaction and integration costs
|
1.1
|
|
|
2.2
|
|
|
0.3
|
|
Impairment charges
|
6.4
|
|
|
6.3
|
|
|
—
|
|
Depreciation and amortization
|
3.7
|
|
|
3.9
|
|
|
3.8
|
|
Total operating expenses
|
97.8
|
|
|
90.3
|
|
|
78.0
|
|
Net gain (loss) on disposals and deconsolidations
|
—
|
|
|
0.2
|
|
|
1.4
|
|
Equity in earnings of unconsolidated affiliates
|
0.3
|
|
|
0.7
|
|
|
0.6
|
|
Operating income
|
2.4
|
|
|
10.6
|
|
|
24.1
|
|
Interest expense, net
|
3.0
|
|
|
4.1
|
|
|
4.7
|
|
Debt extinguishment costs
|
—
|
|
|
0.9
|
|
|
—
|
|
Other income, net
|
0.1
|
|
|
—
|
|
|
—
|
|
Earnings (loss) from continuing operations before income taxes
|
(0.4
|
)
|
|
5.7
|
|
|
19.3
|
|
Income tax expense (benefit)
|
(6.4
|
)
|
|
(0.1
|
)
|
|
4.4
|
|
Net earnings from continuing operations
|
6.0
|
|
|
5.8
|
|
|
14.9
|
|
Discontinued operations:
|
|
|
|
|
|
|||
Earnings (loss) from discontinued operations
|
(5.9
|
)
|
|
0.2
|
|
|
(0.1
|
)
|
Income tax (expense) benefit from discontinued operations
|
(0.4
|
)
|
|
(0.1
|
)
|
|
—
|
|
Net earnings (loss) from discontinued operations
|
(6.3
|
)
|
|
0.1
|
|
|
—
|
|
Net earnings (loss)
|
(0.3
|
)
|
|
5.9
|
|
|
14.9
|
|
Less net earnings attributable to noncontrolling interests
|
2.6
|
|
|
6.4
|
|
|
8.5
|
|
Net earnings (loss) attributable to Envision Healthcare Corporation stockholders
|
(2.9
|
)%
|
|
(0.5
|
)%
|
|
6.4
|
%
|
•
|
our operating results for the year ended
December 31, 2017
include the full year of operating results of EHH;
|
•
|
transaction and integration costs associated with the Merger;
|
•
|
additional interest expense and related charges associated with the debt refinancing completed as part of the Merger;
|
•
|
we completed acquisitions in both our physician services and ambulatory services segments; and
|
•
|
we experienced an increase in our same contract and same center growth during
2017
.
|
56
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
•
|
an increase of
$4.31 billion
associated with our physician services segment driven primarily by a full period of results of operations received from the Merger in the current year, acquisitions completed in
2016
and
2017
, increases in our same-contract growth and a full period of results after the consolidation of a partnership previously accounted for as an equity method investment through the second quarter of 2016; and
|
•
|
an increase of
$8.7 million
associated with our ambulatory services segment driven primarily by acquisitions completed in
2016
and
2017
and increases in our same-center growth offset by disposal and deconsolidation activity.
|
•
|
a full year's results from the Merger reflected in our 2017 results as compared to just one month in 2016;
|
•
|
additional operating income from acquisitions completed during
2016
and
2017
;
|
•
|
an increase of
$22.4 million
associated our ambulatory services segment as the result of operations of recent acquisitions and same-center growth offset by disposal and deconsolidation activity;
|
•
|
a $500.0 million non-cash charge related to the goodwill impairment recorded within our physician services segment during the fourth quarter of 2017 and
$221.3 million
non-cash impairment charge related to our decision to rebrand our physician services segment and ceasing the use of the Sheridan trade name which occurred during the fourth quarter of 2016; and
|
•
|
transaction and integration costs totaling
$88.7 million
in
2017
, most of which directly relate to the Merger compared to
$76.3 million
during
2016
.
|
57
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
•
|
our operating results for the year ended December 31, 2016 include the operating results of EHH from December 1, 2016 through December 31, 2016;
|
•
|
transaction costs associated with the Merger;
|
•
|
additional interest expense and related charges associated with the debt refinancing completed as part of the Merger;
|
•
|
we completed acquisitions in both our physician services and ambulatory services segments; and
|
•
|
we experienced an increase in our same contract organic and same center growth during 2016.
|
•
|
an increase of $892.9 million associated with our physician services segment driven primarily by completed acquisitions in
2015
and
2016
, increases in our same-contract growth, the consolidation of a partnership previously accounted for as an equity method investment and contribution from the Merger; and
|
•
|
an increase of $38.1 million associated with our ambulatory services segment driven primarily by completed acquisitions in
2015
and
2016
and increases in our same-center growth.
|
•
|
a decrease of $195.0 million resulting substantially from the impairment charge experienced by our physician services segment associated with the Merger of approximately $221.3 million related to our decision to rebrand our physician services segment and cease the use of the Sheridan trade name which occurred during the fourth quarter of 2016. See Note
10
in Item 8 for additional information. This decrease was offset by additional operating income due to the Merger and acquisitions completed during
2015
and
2016
;
|
•
|
a decrease of $52.6 million associated our ambulatory services segment as the result of deconsolidation activity offset in part by the operations of recent acquisitions and same-center growth; and
|
•
|
total charges of
$76.3 million
related to transaction and integration charges and $73.8 million directly related to the Merger.
|
58
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
2017
|
|
2016
|
|
2015
|
|||
Contribution to Net Revenue Growth:
|
|
|
|
|
|
|||
Same contract
|
1.6
|
%
|
|
4.9
|
%
|
|
7.5
|
%
|
New contract
|
6.5
|
|
|
3.1
|
|
|
4.5
|
|
Terminated contracts
|
(9.0
|
)
|
|
(1.8
|
)
|
|
(2.5
|
)
|
Acquired contract and other
(1)
|
9.5
|
|
|
34.5
|
|
|
14.9
|
|
EHH Physician Services
(2)
|
—
|
|
|
26.1
|
|
|
—
|
|
Total net revenue growth
|
8.6
|
%
|
|
66.8
|
%
|
|
24.4
|
%
|
|
|
|
|
|
|
|||
Patient encounters per day (day adjusted)
(3)
|
1.5
|
%
|
|
3.7
|
%
|
|
4.8
|
%
|
Net revenue per encounter
(3)
|
0.9
|
|
|
2.6
|
|
|
5.1
|
|
Same contract revenue growth
(3)
|
2.4
|
%
|
|
6.3
|
%
|
|
9.9
|
%
|
|
(1)
|
Includes net revenue growth related to the consolidation on July 1, 2016 of a previously unconsolidated affiliate of 5.5% in the year ended December 31, 2016.
|
(2)
|
Includes results of EHH for the period December 1, 2016 (the date of the Merger) through December 31, 2016.
|
(3)
|
Amount excludes the one month impact from EHH for the period December 1, 2016 (the date of the Merger) through December 31, 2016.
|
|
Percentage of Net Revenue
|
|
Percentage of Total Volume
|
||||||||||||||
|
Year Ended December 31,
|
|
Year Ended December 31,
|
||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2017
|
|
2016
|
|
2015
|
||||||
Medicare
|
20
|
%
|
|
15
|
%
|
|
13
|
%
|
|
33
|
%
|
|
33
|
%
|
|
36
|
%
|
Medicaid
|
8
|
|
|
6
|
|
|
5
|
|
|
23
|
|
|
22
|
|
|
22
|
|
Commercial and managed care
|
55
|
|
|
68
|
|
|
71
|
|
|
31
|
|
|
34
|
|
|
33
|
|
Self-pay
|
2
|
|
|
1
|
|
|
1
|
|
|
13
|
|
|
11
|
|
|
9
|
|
Net fee for service revenue
|
85
|
%
|
|
90
|
%
|
|
90
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Contract and other revenue
|
15
|
|
|
10
|
|
|
10
|
|
|
|
|
|
|
|
|||
Net revenue for physician services
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
59
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
Year Ended December 31,
|
|||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|||||||||||||||
Net revenue
|
$
|
6,542.4
|
|
|
100.0
|
%
|
|
$
|
2,229.7
|
|
|
100.0
|
%
|
|
$
|
1,336.8
|
|
|
100.0
|
%
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Salaries and benefits
|
5,241.8
|
|
|
80.1
|
|
|
1,670.0
|
|
|
74.9
|
|
|
972.2
|
|
|
72.7
|
|
|||
Supply cost
|
22.1
|
|
|
0.3
|
|
|
6.6
|
|
|
0.3
|
|
|
2.5
|
|
|
0.2
|
|
|||
Insurance expense
|
136.9
|
|
|
2.1
|
|
|
38.9
|
|
|
1.7
|
|
|
24.3
|
|
|
1.8
|
|
|||
Other operating expenses
|
520.9
|
|
|
8.0
|
|
|
164.8
|
|
|
7.4
|
|
|
95.9
|
|
|
7.2
|
|
|||
Transaction and integration costs
|
79.8
|
|
|
1.2
|
|
|
49.0
|
|
|
2.2
|
|
|
6.6
|
|
|
0.5
|
|
|||
Impairment charges
|
500.3
|
|
|
7.6
|
|
|
221.3
|
|
|
9.9
|
|
|
—
|
|
|
—
|
|
|||
Depreciation and amortization
|
249.5
|
|
|
3.8
|
|
|
101.4
|
|
|
4.5
|
|
|
61.7
|
|
|
4.6
|
|
|||
Total operating expenses
|
6,751.3
|
|
|
103.2
|
|
|
2,252.0
|
|
|
101.0
|
|
|
1,163.2
|
|
|
87.0
|
|
|||
Net loss on disposals and deconsolidations
|
(11.0
|
)
|
|
(0.2
|
)
|
|
—
|
|
|
—
|
|
|
(6.5
|
)
|
|
(0.5
|
)
|
|||
Equity in earnings (loss) of unconsolidated affiliates
|
(1.4
|
)
|
|
—
|
|
|
4.1
|
|
|
0.2
|
|
|
9.7
|
|
|
0.7
|
|
|||
Operating income (loss)
|
$
|
(221.3
|
)
|
|
(3.4
|
)%
|
|
$
|
(18.2
|
)
|
|
(0.8
|
)%
|
|
$
|
176.8
|
|
|
13.2
|
%
|
60
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
61
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Procedures performed during the period at consolidated centers
|
1,715,595
|
|
|
1,721,399
|
|
|
1,729,262
|
|
|||
Centers in operation, end of period (consolidated)
|
234
|
|
|
238
|
|
|
236
|
|
|||
Centers in operation, end of period (unconsolidated)
|
30
|
|
|
22
|
|
|
21
|
|
|||
Average number of continuing centers in operation (consolidated)
|
237
|
|
|
237
|
|
|
238
|
|
|||
New centers added, during period
|
10
|
|
|
8
|
|
|
11
|
|
|||
Centers merged into existing centers, during period
|
—
|
|
|
1
|
|
|
—
|
|
|||
Centers disposed, during period
|
6
|
|
|
4
|
|
|
—
|
|
|||
Surgical hospitals in operation, end of period (unconsolidated)
|
1
|
|
|
1
|
|
|
1
|
|
|||
Centers under letter of intent, end of period
|
2
|
|
|
3
|
|
|
5
|
|
|||
Average revenue per consolidated center (in thousands)
|
$
|
5,392
|
|
|
$
|
5,352
|
|
|
$
|
5,168
|
|
Same center revenues increase, day adjusted (consolidated)
|
1.8
|
%
|
|
4.3
|
%
|
|
6.0
|
%
|
|
December 31,
|
|||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|||||||||||||||
Net revenue
|
$
|
1,276.9
|
|
|
100.0
|
%
|
|
$
|
1,268.2
|
|
|
100.0
|
%
|
|
$
|
1,230.1
|
|
|
100.0
|
%
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Salaries and benefits
|
385.6
|
|
|
30.2
|
|
|
390.6
|
|
|
30.8
|
|
|
372.2
|
|
|
30.3
|
|
|||
Supply cost
|
200.6
|
|
|
15.7
|
|
|
191.8
|
|
|
15.1
|
|
|
181.8
|
|
|
14.8
|
|
|||
Insurance expense
|
7.3
|
|
|
0.6
|
|
|
6.6
|
|
|
0.5
|
|
|
6.9
|
|
|
0.6
|
|
|||
Other operating expenses
|
256.8
|
|
|
20.1
|
|
|
252.9
|
|
|
19.9
|
|
|
240.6
|
|
|
19.6
|
|
|||
Transaction and integration costs
|
8.9
|
|
|
0.7
|
|
|
27.3
|
|
|
2.2
|
|
|
1.8
|
|
|
0.1
|
|
|||
Depreciation and amortization
|
39.4
|
|
|
3.1
|
|
|
36.2
|
|
|
2.9
|
|
|
35.8
|
|
|
2.9
|
|
|||
Total operating expenses
|
898.6
|
|
|
70.4
|
|
|
905.4
|
|
|
71.4
|
|
|
839.1
|
|
|
68.2
|
|
|||
Net gain on deconsolidations
|
8.6
|
|
|
0.7
|
|
|
5.7
|
|
|
0.4
|
|
|
43.2
|
|
|
3.5
|
|
|||
Equity in earnings of unconsolidated affiliates
|
23.6
|
|
|
1.8
|
|
|
19.6
|
|
|
1.5
|
|
|
6.5
|
|
|
0.5
|
|
|||
Operating income
|
$
|
410.5
|
|
|
32.1
|
%
|
|
$
|
388.1
|
|
|
30.6
|
%
|
|
$
|
440.7
|
|
|
35.8
|
%
|
62
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
•
|
revenue growth of $16.8 million for the year ended
December 31, 2017
recognized by our
2017
same-center group, reflecting a
1.8%
increase in our
2017
same-center group attributable to a
1.1%
increase in procedures and a
0.7%
increase in revenue per procedure;
|
•
|
centers acquired in
2016
, which contributed $14.8 million of additional revenues in the year ended
December 31, 2017
, due to a full year of contribution in
2017
;
|
•
|
centers acquired or opened in
2017
, which generated $13.0 million in revenues during the year ended
December 31, 2017
;
|
•
|
reduced revenue recognized during the year ended
December 31, 2017
of $16.7 million resulting from the deconsolidation of centers previously consolidated as we sold all or a portion of our ownership interest. Our share of the results of operations from the deconsolidated centers is reflected in equity in earnings of unconsolidated affiliates in our consolidated statements of operations; and
|
•
|
reduced revenue recognized during the year ended
December 31, 2017
of $20.4 million resulting from the disposal of centers that had a full year of operations during the year ended
December 31, 2016
.
|
•
|
an increase of $6.4 million at our
2017
same-center group;
|
•
|
centers acquired or opened during
2016
and
2017
, which resulted in an increase of $5.5 million;
|
•
|
disposal or deconsolidation of centers in the prior year, which resulted in a decrease of $8.9 million;
|
63
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
•
|
revenue growth of $48.2 million for the year ended December 31, 2016 recognized by our 2016 same-center group, reflecting a 4.3% increase in our 2016 same-center group attributable to a 2.5% increase in procedures and a 1.8% increase in revenue per procedure;
|
•
|
centers acquired in 2015, which contributed $34.2 million of additional revenues in the year ended December 31, 2016, due to a full year of contribution in 2016;
|
•
|
centers acquired or opened in 2016, which generated $14.3 million in revenues during the year ended December 31, 2016;
|
•
|
reduced revenue recognized during the year ended December 31, 2016 of $52.3 million resulting from the deconsolidation of centers previously consolidated as we sold all or a portion of our ownership interest. Our share of the results of operations from the deconsolidated centers is reflected in equity in earnings of unconsolidated affiliates in our consolidated statements of operations; and
|
•
|
reduced revenue recognized during the year ended December 31, 2016 of $7.6 million resulting from the disposal of centers that had a full year of operations during the year ended December 31, 2015.
|
•
|
an increase of $14.6 million in other operating expenses at our 2016 same-center group in the year ended December 31, 2016;
|
•
|
centers acquired during 2015, which resulted in an increase of $5.0 million in other operating expenses in the year ended December 31, 2016;
|
•
|
centers acquired or opened during 2016, which resulted in an increase of $2.6 million in other operating expenses in the year ended December 31, 2016;
|
•
|
reduced operating expense during the year ended December 31, 2016 of $11.0 million resulting from the deconsolidation of centers that were previously consolidated;
|
•
|
reduced operating expense during the year ended December 31, 2016 of $2.2 million resulting from the disposal of centers that had a full year of operations during the year ended December 31, 2015.
|
64
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Net cash provided by (used in):
|
|
|
|
|
|
||||||
Operating activities
|
$
|
797.4
|
|
|
$
|
419.8
|
|
|
$
|
538.0
|
|
Investing activities
|
(982.1
|
)
|
|
(303.7
|
)
|
|
(1,016.8
|
)
|
|||
Financing activities
|
205.3
|
|
|
108.8
|
|
|
377.4
|
|
•
|
increased operating cash flow as a result of the Merger;
|
•
|
income tax payments of
$24.5 million
, which was
$74.1 million
lower in
2017
compared to
2016
;
|
•
|
payments of transaction and integration costs primarily related to the Merger of $96.4 million; and
|
•
|
increase in interest payments by
$192.4 million
due to the Merger-related debt refinancing.
|
65
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
•
|
$584.1 million
for the acquisition of physician practices;
|
•
|
$47.3 million
for the acquisition of interests in surgery centers;
|
•
|
$119.4 million
for the acquisitions in our medical transportation business; and
|
•
|
$208.9 million
for new or replacement property, excluding
$4.3 million
in new capital leases.
|
66
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
67
|
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued)
|
|
Payments Due by Period
|
||||||||||||||||||
|
|
|
Less than
|
|
|
|
|
|
More than
|
||||||||||
Contractual obligations
(1)
:
|
Total
|
|
1 Year
|
|
1-3 Years
|
|
3-5 Years
|
|
5 Years
|
||||||||||
Long-term debt, including interest
(2)
|
$
|
8,129.7
|
|
|
$
|
367.1
|
|
|
$
|
721.1
|
|
|
$
|
2,508.9
|
|
|
$
|
4,532.6
|
|
Capital lease obligations, including interest
|
47.8
|
|
|
5.4
|
|
|
9.8
|
|
|
6.3
|
|
|
26.3
|
|
|||||
Operating leases, including renewal option periods
(3)
|
832.0
|
|
|
96.3
|
|
|
167.9
|
|
|
157.7
|
|
|
410.1
|
|
|||||
Other
(4)
|
16.0
|
|
|
6.8
|
|
|
6.2
|
|
|
3.0
|
|
|
—
|
|
|||||
Subtotal
|
9,025.5
|
|
|
475.6
|
|
|
905.0
|
|
|
2,675.9
|
|
|
4,969.0
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Other commitments
(1)
:
|
|
|
|
|
|
|
|
|
|
||||||||||
Guarantees of surety bonds
|
2.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.9
|
|
|||||
Letters of credit
(5)
|
68.6
|
|
|
68.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Subtotal
|
71.5
|
|
|
68.6
|
|
|
—
|
|
|
—
|
|
|
2.9
|
|
|||||
Total obligations and commitments
|
$
|
9,097.0
|
|
|
$
|
544.2
|
|
|
$
|
905.0
|
|
|
$
|
2,675.9
|
|
|
$
|
4,971.9
|
|
|
(1)
|
These amounts do not include obligations directly attributable to discontinued operations.
|
(2)
|
Our long-term debt may increase based on future acquisition activity. We intend to either use our operating cash flow to repay our long-term debt or refinance such obligations as they come due.
|
(3)
|
Operating lease obligations do not include common area maintenance, insurance or tax payments for which we were also obligated.
|
(4)
|
Includes contingent consideration related to certain acquisitions, liability for unrecognized tax benefits and other purchase obligations of goods and services.
|
(5)
|
Letters of credit are primarily collateralized by our ABL Facility.
|
68
|
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value at
|
||||||||||||||||
|
Years Ended December 31,
|
|
|
|
|
|
December 31,
|
||||||||||||||||||||||||
|
2018
|
|
2019
|
|
2020
|
|
2021
|
|
2022
|
|
Thereafter
|
|
Total
|
|
2017
|
||||||||||||||||
Fixed rate
|
$
|
11.9
|
|
|
$
|
10.2
|
|
|
$
|
6.6
|
|
|
$
|
4.3
|
|
|
$
|
1,852.9
|
|
|
$
|
569.5
|
|
|
$
|
2,455.4
|
|
|
$
|
2,465.1
|
|
Average interest rate
|
3.9
|
%
|
|
4.1
|
%
|
|
4.4
|
%
|
|
4.7
|
%
|
|
5.4
|
%
|
|
6.3
|
%
|
|
|
|
|
|
|||||||||
Variable rate
|
$
|
40.3
|
|
|
$
|
40.2
|
|
|
$
|
40.1
|
|
|
$
|
40.1
|
|
|
$
|
40.1
|
|
|
$
|
3,756.5
|
|
|
$
|
3,957.3
|
|
|
$
|
3,957.3
|
|
Average interest rate
|
4.0
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
|
4.0
|
%
|
|
|
|
|
69
|
Item 8. Financial Statements and Supplementary Data
|
70
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Balance Sheets
(Dollars in millions, shares in thousands)
|
|||||||
|
December 31,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
312.2
|
|
|
$
|
316.9
|
|
Insurance collateral
|
86.2
|
|
|
87.0
|
|
||
Accounts receivable, net of allowance of $2,554.5 and $584.0, respectively
|
1,405.8
|
|
|
1,297.8
|
|
||
Supplies inventory
|
22.7
|
|
|
23.4
|
|
||
Prepaid and other current assets
|
165.6
|
|
|
135.1
|
|
||
Current assets held for sale
|
2,751.8
|
|
|
551.1
|
|
||
Total current assets
|
4,744.3
|
|
|
2,411.3
|
|
||
Property and equipment, net
|
302.7
|
|
|
300.8
|
|
||
Investments in unconsolidated affiliates
|
156.7
|
|
|
114.7
|
|
||
Goodwill
|
7,536.1
|
|
|
7,584.0
|
|
||
Intangible assets, net
|
3,665.5
|
|
|
3,675.5
|
|
||
Other assets
|
167.3
|
|
|
134.2
|
|
||
Noncurrent assets held for sale
|
—
|
|
|
2,488.4
|
|
||
Total assets
|
$
|
16,572.6
|
|
|
$
|
16,708.9
|
|
Liabilities and Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Current portion of long-term debt
|
$
|
52.1
|
|
|
$
|
46.6
|
|
Accounts payable
|
62.2
|
|
|
69.9
|
|
||
Accrued salaries and benefits
|
548.0
|
|
|
483.8
|
|
||
Accrued interest
|
52.1
|
|
|
51.4
|
|
||
Other accrued liabilities
|
281.6
|
|
|
253.2
|
|
||
Current liabilities held for sale
|
399.1
|
|
|
249.4
|
|
||
Total current liabilities
|
1,395.1
|
|
|
1,154.3
|
|
||
Long-term debt, net of deferred financing costs of $97.3 and $111.0, respectively
|
6,263.3
|
|
|
5,790.2
|
|
||
Deferred income taxes
|
1,089.3
|
|
|
1,343.7
|
|
||
Insurance reserves
|
318.5
|
|
|
278.9
|
|
||
Other long-term liabilities
|
149.9
|
|
|
102.4
|
|
||
Noncurrent liabilities held for sale
|
—
|
|
|
468.6
|
|
||
Commitments and contingencies
|
|
|
|
||||
Noncontrolling interests – redeemable
|
187.1
|
|
|
182.9
|
|
||
Equity:
|
|
|
|
||||
Preferred stock, $0.01 par value, 100,000 shares authorized, 0 and 1,725 shares issued and outstanding, respectively
|
—
|
|
|
0.1
|
|
||
Common stock, $0.01 par value, 1,000,000 shares authorized, 121,021 and 117,478 shares issued and outstanding, respectively
|
1.2
|
|
|
1.2
|
|
||
Additional paid-in capital
|
6,008.9
|
|
|
5,976.3
|
|
||
Retained earnings
|
521.2
|
|
|
753.7
|
|
||
Accumulated other comprehensive loss
|
(4.2
|
)
|
|
(0.2
|
)
|
||
Total Envision Healthcare Corporation equity
|
6,527.1
|
|
|
6,731.1
|
|
||
Noncontrolling interests – non-redeemable
|
642.3
|
|
|
656.8
|
|
||
Total equity
|
7,169.4
|
|
|
7,387.9
|
|
||
Total liabilities and equity
|
$
|
16,572.6
|
|
|
$
|
16,708.9
|
|
71
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Statements of Operations
(Dollars in millions, except earnings per share)
|
|||||||||||
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues
|
$
|
12,177.5
|
|
|
$
|
4,322.4
|
|
|
$
|
2,833.0
|
|
Provision for uncollectibles
|
(4,358.2
|
)
|
|
(824.5
|
)
|
|
(266.1
|
)
|
|||
Net revenue
|
7,819.3
|
|
|
3,497.9
|
|
|
2,566.9
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Salaries and benefits
|
5,627.4
|
|
|
2,060.6
|
|
|
1,344.4
|
|
|||
Supply cost
|
222.7
|
|
|
198.4
|
|
|
184.3
|
|
|||
Insurance expense
|
144.2
|
|
|
45.5
|
|
|
31.2
|
|
|||
Other operating expenses
|
777.7
|
|
|
417.7
|
|
|
336.5
|
|
|||
Transaction and integration costs
|
88.7
|
|
|
76.3
|
|
|
8.4
|
|
|||
Impairment charges
|
500.3
|
|
|
221.3
|
|
|
—
|
|
|||
Depreciation and amortization
|
288.9
|
|
|
137.6
|
|
|
97.5
|
|
|||
Total operating expenses
|
7,649.9
|
|
|
3,157.4
|
|
|
2,002.3
|
|
|||
Net gain (loss) on disposals and deconsolidations
|
(2.4
|
)
|
|
5.7
|
|
|
36.7
|
|
|||
Equity in earnings of unconsolidated affiliates
|
22.2
|
|
|
23.7
|
|
|
16.2
|
|
|||
Operating income
|
189.2
|
|
|
369.9
|
|
|
617.5
|
|
|||
Interest expense, net
|
231.1
|
|
|
142.4
|
|
|
121.5
|
|
|||
Debt extinguishment costs
|
—
|
|
|
30.3
|
|
|
—
|
|
|||
Other income, net
|
11.0
|
|
|
1.0
|
|
|
—
|
|
|||
Earnings (loss) from continuing operations before income taxes
|
(30.9
|
)
|
|
198.2
|
|
|
496.0
|
|
|||
Income tax expense (benefit)
|
(496.8
|
)
|
|
(3.3
|
)
|
|
113.8
|
|
|||
Net earnings from continuing operations
|
465.9
|
|
|
201.5
|
|
|
382.2
|
|
|||
Discontinued operations:
|
|
|
|
|
|
||||||
Earnings (loss) from discontinued operations
|
(461.2
|
)
|
|
6.4
|
|
|
(1.7
|
)
|
|||
Income tax (expense) benefit from discontinued operations
|
(30.7
|
)
|
|
(2.4
|
)
|
|
0.7
|
|
|||
Net earnings (loss) from discontinued operations
|
(491.9
|
)
|
|
4.0
|
|
|
(1.0
|
)
|
|||
Net earnings (loss)
|
(26.0
|
)
|
|
205.5
|
|
|
381.2
|
|
|||
Less net earnings attributable to noncontrolling interests
|
202.0
|
|
|
224.1
|
|
|
218.2
|
|
|||
Net earnings (loss) attributable to Envision Healthcare Corporation stockholders
|
(228.0
|
)
|
|
(18.6
|
)
|
|
163.0
|
|
|||
Preferred stock dividends
|
(4.5
|
)
|
|
(9.1
|
)
|
|
(9.1
|
)
|
|||
Net earnings (loss) attributable to Envision Healthcare Corporation common stockholders
|
$
|
(232.5
|
)
|
|
$
|
(27.7
|
)
|
|
$
|
153.9
|
|
|
|
|
|
|
|
||||||
Amounts attributable to Envision Healthcare Corporation common stockholders:
|
|
|
|
|
|
||||||
Earnings (loss) from continuing operations, net of income tax
|
$
|
259.4
|
|
|
$
|
(31.7
|
)
|
|
$
|
154.9
|
|
Earnings (loss) from discontinued operations, net of income tax
|
(491.9
|
)
|
|
4.0
|
|
|
(1.0
|
)
|
|||
Net earnings (loss) attributable to Envision Healthcare Corporation common stockholders
|
$
|
(232.5
|
)
|
|
$
|
(27.7
|
)
|
|
$
|
153.9
|
|
|
|
|
|
|
|
||||||
Basic earnings (loss) per share attributable to common stockholders:
|
|
|
|
|
|
||||||
Net earnings (loss) from continuing operations
|
$
|
2.19
|
|
|
$
|
(0.54
|
)
|
|
$
|
3.22
|
|
Net earnings (loss) from discontinued operations
|
(4.15
|
)
|
|
0.07
|
|
|
(0.02
|
)
|
|||
Net earnings (loss)
|
$
|
(1.96
|
)
|
|
$
|
(0.47
|
)
|
|
$
|
3.20
|
|
Diluted earnings (loss) per share attributable to common stockholders:
|
|
|
|
|
|||||||
Net earnings (loss) from continuing operations
|
$
|
2.14
|
|
|
$
|
(0.54
|
)
|
|
$
|
3.18
|
|
Net earnings (loss) from discontinued operations
|
(4.07
|
)
|
|
0.07
|
|
|
(0.02
|
)
|
|||
Net earnings (loss)
|
$
|
(1.93
|
)
|
|
$
|
(0.47
|
)
|
|
$
|
3.16
|
|
|
|
|
|
|
|
||||||
Weighted average number of shares and share equivalents outstanding (in thousands):
|
|
|
|
|
|
||||||
Basic
|
118,397
|
|
|
59,002
|
|
|
48,058
|
|
|||
Diluted
|
120,943
|
|
|
59,002
|
|
|
51,612
|
|
72
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Statements of Comprehensive Income (Loss)
(In millions)
|
|||||||||||
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Net earnings (loss)
|
$
|
(26.0
|
)
|
|
$
|
205.5
|
|
|
$
|
381.2
|
|
Other comprehensive income, net of income tax:
|
|
|
|
|
|
||||||
Unrealized holding loss during the period, net of income tax
|
(4.0
|
)
|
|
(0.2
|
)
|
|
—
|
|
|||
Comprehensive income (loss), net of income tax
|
(30.0
|
)
|
|
205.3
|
|
|
381.2
|
|
|||
Less comprehensive income attributable to noncontrolling interests
|
202.0
|
|
|
224.1
|
|
|
218.2
|
|
|||
Comprehensive income (loss) attributable to Envision Healthcare Corporation stockholders
|
$
|
(232.0
|
)
|
|
$
|
(18.8
|
)
|
|
$
|
163.0
|
|
73
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Statements of Changes in Equity
(Dollars in millions, shares in thousands)
|
|||||||||||||||||||||||||||||||||||||
|
Envision Healthcare Corporation Stockholders
|
|
|
|
|
|
Noncontrolling
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
Noncontrolling
|
|
|
|
Interests –
|
||||||||||||||||||||
|
|
|
|
|
|
|
Additional
|
|
|
|
Other
|
|
Interests –
|
|
Total
|
|
Redeemable
|
||||||||||||||||||||
|
Common Stock
|
|
Preferred Stock
|
|
Paid-in
|
|
Retained
|
|
Comprehensive
|
|
Non-
|
|
Equity
|
|
(Temporary
|
||||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
Earnings
|
|
Loss
|
|
Redeemable
|
|
(Permanent)
|
|
Equity)
|
||||||||||||||||||
Balance at January 1, 2015
|
48,113
|
|
|
$
|
885.4
|
|
|
1,725
|
|
|
$
|
166.6
|
|
|
$
|
—
|
|
|
$
|
627.5
|
|
|
$
|
—
|
|
|
$
|
418.7
|
|
|
$
|
2,098.2
|
|
|
$
|
184.1
|
|
Net earnings
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
163.0
|
|
|
—
|
|
|
67.6
|
|
|
230.6
|
|
|
150.6
|
|
||||||||
Issuance of stock
|
5,835
|
|
|
447.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
447.7
|
|
|
—
|
|
||||||||
Issuance of restricted stock
|
314
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Cancellation of restricted stock
|
(14
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Stock options exercised
|
113
|
|
|
2.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.6
|
|
|
—
|
|
||||||||
Stock repurchased
|
(67
|
)
|
|
(3.7
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3.7
|
)
|
|
—
|
|
||||||||
Share-based compensation
|
—
|
|
|
15.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
15.0
|
|
|
—
|
|
||||||||
Tax benefit related to exercise of share-based awards
|
—
|
|
|
4.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
|
—
|
|
||||||||
Dividends paid on preferred stock
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9.1
|
)
|
|
—
|
|
|
—
|
|
|
(9.1
|
)
|
|
—
|
|
||||||||
Acquisitions and other transactions impacting noncontrolling interests
|
—
|
|
|
1.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
81.9
|
|
|
82.9
|
|
|
(0.7
|
)
|
||||||||
Distributions to noncontrolling interests, net of capital contributions
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(66.3
|
)
|
|
(66.3
|
)
|
|
(147.2
|
)
|
||||||||
Disposals and other transactions impacting noncontrolling interests
|
—
|
|
|
(6.6
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(30.6
|
)
|
|
(37.2
|
)
|
|
(11.1
|
)
|
||||||||
Balance at December 31, 2015
|
54,294
|
|
|
$
|
1,345.4
|
|
|
1,725
|
|
|
$
|
166.6
|
|
|
$
|
—
|
|
|
$
|
781.4
|
|
|
$
|
—
|
|
|
$
|
471.3
|
|
|
2,764.7
|
|
|
$
|
175.7
|
|
|
Net earnings
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(18.6
|
)
|
|
—
|
|
|
73.6
|
|
|
55.0
|
|
|
150.5
|
|
||||||||
Conversion of stock to $0.01 par value
|
—
|
|
|
(1,344.8
|
)
|
|
—
|
|
|
(166.5
|
)
|
|
1,511.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Issuance of stock at Merger
|
62,582
|
|
|
0.6
|
|
|
—
|
|
|
—
|
|
|
4,262.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,263.1
|
|
|
—
|
|
||||||||
Replacement share-based compensation awards issued at Merger
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
180.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
180.3
|
|
|
—
|
|
||||||||
Issuance of restricted stock
|
662
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Cancellation of restricted stock
|
(17
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Stock options exercised
|
40
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
||||||||
Stock repurchased
|
(83
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6.1
|
)
|
|
—
|
|
||||||||
Share-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
29.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
29.4
|
|
|
—
|
|
||||||||
Tax benefit related to exercise of share-based awards
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
||||||||
Dividends paid on preferred stock
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9.1
|
)
|
|
—
|
|
|
—
|
|
|
(9.1
|
)
|
|
—
|
|
||||||||
Acquisitions and other transactions impacting noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
—
|
|
|
189.0
|
|
|
190.8
|
|
|
4.0
|
|
||||||||
Distributions to noncontrolling interests, net of capital contributions
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(75.8
|
)
|
|
(75.8
|
)
|
|
(150.9
|
)
|
||||||||
Disposals and other transactions impacting noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7.5
|
)
|
|
—
|
|
|
—
|
|
|
(1.3
|
)
|
|
(8.8
|
)
|
|
3.6
|
|
||||||||
Unrealized holding gain on investments, net of income tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.2
|
)
|
|
—
|
|
|
(0.2
|
)
|
|
—
|
|
||||||||
Balance at December 31, 2016
|
117,478
|
|
|
$
|
1.2
|
|
|
1,725
|
|
|
$
|
0.1
|
|
|
$
|
5,976.3
|
|
|
$
|
753.7
|
|
|
$
|
(0.2
|
)
|
|
$
|
656.8
|
|
|
$
|
7,387.9
|
|
|
$
|
182.9
|
|
74
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Statements of Changes in Equity - (continued)
(Dollars in millions, shares in thousands)
|
|||||||||||||||||||||||||||||||||||||
|
Envision Healthcare Corporation Stockholders
|
|
|
|
|
|
Noncontrolling
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
Noncontrolling
|
|
|
|
Interests –
|
||||||||||||||||||||
|
|
|
|
|
|
|
Additional
|
|
|
|
Other
|
|
Interests –
|
|
Total
|
|
Redeemable
|
||||||||||||||||||||
|
Common Stock
|
|
Preferred Stock
|
|
Paid-in
|
|
Retained
|
|
Comprehensive
|
|
Non-
|
|
Equity
|
|
(Temporary
|
||||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
Earnings
|
|
Loss
|
|
Redeemable
|
|
(Permanent)
|
|
Equity)
|
||||||||||||||||||
Balance at December 31, 2016
|
117,478
|
|
|
$
|
1.2
|
|
|
1,725
|
|
|
$
|
0.1
|
|
|
$
|
5,976.3
|
|
|
$
|
753.7
|
|
|
$
|
(0.2
|
)
|
|
$
|
656.8
|
|
|
$
|
7,387.9
|
|
|
$
|
182.9
|
|
Net earnings (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(228.0
|
)
|
|
—
|
|
|
65.8
|
|
|
(162.2
|
)
|
|
136.2
|
|
||||||||
Issuance of restricted stock
|
71
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Cancellation of restricted stock
|
(45
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Conversion of preferred stock
|
3,128
|
|
|
—
|
|
|
(1,725
|
)
|
|
(0.1
|
)
|
|
0.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Stock options exercised
|
523
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5.4
|
|
|
—
|
|
||||||||
Stock repurchased
|
(134
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9.5
|
)
|
|
—
|
|
||||||||
Share-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
48.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
48.7
|
|
|
—
|
|
||||||||
Dividends paid on preferred stock
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4.5
|
)
|
|
—
|
|
|
—
|
|
|
(4.5
|
)
|
|
—
|
|
||||||||
Acquisitions and other transactions impacting noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.8
|
|
|
—
|
|
|
—
|
|
|
23.7
|
|
|
24.5
|
|
|
(0.5
|
)
|
||||||||
Distributions to noncontrolling interests, net of capital contributions
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(83.4
|
)
|
|
(83.4
|
)
|
|
(145.4
|
)
|
||||||||
Disposals and other transactions impacting noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(12.9
|
)
|
|
—
|
|
|
—
|
|
|
(20.6
|
)
|
|
(33.5
|
)
|
|
13.9
|
|
||||||||
Unrealized holding gain on investments, net of income tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4.0
|
)
|
|
—
|
|
|
(4.0
|
)
|
|
—
|
|
||||||||
Balance at December 31, 2017
|
121,021
|
|
|
$
|
1.2
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
6,008.9
|
|
|
$
|
521.2
|
|
|
$
|
(4.2
|
)
|
|
$
|
642.3
|
|
|
$
|
7,169.4
|
|
|
$
|
187.1
|
|
75
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Envision Healthcare Corporation
Consolidated Statements of Cash Flows
(In millions
)
|
|||||||||||
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
|||||
Net earnings (loss)
|
$
|
(26.0
|
)
|
|
$
|
205.5
|
|
|
$
|
381.2
|
|
Adjustments to reconcile net earnings (loss) to net cash flows provided by operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization
|
434.0
|
|
|
149.9
|
|
|
97.5
|
|
|||
Amortization of deferred loan costs
|
17.2
|
|
|
9.2
|
|
|
8.4
|
|
|||
Provision for uncollectibles
|
5,276.2
|
|
|
917.2
|
|
|
287.4
|
|
|||
Net (gain) loss on disposals and deconsolidations
|
2.4
|
|
|
(5.7
|
)
|
|
(36.7
|
)
|
|||
Share-based compensation
|
48.7
|
|
|
29.4
|
|
|
15.0
|
|
|||
Deferred income taxes
|
(481.4
|
)
|
|
(78.9
|
)
|
|
19.0
|
|
|||
Equity in earnings of unconsolidated affiliates
|
(22.7
|
)
|
|
(23.7
|
)
|
|
(16.2
|
)
|
|||
Debt extinguishment costs
|
—
|
|
|
30.3
|
|
|
—
|
|
|||
Impairment charges
|
500.3
|
|
|
221.3
|
|
|
—
|
|
|||
Net change in fair value of contingent consideration
|
0.1
|
|
|
(2.6
|
)
|
|
8.8
|
|
|||
Loss on assets held for sale
|
515.2
|
|
|
—
|
|
|
—
|
|
|||
Other, net
|
—
|
|
|
(3.9
|
)
|
|
(4.0
|
)
|
|||
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
|
|
|
|
|
|
||||||
Accounts receivable
|
(5,455.5
|
)
|
|
(1,003.0
|
)
|
|
(326.2
|
)
|
|||
Supplies inventory
|
1.0
|
|
|
(0.9
|
)
|
|
(0.3
|
)
|
|||
Prepaid and other current assets
|
(13.8
|
)
|
|
(42.3
|
)
|
|
25.9
|
|
|||
Accounts payable
|
(12.1
|
)
|
|
(1.6
|
)
|
|
3.1
|
|
|||
Accrued expenses and other liabilities
|
9.4
|
|
|
2.3
|
|
|
66.6
|
|
|||
Other, net
|
4.4
|
|
|
17.3
|
|
|
8.5
|
|
|||
Net cash flows provided by operating activities
|
797.4
|
|
|
419.8
|
|
|
538.0
|
|
|||
Cash flows from investing activities:
|
|
|
|
|
|
||||||
Acquisitions and related expenses, net of cash acquired
|
(757.8
|
)
|
|
(394.3
|
)
|
|
(962.7
|
)
|
|||
Acquisition of property and equipment
|
(208.9
|
)
|
|
(99.5
|
)
|
|
(60.3
|
)
|
|||
Increase in cash due to merger (see Notes 1 and 4)
|
—
|
|
|
165.8
|
|
|
—
|
|
|||
Increase in cash due to consolidation of previously unconsolidated affiliates
|
—
|
|
|
31.4
|
|
|
—
|
|
|||
Purchases of marketable securities
|
(24.5
|
)
|
|
(1.6
|
)
|
|
(3.9
|
)
|
|||
Maturities of marketable securities
|
15.0
|
|
|
3.8
|
|
|
4.2
|
|
|||
Other, net
|
(5.9
|
)
|
|
(9.3
|
)
|
|
5.9
|
|
|||
Net cash flows used in investing activities
|
(982.1
|
)
|
|
(303.7
|
)
|
|
(1,016.8
|
)
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
||||||
Proceeds from long-term borrowings
|
801.9
|
|
|
4,509.2
|
|
|
560.1
|
|
|||
Repayment on long-term borrowings
|
(341.7
|
)
|
|
(4,062.1
|
)
|
|
(392.6
|
)
|
|||
Distributions to noncontrolling interests
|
(229.8
|
)
|
|
(227.9
|
)
|
|
(214.9
|
)
|
|||
Proceeds from common stock offering
|
—
|
|
|
—
|
|
|
466.8
|
|
|||
Proceeds from issuance of common stock upon exercise of stock options
|
5.4
|
|
|
0.7
|
|
|
2.6
|
|
|||
Repurchase of common stock
|
(9.5
|
)
|
|
(6.1
|
)
|
|
(3.7
|
)
|
|||
Payments of equity issuance costs
|
—
|
|
|
—
|
|
|
(19.1
|
)
|
|||
Financing costs incurred
|
(3.5
|
)
|
|
(103.4
|
)
|
|
(1.1
|
)
|
|||
Other, net
|
(17.5
|
)
|
|
(1.6
|
)
|
|
(20.7
|
)
|
|||
Net cash flows provided by financing activities
|
205.3
|
|
|
108.8
|
|
|
377.4
|
|
|||
Net increase (decrease) in cash and cash equivalents
|
20.6
|
|
|
224.9
|
|
|
(101.4
|
)
|
|||
Cash and cash equivalents, beginning of period
|
331.6
|
|
|
106.7
|
|
|
208.1
|
|
|||
Less cash and cash equivalents of held for sale assets, end of period
|
40.0
|
|
|
14.7
|
|
|
—
|
|
|||
Cash and cash equivalents, end of period
|
$
|
312.2
|
|
|
$
|
316.9
|
|
|
$
|
106.7
|
|
76
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
77
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Supplemental cash flow information:
|
|
|
|
|
|
||||||
Interest payments
|
$
|
305.3
|
|
|
$
|
112.9
|
|
|
$
|
112.7
|
|
Income tax payments, net of refunds
|
$
|
24.5
|
|
|
$
|
98.6
|
|
|
$
|
74.6
|
|
78
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
•
|
ASU No. 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)”
|
•
|
ASU No. 2016-10 “Identifying Performance Obligations and Licensing”
|
•
|
ASU No. 2016-12 “Narrow-Scope Improvements and Practical Expedients”
|
•
|
ASU No. 2016-20 “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers”
|
•
|
ASU No. 2017-13 “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior Securities and Exchange Commission (SEC) Staff Announcements and Observer Comments (SEC Update)”
|
79
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
80
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
81
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
82
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Year Ended December 31,
|
|||||||||||||||||||
|
2017
|
|
2016
(1)
|
|
2015
|
|||||||||||||||
Medicare
|
$
|
1,902.1
|
|
|
24
|
%
|
|
$
|
747.6
|
|
|
22
|
%
|
|
$
|
508.6
|
|
|
20
|
%
|
Medicaid
|
657.1
|
|
|
8
|
|
|
187.1
|
|
|
5
|
|
|
96.1
|
|
|
4
|
|
|||
Commercial and managed care
|
5,057.1
|
|
|
65
|
|
|
2,526.1
|
|
|
73
|
|
|
1,881.2
|
|
|
73
|
|
|||
Self-pay
|
3,568.0
|
|
|
46
|
|
|
643.1
|
|
|
18
|
|
|
217.3
|
|
|
8
|
|
|||
Net fee for service revenue
|
11,184.3
|
|
|
143
|
|
|
4,103.9
|
|
|
118
|
|
|
2,703.2
|
|
|
105
|
|
|||
Contract and other revenue
|
993.2
|
|
|
13
|
|
|
218.5
|
|
|
6
|
|
|
129.8
|
|
|
5
|
|
|||
Provision for uncollectibles
|
(4,358.2
|
)
|
|
(56
|
)
|
|
(824.5
|
)
|
|
(24
|
)
|
|
(266.1
|
)
|
|
(10
|
)
|
|||
Net revenue
|
$
|
7,819.3
|
|
|
100
|
%
|
|
$
|
3,497.9
|
|
|
100
|
%
|
|
$
|
2,566.9
|
|
|
100
|
%
|
|
(1)
|
On December 1, 2016, the Company completed the Merger. Accordingly, historical amounts from EHH for periods prior to that date are not included.
|
83
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Balance at Beginning of Period
|
|
Charged to Cost and Expenses
|
|
Charge-off Against Allowances
|
|
Balance at End of Period
|
||||||||
Year ended December 31, 2017
|
$
|
584.0
|
|
|
$
|
4,383.4
|
|
|
$
|
(2,412.9
|
)
|
|
$
|
2,554.5
|
|
Year ended December 31, 2016
|
167.4
|
|
|
849.0
|
|
|
(432.4
|
)
|
|
584.0
|
|
||||
Year ended December 31, 2015
|
113.4
|
|
|
287.4
|
|
|
(233.4
|
)
|
|
167.4
|
|
84
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Acquired Operations
|
|
Location
|
|
Date Acquired
|
|
Specialty
|
Sunshine Radiology, LLC
|
|
Tampa Bay, FL
|
|
January 2017
|
|
Radiology
|
Emergency Professional Services
|
|
Phoenix, AZ
|
|
January 2017
|
|
Emergency
|
Hamilton Anesthesia Associates, PC
|
|
Trenton, NJ
|
|
February 2017
|
|
Anesthesia
|
Imaging Advantage, LLC
|
|
Phoenix, AZ
|
|
April 2017
|
|
Radiology
|
Gwinnett Emergency Specialists, PC
|
|
Lawrenceville, GA
|
|
May 2017
|
|
Emergency
|
Arizona Professional Corp
|
|
Phoenix, AZ
|
|
June 2017
|
|
Anesthesia
|
Anesthesia Associates of New London, PC
|
|
New London, CT
|
|
June 2017
|
|
Anesthesia
|
Northside Emergency Associates, PC
|
|
Atlanta, GA
|
|
June 2017
|
|
Emergency
|
Infinity Healthcare, Inc.
|
|
Milwaukee, WI
|
|
June 2017
|
|
Emergency
|
Cape Anesthesia & Pain Management Associates
|
|
Cape May Court, NJ
|
|
August 2017
|
|
Anesthesia
|
Meriden Wallingford Anesthesia Group, PC
|
|
Meriden, CT
|
|
November 2017
|
|
Anesthesia
|
Nova Anesthesia Professionals
|
|
Villanova, PA
|
|
December 2017
|
|
Anesthesia
|
Acquired Operations
|
|
Location
|
|
Date Acquired
|
|
Specialty
|
MidAtlantic Endoscopy, LLC (two locations)
|
|
Lancaster, PA
|
|
February 2017
|
|
Gastroenterology
|
Northeast Endoscopy Center, LLC
|
|
Lowell, MA
|
|
June 2017
|
|
Gastroenterology
|
Maryland Surgery Center for Women, LLC
|
|
Rockville, MD
|
|
June 2017
|
|
Multispecialty
|
85
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Cash and cash equivalents
|
$
|
165.8
|
|
Insurance collateral
|
59.9
|
|
|
Accounts receivable
|
1,153.2
|
|
|
Supplies inventory
|
38.7
|
|
|
Prepaid and other current assets
|
115.7
|
|
|
Property and equipment
|
375.9
|
|
|
Goodwill
|
4,624.1
|
|
|
Intangible assets
|
3,030.8
|
|
|
Other long-term assets
|
98.5
|
|
|
Accounts payable
|
(64.4
|
)
|
|
Accrued salaries and benefits
|
(338.0
|
)
|
|
Accrued interest
|
(17.3
|
)
|
|
Other accrued liabilities
|
(360.2
|
)
|
|
Deferred income taxes
|
(883.2
|
)
|
|
Long term insurance reserves
|
(318.1
|
)
|
|
Other long-term liabilities
|
(60.3
|
)
|
|
Long-term debt
|
(3,063.1
|
)
|
|
Total fair value
|
4,558.0
|
|
|
Less: Fair value attributable to noncontrolling interests
|
114.6
|
|
|
Acquisition date fair value of total consideration transferred
|
$
|
4,443.4
|
|
86
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
(1)
|
|
2016
|
||||
Accounts receivable
|
$
|
58.2
|
|
|
$
|
28.5
|
|
Supplies inventory
|
0.3
|
|
|
0.8
|
|
||
Prepaid and other current assets
|
5.8
|
|
|
1.8
|
|
||
Property and equipment
|
3.1
|
|
|
17.2
|
|
||
Goodwill
|
472.2
|
|
|
300.8
|
|
||
Intangible assets
|
271.8
|
|
|
136.8
|
|
||
Other long-term assets
|
1.0
|
|
|
3.6
|
|
||
Accounts payable
|
(8.4
|
)
|
|
(1.1
|
)
|
||
Accrued salaries and benefits
|
(23.9
|
)
|
|
(5.9
|
)
|
||
Other accrued liabilities
|
(39.3
|
)
|
|
(5.5
|
)
|
||
Deferred income taxes
|
(37.4
|
)
|
|
(27.6
|
)
|
||
Other long-term liabilities
|
(40.8
|
)
|
|
(4.2
|
)
|
||
Long-term debt
|
(0.5
|
)
|
|
(12.6
|
)
|
||
Total fair value
|
662.1
|
|
|
432.6
|
|
||
Less: Fair value attributable to noncontrolling interests
|
30.8
|
|
|
26.9
|
|
||
Acquisition date fair value of total consideration transferred
|
$
|
631.3
|
|
|
$
|
405.7
|
|
|
(1)
|
Represents the preliminary allocation of fair value of acquired assets and liabilities associated with acquisitions completed during
December 31, 2017
, including subsequent post acquisition date adjustments.
|
87
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Year Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
Net revenue
|
$
|
363.6
|
|
|
$
|
104.0
|
|
|
|
|
|
||||
Net earnings
|
13.9
|
|
|
12.3
|
|
||
Less: Net earnings attributable to noncontrolling interests
|
2.9
|
|
|
2.2
|
|
||
Net earnings attributable to Envision Healthcare Corporation stockholders
|
$
|
11.0
|
|
|
$
|
10.1
|
|
|
Year Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
Net revenue
|
$
|
8,032.8
|
|
|
$
|
7,788.5
|
|
Net earnings from continuing operations attributable to Envision Healthcare Corporation stockholders
|
286.9
|
|
|
233.3
|
|
88
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
December 31,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
40.0
|
|
|
$
|
14.7
|
|
Insurance collateral
(1)
|
1.3
|
|
|
—
|
|
||
Accounts receivable, net
|
479.9
|
|
|
457.2
|
|
||
Supplies inventory
|
36.3
|
|
|
37.8
|
|
||
Prepaid and other current assets
|
31.7
|
|
|
41.4
|
|
||
Property and equipment, net
|
310.2
|
|
|
294.4
|
|
||
Investments in unconsolidated affiliates
|
0.4
|
|
|
2.2
|
|
||
Goodwill
|
930.0
|
|
|
1,235.0
|
|
||
Intangible assets, net
|
899.0
|
|
|
929.4
|
|
||
Other assets
|
23.1
|
|
|
27.4
|
|
||
Total assets held for sale
|
$
|
2,751.9
|
|
|
$
|
3,039.5
|
|
Liabilities
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Current portion of long-term debt
|
$
|
0.1
|
|
|
$
|
0.4
|
|
Accounts payable
|
27.4
|
|
|
31.4
|
|
||
Accrued salaries and benefits
|
67.0
|
|
|
77.4
|
|
||
Other accrued liabilities
|
177.2
|
|
|
140.2
|
|
||
Long-term debt
|
1.3
|
|
|
1.4
|
|
||
Deferred income taxes
(2)
|
—
|
|
|
337.0
|
|
||
Insurance reserves
|
94.3
|
|
|
91.6
|
|
||
Other long-term liabilities
|
31.8
|
|
|
38.6
|
|
||
Total liabilities held for sale
|
$
|
399.1
|
|
|
$
|
718.0
|
|
|
(1)
|
Insurance collateral for claims related to the medical transportation business are generally held within a captive insurance company. Such balances are available to settle the insurance claims of the medical transportation business but are not recorded into assets held for sale as the captive insurance company is a subsidiary of the Company, not the medical transportation business.
|
(2)
|
Substantially all of the deferred income taxes were transferred from discontinued operations to continuing operations as a result of the expected tax structure of the transaction discussed above.
|
89
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Year Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
Net revenues
|
$
|
2,523.0
|
|
|
$
|
198.1
|
|
Operating expenses:
|
|
|
|
||||
Salaries and benefits
|
1,380.8
|
|
|
114.7
|
|
||
Supply cost
|
57.5
|
|
|
4.8
|
|
||
Insurance expense
|
82.3
|
|
|
6.7
|
|
||
Other operating expenses
|
687.7
|
|
|
49.5
|
|
||
Transaction and integration costs
|
26.8
|
|
|
3.7
|
|
||
Loss on assets held for sale
|
515.2
|
|
|
—
|
|
||
Depreciation and amortization
|
145.0
|
|
|
12.3
|
|
||
Total operating expenses
|
2,895.3
|
|
|
191.7
|
|
||
Equity in earnings of unconsolidated affiliates
|
0.5
|
|
|
—
|
|
||
Operating income (loss)
|
(371.8
|
)
|
|
6.4
|
|
||
Interest expense, net
|
89.4
|
|
|
—
|
|
||
Earnings (loss) before income taxes
|
$
|
(461.2
|
)
|
|
$
|
6.4
|
|
|
|
|
|
||||
Results of discontinued operations:
|
|
|
|
||||
Earnings (loss) from discontinued operations
|
$
|
(461.2
|
)
|
|
$
|
6.4
|
|
Income tax expense of discontinued operations
|
(30.7
|
)
|
|
(2.4
|
)
|
||
Net earnings (loss) from discontinued operations
|
$
|
(491.9
|
)
|
|
$
|
4.0
|
|
90
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
U.S. Treasuries
|
$
|
1.8
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1.8
|
|
Corporate bonds/Fixed income
|
10.4
|
|
|
30.8
|
|
|
—
|
|
|
41.2
|
|
||||
Corporate equity
|
12.4
|
|
|
—
|
|
|
—
|
|
|
12.4
|
|
||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Contingent consideration
|
—
|
|
|
—
|
|
|
8.0
|
|
|
8.0
|
|
|
2016
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
U.S. Treasuries
|
$
|
0.4
|
|
|
$
|
0.6
|
|
|
$
|
—
|
|
|
$
|
1.0
|
|
Corporate bonds/Fixed income
|
22.8
|
|
|
5.5
|
|
|
—
|
|
|
28.3
|
|
||||
Corporate equity
|
14.2
|
|
|
—
|
|
|
—
|
|
|
14.2
|
|
||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Contingent consideration
|
—
|
|
|
—
|
|
|
1.0
|
|
|
1.0
|
|
Balance at December 31, 2016
|
$
|
1.0
|
|
Increase due to current period acquisitions
|
7.1
|
|
|
Net change in fair value
|
(0.1
|
)
|
|
Balance at December 31, 2017
|
$
|
8.0
|
|
91
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Available-for-sale securities:
|
|
|
|
||||
U.S. Treasuries
|
$
|
1.8
|
|
|
$
|
1.0
|
|
Corporate bonds/Fixed income
|
41.2
|
|
|
28.3
|
|
||
Corporate equity
|
12.4
|
|
|
14.2
|
|
||
Total available-for-sale securities
|
55.4
|
|
|
43.5
|
|
||
Cash deposits and other
|
30.8
|
|
|
43.5
|
|
||
Insurance Collateral
|
$
|
86.2
|
|
|
$
|
87.0
|
|
|
December 31, 2017
|
||||||||||||||
|
|
|
Gross
|
|
Gross
|
|
|
||||||||
|
Cost
|
|
Unrealized
|
|
Unrealized
|
|
Fair
|
||||||||
|
Basis
|
|
Gains
|
|
Losses
|
|
Value
|
||||||||
Description:
|
|
|
|
|
|
|
|
||||||||
U.S. Treasuries
|
$
|
1.8
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1.8
|
|
Corporate bonds/Fixed income
|
40.7
|
|
|
0.7
|
|
|
(0.2
|
)
|
|
41.2
|
|
||||
Corporate equity
|
10.5
|
|
|
1.9
|
|
|
—
|
|
|
12.4
|
|
||||
Total available-for-sale securities
|
$
|
53.0
|
|
|
$
|
2.6
|
|
|
$
|
(0.2
|
)
|
|
$
|
55.4
|
|
|
December 31, 2016
|
||||||||||||||
|
|
|
Gross
|
|
Gross
|
|
|
||||||||
|
Cost
|
|
Unrealized
|
|
Unrealized
|
|
Fair
|
||||||||
|
Basis
|
|
Gains
|
|
Losses
|
|
Value
|
||||||||
Description:
|
|
|
|
|
|
|
|
||||||||
U.S. Treasuries
|
$
|
1.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1.0
|
|
Corporate bonds/Fixed income
|
28.3
|
|
|
—
|
|
|
—
|
|
|
28.3
|
|
||||
Corporate equity
|
14.4
|
|
|
0.1
|
|
|
(0.3
|
)
|
|
14.2
|
|
||||
Total available-for-sale securities
|
$
|
43.7
|
|
|
$
|
0.1
|
|
|
$
|
(0.3
|
)
|
|
$
|
43.5
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||
|
Fair
|
|
Unrealized
|
|
Fair
|
|
Unrealized
|
||||||||
|
Value
|
|
Losses
|
|
Value
|
|
Losses
|
||||||||
Description:
|
|
|
|
|
|
|
|
||||||||
Corporate bonds/Fixed income
|
$
|
16.0
|
|
|
$
|
(0.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
Corporate equity
|
—
|
|
|
—
|
|
|
7.6
|
|
|
(0.3
|
)
|
||||
|
$
|
16.0
|
|
|
$
|
(0.2
|
)
|
|
$
|
7.6
|
|
|
$
|
(0.3
|
)
|
92
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Income taxes receivable
|
$
|
74.3
|
|
|
$
|
60.4
|
|
Prepaid expenses
|
59.9
|
|
|
38.6
|
|
||
Other
|
31.4
|
|
|
36.1
|
|
||
Total prepaid and other current assets
|
$
|
165.6
|
|
|
$
|
135.1
|
|
Property Type
|
|
Estimated lives
|
Building and building improvements
|
|
20 to 40 years
|
Leasehold improvements
|
|
Shorter of useful life or lease term
(1)
|
Medical equipment and other
|
|
5 to 10 years
|
Vehicles
|
|
5 to 7 years
|
Computer hardware
|
|
3 to 5 years
|
|
(1)
|
Lease term is defined as the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Leases in which the Company includes the renewal options due to the perceived penalty primarily related to surgery centers in the Company's ambulatory services segment.
|
93
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Land
|
$
|
0.2
|
|
|
$
|
0.3
|
|
Building and leasehold improvements
|
243.1
|
|
|
234.7
|
|
||
Medical equipment and other
|
255.2
|
|
|
249.4
|
|
||
Vehicles
|
14.5
|
|
|
14.2
|
|
||
Computer hardware
|
71.5
|
|
|
60.9
|
|
||
Construction in progress
|
26.2
|
|
|
8.5
|
|
||
Property and equipment
|
610.7
|
|
|
568.0
|
|
||
Less accumulated depreciation
|
(308.0
|
)
|
|
(267.2
|
)
|
||
Property and equipment, net
|
$
|
302.7
|
|
|
$
|
300.8
|
|
94
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
95
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Physician Services
|
|
Ambulatory Services
|
|
Total
|
||||||
Balance at January 1, 2016
|
$
|
1,956.7
|
|
|
$
|
2,013.5
|
|
|
$
|
3,970.2
|
|
Goodwill acquired, including post acquisition adjustments
|
3,553.0
|
|
|
63.9
|
|
|
3,616.9
|
|
|||
Goodwill disposed, including impact of deconsolidation transactions
|
—
|
|
|
(3.1
|
)
|
|
(3.1
|
)
|
|||
Balance at December 31, 2016
|
$
|
5,509.7
|
|
|
$
|
2,074.3
|
|
|
$
|
7,584.0
|
|
Goodwill acquired, including post acquisition adjustments
|
400.9
|
|
|
75.3
|
|
|
476.2
|
|
|||
Goodwill disposed, including impact of deconsolidation transactions
|
—
|
|
|
(24.1
|
)
|
|
(24.1
|
)
|
|||
Goodwill impairment charges
|
(500.0
|
)
|
|
—
|
|
|
(500.0
|
)
|
|||
Balance at December 31, 2017
|
$
|
5,410.6
|
|
|
$
|
2,125.5
|
|
|
$
|
7,536.1
|
|
Amortizable Intangible Assets
|
|
Estimated Economic Useful Life
|
|
Weighted Average Amortization Period
|
Customer relationships
|
|
17 to 20 years
|
|
18.2
|
Capitalized software
|
|
3 to 7 years
|
|
4.5
|
Agreements, contracts and other
|
|
3 to 10 years
|
|
3.4
|
|
2017
|
|
2016
|
||||||||||||||||||||
|
Gross
|
|
|
|
|
|
Gross
|
|
|
|
|
||||||||||||
|
Carrying
|
|
Accumulated
|
|
|
|
Carrying
|
|
Accumulated
|
|
|
||||||||||||
|
Amount
|
|
Amortization
|
|
Net
|
|
Amount
|
|
Amortization
|
|
Net
|
||||||||||||
Amortizable intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Customer relationships with hospitals
|
$
|
3,446.7
|
|
|
$
|
(321.8
|
)
|
|
$
|
3,124.9
|
|
|
$
|
3,235.0
|
|
|
$
|
(154.6
|
)
|
|
$
|
3,080.4
|
|
Capitalized software
|
166.9
|
|
|
(73.3
|
)
|
|
93.6
|
|
|
136.5
|
|
|
(41.8
|
)
|
|
94.7
|
|
||||||
Trade names
|
25.0
|
|
|
(25.0
|
)
|
|
—
|
|
|
25.0
|
|
|
(2.1
|
)
|
|
22.9
|
|
||||||
Agreements, contracts and other
|
13.5
|
|
|
(4.9
|
)
|
|
8.6
|
|
|
13.2
|
|
|
(4.7
|
)
|
|
8.5
|
|
||||||
Total amortizable intangible assets
|
3,652.1
|
|
|
(425.0
|
)
|
|
3,227.1
|
|
|
3,409.7
|
|
|
(203.2
|
)
|
|
3,206.5
|
|
||||||
Non-amortizable intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Trade names
|
430.0
|
|
|
—
|
|
|
430.0
|
|
|
460.0
|
|
|
—
|
|
|
460.0
|
|
||||||
Restrictive covenant arrangements
|
8.4
|
|
|
—
|
|
|
8.4
|
|
|
9.0
|
|
|
—
|
|
|
9.0
|
|
||||||
Total non-amortizable intangible assets
|
438.4
|
|
|
—
|
|
|
438.4
|
|
|
469.0
|
|
|
—
|
|
|
469.0
|
|
||||||
Total intangible assets
|
$
|
4,090.5
|
|
|
$
|
(425.0
|
)
|
|
$
|
3,665.5
|
|
|
$
|
3,878.7
|
|
|
$
|
(203.2
|
)
|
|
$
|
3,675.5
|
|
96
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Deferred compensation fund
|
$
|
59.4
|
|
|
$
|
37.1
|
|
Insurance receivable
|
86.8
|
|
|
82.7
|
|
||
Other
|
21.1
|
|
|
14.4
|
|
||
Total other assets
|
$
|
167.3
|
|
|
$
|
134.2
|
|
|
2017
|
|
2016
|
||||
Insurance reserves
|
$
|
77.1
|
|
|
$
|
78.2
|
|
Deferred revenue
|
18.9
|
|
|
9.4
|
|
||
Refunds payable
|
28.9
|
|
|
33.6
|
|
||
Other
|
156.7
|
|
|
132.0
|
|
||
Total other accrued liabilities
|
$
|
281.6
|
|
|
$
|
253.2
|
|
|
2017
|
|
2016
|
||||
ABL Facility
|
$
|
—
|
|
|
$
|
—
|
|
Term Loan B - 2023
|
3,956.3
|
|
|
3,495.0
|
|
||
Senior Unsecured Notes due 2022 (5.625%)
|
1,100.0
|
|
|
1,100.0
|
|
||
Senior Unsecured Notes due 2022 (5.125%)
|
750.0
|
|
|
750.0
|
|
||
Senior Unsecured Notes due 2024 (6.250%)
|
550.0
|
|
|
550.0
|
|
||
Other debt due through 2025
|
24.1
|
|
|
20.9
|
|
||
Capitalized lease arrangements due through 2031
|
32.3
|
|
|
31.9
|
|
||
|
6,412.7
|
|
|
5,947.8
|
|
||
Less current portion
|
52.1
|
|
|
46.6
|
|
||
Less net deferred financing costs
|
97.3
|
|
|
111.0
|
|
||
Long-term debt
|
$
|
6,263.3
|
|
|
$
|
5,790.2
|
|
97
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
a.
|
Term Loan B - 2023
|
b.
|
ABL Facility
|
98
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
c.
|
Senior Unsecured Notes
|
Period
|
|
Redemption Price
|
|
2017
|
|
104.219
|
%
|
2018
|
|
102.813
|
%
|
2019
|
|
101.406
|
%
|
2020 and thereafter
|
|
100.000
|
%
|
99
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
Period
|
|
Redemption Price
|
|
2017
|
|
103.884
|
%
|
2018
|
|
102.563
|
%
|
2019
|
|
101.281
|
%
|
2020 and thereafter
|
|
100.000
|
%
|
Period
|
|
Redemption Price
|
|
2019
|
|
104.688
|
%
|
2020
|
|
103.125
|
%
|
2021
|
|
101.563
|
%
|
2022 and thereafter
|
|
100.000
|
%
|
100
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
d.
|
Other debt
|
e.
|
Certain Limitations on Restricted Payments
|
101
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Earnings (loss) from continuing operations
|
$
|
(496.8
|
)
|
|
$
|
(3.3
|
)
|
|
$
|
113.8
|
|
Net loss from discontinued operations
|
30.7
|
|
|
2.4
|
|
|
(0.7
|
)
|
|||
Stockholders’ equity
|
—
|
|
|
(2.1
|
)
|
|
(2.2
|
)
|
|||
Total
|
$
|
(466.1
|
)
|
|
$
|
(3.0
|
)
|
|
$
|
110.9
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Current:
|
|
|
|
|
|
||||||
Federal
|
$
|
2.4
|
|
|
$
|
62.9
|
|
|
$
|
83.2
|
|
State
|
0.5
|
|
|
10.5
|
|
|
14.3
|
|
|||
Deferred:
|
|
|
|
|
|
||||||
Federal
|
(543.9
|
)
|
|
(66.7
|
)
|
|
11.7
|
|
|||
State
|
44.2
|
|
|
(10.0
|
)
|
|
4.6
|
|
|||
Income tax expense (benefit)
|
$
|
(496.8
|
)
|
|
$
|
(3.3
|
)
|
|
$
|
113.8
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Statutory federal income tax
|
$
|
(10.8
|
)
|
|
$
|
69.4
|
|
|
$
|
173.6
|
|
Less federal income tax assumed directly by noncontrolling interests
|
(70.7
|
)
|
|
(78.4
|
)
|
|
(76.4
|
)
|
|||
State income taxes, net of federal income tax benefit
|
17.1
|
|
|
1.0
|
|
|
11.6
|
|
|||
Increase (decrease) in valuation allowances
|
—
|
|
|
(11.0
|
)
|
|
0.3
|
|
|||
Transaction-related items
|
0.5
|
|
|
13.5
|
|
|
1.1
|
|
|||
Impairment of goodwill
|
147.7
|
|
|
—
|
|
|
—
|
|
|||
U.S. Tax Reform - corporate rate reduction
|
(596.6
|
)
|
|
—
|
|
|
—
|
|
|||
Interest related to unrecognized tax benefits
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
|||
Other
|
16.0
|
|
|
2.2
|
|
|
4.1
|
|
|||
Income tax expense (benefit)
|
$
|
(496.8
|
)
|
|
$
|
(3.3
|
)
|
|
$
|
113.8
|
|
102
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Balance at beginning of year
|
$
|
4.4
|
|
|
$
|
3.4
|
|
|
$
|
7.3
|
|
Additions for current year acquisitions
|
—
|
|
|
14.9
|
|
|
—
|
|
|||
Additions for tax positions of current year
|
0.1
|
|
|
—
|
|
|
—
|
|
|||
Decreases for amounts classified as held for sale
|
—
|
|
|
(12.8
|
)
|
|
—
|
|
|||
Increases (decreases) for tax positions taken during a prior period
|
—
|
|
|
—
|
|
|
(1.0
|
)
|
|||
Lapse of statute of limitations
|
(2.1
|
)
|
|
(1.1
|
)
|
|
(2.9
|
)
|
|||
Balance at end of year
|
$
|
2.4
|
|
|
$
|
4.4
|
|
|
$
|
3.4
|
|
|
2017
|
|
2016
|
||||
Deferred tax assets:
|
|
|
|
|
|||
Allowance for uncollectible accounts
|
$
|
21.4
|
|
|
$
|
9.5
|
|
Share-based compensation
|
51.8
|
|
|
86.4
|
|
||
Deferred compensation
|
25.1
|
|
|
45.1
|
|
||
Accrued liabilities and other
|
34.8
|
|
|
50.1
|
|
||
Medical malpractice
|
47.4
|
|
|
50.2
|
|
||
Operating and capital loss carryforwards
|
84.0
|
|
|
48.2
|
|
||
Valuation allowances
|
(30.5
|
)
|
|
(11.8
|
)
|
||
Total deferred tax assets
|
234.0
|
|
|
277.7
|
|
||
Deferred tax liabilities:
|
|
|
|
||||
Prepaid expenses and other
|
7.7
|
|
|
2.6
|
|
||
Accrual to cash
|
130.7
|
|
|
172.8
|
|
||
Property and equipment
|
79.3
|
|
|
49.0
|
|
||
Outside basis difference in stock
|
9.4
|
|
|
—
|
|
||
Intangible assets
|
1,096.2
|
|
|
1,397.0
|
|
||
Total deferred tax liabilities
|
1,323.3
|
|
|
1,621.4
|
|
||
Net deferred tax liabilities
|
$
|
1,089.3
|
|
|
$
|
1,343.7
|
|
103
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Third-party insurance reserves
|
$
|
111.3
|
|
|
$
|
92.8
|
|
Estimated losses under self-insured programs
|
170.3
|
|
|
170.0
|
|
||
Incurred but not reported losses
|
114.0
|
|
|
94.3
|
|
||
Total accrued insurance reserves
|
395.6
|
|
|
357.1
|
|
||
Less estimated losses payable within one year
|
77.1
|
|
|
78.2
|
|
||
Total
|
$
|
318.5
|
|
|
$
|
278.9
|
|
|
2017
|
|
2016
|
||||
Balance, beginning of year
|
$
|
357.1
|
|
|
$
|
82.2
|
|
Assumed liabilities through acquisitions
|
31.5
|
|
|
255.5
|
|
||
Provision related to current period self-insurance reserves
(1)
|
71.4
|
|
|
25.4
|
|
||
Payments for current period self-insurance reserves
|
(2.2
|
)
|
|
(1.5
|
)
|
||
Benefit related to changes in prior period self-insurance reserves
|
(5.6
|
)
|
|
(0.9
|
)
|
||
Payments for prior period self-insurance reserves
|
(69.5
|
)
|
|
(13.4
|
)
|
||
Change in third-party insurance reserves
|
10.8
|
|
|
12.6
|
|
||
Other, net
|
2.1
|
|
|
(2.8
|
)
|
||
Balance, end of year
|
$
|
395.6
|
|
|
$
|
357.1
|
|
|
(1)
|
Total insurance expense for the years ended
December 31, 2017
and
2016
were
$144.2 million
and
$45.5 million
, respectively,which also included premiums paid to third-party insurers and premiums paid to captive insurance companies of certain of our joint venture partners.
|
104
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||
Deferred rent
|
$
|
36.8
|
|
|
$
|
33.7
|
|
Tax-effected unrecognized benefits
|
2.4
|
|
|
4.4
|
|
||
Deferred compensation liabilities
|
58.0
|
|
|
36.0
|
|
||
Other
|
52.7
|
|
|
28.3
|
|
||
Other long-term liabilities
|
$
|
149.9
|
|
|
$
|
102.4
|
|
Year Ended December 31,
|
|
Capital Leases
|
|
Operating Leases
|
||||
2018
|
|
$
|
5.4
|
|
|
$
|
96.3
|
|
2019
|
|
5.6
|
|
|
85.1
|
|
||
2020
|
|
4.2
|
|
|
82.8
|
|
||
2021
|
|
3.4
|
|
|
79.9
|
|
||
2022
|
|
2.9
|
|
|
77.8
|
|
||
Thereafter
|
|
26.3
|
|
|
410.1
|
|
||
Total minimum rentals
|
|
47.8
|
|
|
$
|
832.0
|
|
|
Less amounts representing interest at an average interest rate of 6.1%
|
|
15.5
|
|
|
|
|||
Capital lease obligations
|
|
$
|
32.3
|
|
|
|
|
105
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
106
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
107
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
a.
|
Common Stock
|
b.
|
Preferred Stock
|
c.
|
Stock Incentive Plans
|
108
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
109
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
|
|
|
|
Weighted
|
|||
|
|
|
Weighted
|
|
Average
|
|||
|
|
|
Average
|
|
Remaining
|
|||
|
Number
|
|
Exercise
|
|
Contractual
|
|||
|
of Shares
|
|
Price
|
|
Term (in years)
|
|||
Outstanding at January 1, 2015
|
158,721
|
|
|
$
|
22.89
|
|
|
1.7
|
Options exercised with total intrinsic value of $4.9 million
|
(113,220
|
)
|
|
22.81
|
|
|
|
|
Options canceled
|
(11,750
|
)
|
|
23.42
|
|
|
|
|
Outstanding at December 31, 2015
|
33,751
|
|
|
$
|
22.98
|
|
|
1.1
|
Options converted at Merger date
|
3,525,027
|
|
|
20.80
|
|
|
5.2
|
|
Options exercised with total intrinsic value of $1.6 million
|
(40,408
|
)
|
|
18.39
|
|
|
|
|
Options terminated
|
(7,256
|
)
|
|
27.49
|
|
|
|
|
Outstanding at December 31, 2016
|
3,511,114
|
|
|
$
|
20.81
|
|
|
5.1
|
Options granted
|
239
|
|
|
55.98
|
|
|
|
|
Options exercised with total intrinsic value of $21.2 million
|
(523,181
|
)
|
|
12.75
|
|
|
|
|
Options canceled
|
(162,151
|
)
|
|
66.24
|
|
|
|
|
Outstanding at December 31, 2017 with an aggregate intrinsic value of $56.4 million
|
2,826,021
|
|
|
$
|
19.70
|
|
|
4.3
|
Vested and Exercisable at December 31, 2017 with an aggregate intrinsic value of $56.4 million
|
2,597,344
|
|
|
$
|
15.41
|
|
|
3.9
|
Volatility
|
|
31.9%
|
Risk free rate
|
|
0.82% - 1.90%
|
Expected term of options in years
|
|
1.0 - 5.0
|
Expected dividend yield
|
|
0%
|
|
2017
|
|
2016
|
|
2015
|
||||||
Share-based compensation expense from continuing operations
|
$
|
40.9
|
|
|
$
|
28.6
|
|
|
$
|
15.0
|
|
Fair value of shares vested
|
33.1
|
|
|
20.7
|
|
|
13.2
|
|
|||
Cash received from option exercises
|
5.4
|
|
|
0.7
|
|
|
2.6
|
|
|||
Tax expense (benefit) from share based awards
|
2.0
|
|
|
(3.9
|
)
|
|
(4.0
|
)
|
110
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
d.
|
Earnings per Share
|
|
Earnings (Loss)
|
|
Shares
(in thousands)
|
|
Per Share
|
|||||
|
(Numerator)
|
|
(Denominator)
|
|
Amount
|
|||||
For the year ended December 31, 2017:
|
|
|
|
|
|
|
|
|||
Net earnings from continuing operations attributable to Envision Healthcare Corporation common shareholders (basic)
|
$
|
259.4
|
|
|
118,397
|
|
|
$
|
2.19
|
|
Effect of dilutive securities, options and non-vested shares
|
|
|
2,546
|
|
|
|
||||
Net earnings from continuing operations attributable to Envision Healthcare Corporation common stockholders (diluted)
|
$
|
259.4
|
|
|
120,943
|
|
|
$
|
2.14
|
|
|
|
|
|
|
|
|||||
For the year ended December 31, 2016:
|
|
|
|
|
|
|
|
|||
Net earnings from continuing operations attributable to Envision Healthcare Corporation common stockholders (basic and diluted)
|
$
|
(31.7
|
)
|
|
59,002
|
|
|
$
|
(0.54
|
)
|
|
|
|
|
|
|
|||||
For the year ended December 31, 2015:
|
|
|
|
|
|
|
|
|||
Net earnings from continuing operations attributable to Envision Healthcare Corporation common stockholders (basic)
|
$
|
154.9
|
|
|
48,058
|
|
|
$
|
3.22
|
|
Preferred stock dividends
|
9.1
|
|
|
|
|
|
||||
Effect of dilutive securities, options and non-vested shares
|
|
|
3,554
|
|
|
|
||||
Net earnings from continuing operations attributable to Envision Healthcare Corporation common stockholders (diluted)
|
$
|
164.0
|
|
|
51,612
|
|
|
$
|
3.18
|
|
111
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
Year ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Net Revenue:
|
|
|
|
|
|
||||||
Physician Services
(1)
|
$
|
6,542.4
|
|
|
$
|
2,229.7
|
|
|
$
|
1,336.8
|
|
Ambulatory Services
|
1,276.9
|
|
|
1,268.2
|
|
|
1,230.1
|
|
|||
Total
|
$
|
7,819.3
|
|
|
$
|
3,497.9
|
|
|
$
|
2,566.9
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA:
|
|
|
|
|
|
||||||
Physician Services
(1) (2)
|
$
|
655.5
|
|
|
$
|
366.3
|
|
|
$
|
266.2
|
|
Ambulatory Services
(2)
|
253.5
|
|
|
240.1
|
|
|
226.1
|
|
|||
Total
|
$
|
909.0
|
|
|
$
|
606.4
|
|
|
$
|
492.3
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA:
|
$
|
909.0
|
|
|
$
|
606.4
|
|
|
$
|
492.3
|
|
Net earnings attributable to noncontrolling interests
|
202.0
|
|
|
224.1
|
|
|
218.2
|
|
|||
Interest expense, net
|
(231.1
|
)
|
|
(142.4
|
)
|
|
(121.5
|
)
|
|||
Depreciation and amortization
|
(288.9
|
)
|
|
(137.6
|
)
|
|
(97.5
|
)
|
|||
Share-based compensation
|
(40.9
|
)
|
|
(28.6
|
)
|
|
(15.0
|
)
|
|||
Net change in fair value of contingent consideration
|
(0.1
|
)
|
|
2.6
|
|
|
(8.8
|
)
|
|||
Transaction and integration costs
|
(88.7
|
)
|
|
(76.3
|
)
|
|
(8.4
|
)
|
|||
Debt extinguishment costs
|
—
|
|
|
(30.3
|
)
|
|
—
|
|
|||
Impairment charges
|
(500.3
|
)
|
|
(221.3
|
)
|
|
—
|
|
|||
Net gain (loss) on disposals and deconsolidations, net of noncontrolling interests
|
9.7
|
|
|
5.7
|
|
|
36.7
|
|
|||
Net change in deferred taxes due to tax reform attributable to noncontrolling interests
|
(1.6
|
)
|
|
—
|
|
|
—
|
|
|||
Purchase accounting adjustments
|
—
|
|
|
(4.1
|
)
|
|
—
|
|
|||
Earnings (loss) from continuing operations before income taxes
|
$
|
(30.9
|
)
|
|
$
|
198.2
|
|
|
$
|
496.0
|
|
|
|
|
|
|
|
||||||
Acquisition and Capital Expenditures:
|
|
|
|
|
|
||||||
Physician Services
(1)
|
$
|
664.9
|
|
|
$
|
406.4
|
|
|
$
|
854.4
|
|
Ambulatory Services
|
81.8
|
|
|
77.4
|
|
|
168.6
|
|
|||
Total
|
$
|
746.7
|
|
|
$
|
483.8
|
|
|
$
|
1,023.0
|
|
|
2017
|
|
2016
|
||||
Assets:
|
|
|
|
||||
Physician Services
|
$
|
10,975.6
|
|
|
$
|
10,978.5
|
|
Ambulatory Services
|
2,845.2
|
|
|
2,690.9
|
|
||
Assets held for sale
|
2,751.8
|
|
|
3,039.5
|
|
||
Total
|
$
|
16,572.6
|
|
|
$
|
16,708.9
|
|
|
(1)
|
On December 1, 2016, the Company completed the Merger. Accordingly, historical amounts from EHH for periods prior to that date are not included.
|
(2)
|
For the year ended December 31, 2017 and on a before tax basis, approximately
$58.1 million
of general corporate expenses, including allocations for corporate salaries and stock based compensation, general and administrative costs and depreciation, were removed from the medical transportation business and reallocated to the Company's remaining segments. This removal of corporate expenses resulted in a reduction of Adjusted EBITDA in the physician services and ambulatory services segments of
$26.3 million
and
$7.8 million
, respectively, for the year ended December 31, 2017.
|
112
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
113
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
114
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
115
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
116
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
117
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
118
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
119
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
120
|
Item 8. Financial Statements and Supplementary Data - (continued)
|
|
2017
|
|
2016
|
||||||||||||||||||||||||||||
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
(1)
|
||||||||||||||||
|
(In millions, except per share data)
|
||||||||||||||||||||||||||||||
Net revenues
|
$
|
1,878.6
|
|
|
$
|
1,947.0
|
|
|
$
|
1,990.7
|
|
|
$
|
2,003.0
|
|
|
$
|
724.7
|
|
|
$
|
758.5
|
|
|
$
|
822.2
|
|
|
$
|
1,192.5
|
|
Earnings (loss) from continuing operations before income taxes
|
104.6
|
|
|
139.6
|
|
|
118.5
|
|
|
(393.6
|
)
|
|
105.5
|
|
|
136.5
|
|
|
125.2
|
|
|
(169.0
|
)
|
||||||||
Net earnings (loss) from continuing operations
|
87.1
|
|
|
104.0
|
|
|
91.4
|
|
|
183.4
|
|
|
84.7
|
|
|
103.1
|
|
|
95.6
|
|
|
(81.9
|
)
|
||||||||
Net earnings (loss) from discontinued operations
|
(478.2
|
)
|
|
3.9
|
|
|
(12.4
|
)
|
|
(5.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
||||||||
Net earnings (loss)
|
(391.1
|
)
|
|
107.9
|
|
|
79.0
|
|
|
178.2
|
|
|
84.7
|
|
|
103.1
|
|
|
95.6
|
|
|
(77.9
|
)
|
||||||||
Net earnings (loss) attributable to Envision Healthcare Corporation common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Continuing
|
30.7
|
|
|
50.2
|
|
|
40.7
|
|
|
137.8
|
|
|
28.6
|
|
|
43.8
|
|
|
37.7
|
|
|
(141.8
|
)
|
||||||||
Discontinued
|
(478.2
|
)
|
|
3.9
|
|
|
(12.4
|
)
|
|
(5.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
||||||||
Net earnings (loss)
|
$
|
(447.5
|
)
|
|
$
|
54.1
|
|
|
$
|
28.3
|
|
|
$
|
132.6
|
|
|
$
|
28.6
|
|
|
$
|
43.8
|
|
|
$
|
37.7
|
|
|
$
|
(137.8
|
)
|
Basic net earnings (loss) from
continuing operations per share
|
$
|
0.26
|
|
|
$
|
0.43
|
|
|
$
|
0.34
|
|
|
$
|
1.15
|
|
|
$
|
0.53
|
|
|
$
|
0.82
|
|
|
$
|
0.70
|
|
|
$
|
(1.90
|
)
|
Basic net earnings (loss) per share
|
$
|
(3.84
|
)
|
|
$
|
0.46
|
|
|
$
|
0.24
|
|
|
$
|
1.10
|
|
|
$
|
0.53
|
|
|
$
|
0.82
|
|
|
$
|
0.70
|
|
|
$
|
(1.84
|
)
|
Diluted net earnings (loss) from continuing operations per share
|
$
|
0.26
|
|
|
$
|
0.42
|
|
|
$
|
0.33
|
|
|
$
|
1.13
|
|
|
$
|
0.53
|
|
|
$
|
0.80
|
|
|
$
|
0.69
|
|
|
$
|
(1.90
|
)
|
Diluted net earnings (loss) per share
|
$
|
(3.84
|
)
|
|
$
|
0.45
|
|
|
$
|
0.23
|
|
|
$
|
1.08
|
|
|
$
|
0.53
|
|
|
$
|
0.80
|
|
|
$
|
0.69
|
|
|
$
|
(1.84
|
)
|
|
(1)
|
The results of operations for EHH are included beginning December 1, 2016. Fees and expenses associated with the Merger, which includes fees incurred related to the Company's equity issuances and debt financings, was approximately
$199.0 million
during the quarter ended December 31, 2016. Approximately
$94.9 million
was capitalized as deferred financing costs,
$73.8 million
was expensed as transaction costs, and
$30.3 million
was recorded as debt extinguishment costs during the quarter ended December 31, 2016.
|
121
|
122
|
Item 9A. Controls and Procedures - (continued)
|
123
|
Item 9A. Controls and Procedures - (continued)
|
124
|
Item 9A. Controls and Procedures - (continued)
|
125
|
126
|
|
(1)
Financial Statements:
See Item 8 herein.
|
|
|
(2)
Financial Statement Schedules:
|
|
|
(All schedules are omitted because the required information is either not present, not present in material amounts or presented within the consolidated financial statements or notes thereto.)
|
|
|
(3)
Exhibits:
See the exhibit listing set forth below.
|
|
127
|
(3) Exhibits
|
Exhibit
|
Description
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
(3) Exhibits - (continued)
|
Exhibit
|
Description
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
(3) Exhibits - (continued)
|
Exhibit
|
Description
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
(3) Exhibits - (continued)
|
Exhibit
|
Description
|
|
|
|
|
|
||
|
|
|
*
|
||
|
|
|
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
(3) Exhibits - (continued)
|
Exhibit
|
Description
|
|
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
(3) Exhibits - (continued)
|
Exhibit
|
Description
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
*
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
(3) Exhibits - (continued)
|
135
|
Envision Healthcare Corporation
|
|||
Date: March 1, 2018
|
|
|
|
|
|
|
|
|
By:
|
/s/ Christopher A. Holden
|
|
|
|
Christopher A. Holden
|
|
|
|
(President and Chief Executive Officer)
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Christopher A. Holden
|
|
President, Chief Executive Officer and Director (Principal Executive Officer)
|
|
March 1, 2018
|
Christopher A. Holden
|
||||
|
|
|
|
|
/s/ Kevin D. Eastridge
|
|
Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
|
|
March 1, 2018
|
Kevin D. Eastridge
|
||||
|
|
|
|
|
/s/ William A. Sanger
|
|
Chairman and Director
|
|
March 1, 2018
|
William A. Sanger
|
|
|
|
|
|
|
|
|
|
/s/ Carol J. Burt
|
|
Director
|
|
March 1, 2018
|
Carol J. Burt
|
|
|
|
|
|
|
|
|
|
/s/ James A. Deal
|
|
Director
|
|
March 1, 2018
|
James A. Deal
|
|
|
|
|
|
|
|
|
|
/s/ John T. Gawaluck
|
|
Director
|
|
March 1, 2018
|
John T. Gawaluck
|
|
|
|
|
|
|
|
|
|
/s/ Steven I. Geringer
|
|
Director
|
|
March 1, 2018
|
Steven I. Geringer
|
|
|
|
|
|
|
|
|
|
/s/ Joey A. Jacobs
|
|
Director
|
|
March 1, 2018
|
Joey A. Jacobs
|
|
|
|
|
|
|
|
|
|
/s/ Kevin P. Lavender
|
|
Director
|
|
March 1, 2018
|
Kevin P. Lavender
|
|
|
|
|
|
|
|
|
|
/s/ Cynthia S. Miller
|
|
Director
|
|
March 1, 2018
|
Cynthia S. Miller
|
|
|
|
|
|
|
|
|
|
/s/ Leonard M. Riggs, M.D.
|
|
Director
|
|
March 1, 2018
|
Leonard M. Riggs, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ James D. Shelton
|
|
Director
|
|
March 1, 2018
|
James D. Shelton
|
|
|
|
|
|
|
|
|
|
/s/ Michael L. Smith
|
|
Director
|
|
March 1, 2018
|
Michael L. Smith
|
|
|
|
|
a.
|
For all duties rendered by Officer, the Company shall pay Officer a minimum base salary of $575,000 per year, payable in equal bi-weekly installments. In addition thereto, each year Officer's compensation will be reviewed by the Compensation Committee of the Board of Directors (the "Committee"), and after taking into consideration performance and any other factors deemed relevant, the Committee may, in its sole discretion, increase Officer's salary. Officer will be eligible to receive an annual short-term cash incentive payment on the terms and conditions approved by the
Committee.
|
b.
|
All compensation payable hereunder shall be subject to withholding for federal income taxes, FICA and all other applicable federal, state and local withholding requirements.
|
c.
|
The Company shall pay the reasonable expenses incurred by Officer in the performance of his duties under this Agreement (or shall reimburse Officer on account of such expenses paid directly by Officer) in accordance with the Company's policies and procedures. Any
|
d.
|
Officer shall be eligible to receive such equity incentive awards under the Company's equity incentive plans as may be approved from time to time by the Committee. Any such awards shall be subject to such vesting and other terms and conditions as shall be approved by the Committee.
|
a.
|
The Accrued Rights (as defined in Section 7(a) below); and
|
b.
|
Through insurance or on its own account coverage for Officer that will provide payment of Officer's full salary and benefits for six (6) months, with (i) the payment of Officer's salary to commence within thirty (30) days (with the date of such initial payment(s) determined by the Company in its sole discretion) of the Disability Payment Date (as
defined below) and (ii) such payments being paid on the same terms and with the same frequency as Officer's salary was paid prior to such incapacity or illness; provided, that upon completion of each full calendar year of employment commencing January 1, 2018, Officer shall be entitled to one additional month of his salary and benefits payable under this Section 6(b); provided, that in no event shall Officer be entitled to receive his full salary and benefits for a period in excess of twelve (12) months. For the period beyond six (6) months (or such longer period as salary and benefits are provided as described in the prior sentence), the Company shall provide such benefits to Officer as is then available to Officer in accordance with Company policy. To the extent that payments are received from Worker's Compensation or other Company paid disability plans, the Company's obligations will be reduced by amounts so received.
|
a.
|
The Company may terminate Officer's employment for Cause, without any further liability hereunder to Officer, except that Officer shall be entitled to (i) payment of all accrued but unpaid salary through the date of termination, (ii) reimbursement for all incurred but unreimbursed expenses for which Officer is entitled to reimbursement in accordance with Section
4(c),
and (iii) benefits to which the Officer is entitled as of the date of termination of employment under the terms of applicable benefit plans and programs (the "Accrued Rights").
|
b.
|
For the purposes of this Agreement, the Company shall have "Cause" to terminate Officer's employment based upon the following grounds (i) a felony conviction of Officer or the failure of Officer to contest prosecution for a felony, (i i) conviction of a crime involving moral turpitude, or (iii) willful and continued misconduct or gross negligence by Officer in the performance of his duties as an officer after written notice from the Company that reasonably identifies the manner in which the Company believes that he has committed gross negligence or willful misconduct and the failure by Officer to cure such failure with in forty-five (45) days after delivery of such notice. For purposes of this
Section 7
, "willful" shall be determined by the Board of Directors of the Company. In making such determination, the Board of Directors of the Company shall not act unreasonably or arbitrarily and no act or omission by Officer shall be deemed willful if taken by Officer in a good faith belief that such act or omission to act was in the best interests of the Company or if done at the express direction of the Board.
|
c.
|
Prior to making a determination to terminate the Officer's employment for Cause, Officer shall have the opportunity, together with his counsel, to be heard before the Board of Directors.
|
a.
|
The Accrued Rights
.
|
b.
|
Two
years
of annual base salary
as of
the date of the Officer's Separation from Service payable to the Officer on a bi-weekly basis over two calendar
years.
|
c.
|
An annual bonus under the applicable bonus program adopted by the Company with respect to its executive officers for the bonus period in which the termination of employment occurs, based upon the actual performance of the applicable bonus criteria for the year of termination, and prorated for the period of employment during the applicable bonus period.
|
d.
|
Officer shall also continue to be covered under health and life insurance plans of the Company for six (6) months; provided, that upon completion of each full calendar year of employment commencing January 1, 2018, Officer shall be entitled to one additional month of coverage under health and life insurance plans of the Company under this Section 8(c); provided, that in no event shall Officer be entitled to coverage under health
|
a.
|
Confidential
Information
. Officer agrees not to disclose, either during the time he is employed by the Company or following the termination of his employment at the Company, any confidential information concerning the Company, including, but not limited to,
strategies,
customer lists, business plans, contract terms, financial costs, sales
|
b.
|
Non-Compete
. For a period of two (2) years following the date of the termination of Officer's employment with the Company other than in the eve
nt
of a termination by the Officer for Good Reason, Officer agrees that he will not, either as an individual for his own account, as a partner or joint venturer, or as an employee, agent, officer, director, consultant, owner or otherwise, without the written consent of the Company, own, finance,
operate,
manage, design, build,
solicit prospects
for or otherwise
enter
into or
engage
in
any
phase
of
:
|
i.
|
the ambulatory surgery business;
|
ii.
|
any business, the products,
services,
or activities of which include the provision of medical services, including without limitation, the provision of anesthesia services, pain management services, emergency medicine services, gynecological and obstetrical services, primary medical care services, hospitalist services, neonatology services, women's and children's services, pediatric services, perinatology services and radiology services;
|
iii.
|
any business, the products, services, or activities of which include the provision of medical services to patients, health maintenance organizations, preferred payer organizations, third party payors, IPAs, PHOs, MSOs, PSOs (or similar arrangements), employers, labor unions, hospitals, clinics, ambulatory surgery centers, Medicare intermediaries and Medicaid intermediaries;
|
iv.
|
any home health or hospice business or activities related thereto;
|
v.
|
any business the products, services, or activities of which include the provision of administrative services for medical services, including without limitation, quality assurance services, utilization management services, billing services, recruitment services and medical management information services;
|
vi.
|
any other activity, product, services or line of business which are competitive with the activities, products, services or lines of business of the Company or any of its subsidiaries or affiliates
on the date of termination of Officer's employment with the Company; in the case of each of (i) through (vi) above in any state within the United States or in any foreign country or territory in which the Company or any of its subsidiaries, parents, or affiliates conducts business as of the date of termination of Officer's employment with the Company. For purposes of Sections 11(b)(i) through (vi) above, references to the Company shall include all subsidiaries and affiliates of the Company.
|
c.
|
No-Solicitation
.
Upon termination or expiration of his employment, whether voluntary or involuntary, Officer agrees not to directly or indirectly solicit business of the type described in Sections 11(b)(i) through (vi) above from any entity, organization or person which has contracted with the Company, which has been doing business with the Company, or from which the Officer knew or had reason to know that the Company was soliciting or going to solicit business at the time of Officer's termination, for a two-year period from the date of Officer's termination of his employment with the Company.
|
d.
|
Enforcement
. Officer and the Company acknowledge and agree that any of the
|
e.
|
Termination
. Notwithstanding any provision to the contrary otherwise contained in this Agreement, the agreements and covenants contained in this Section 11 shall not terminate upon Officer's termination of his employment with the Company or upon the termination of this Agreement under any other provision of this Agreement.
|
a.
|
"Company" shall mean Envision Healthcare Corporation, any successor entity or their successors or assigns.
|
b.
|
"Good Reason" shall exist if:
|
i.
|
there is a material diminution in the nature or the scope of Officer's authority and responsibilities;
|
ii.
|
there is a material diminution in Officer's rate of base salary or target overall compensation (for reasons other than Company performance or stock price), un less such diminution affects all similarly situated employees in a like manner;
|
iii.
|
the Company changes the principal location in which Officer is required to perform services outside a one-hundred (100) mile radius of such location without Officer's consent; or
|
iv.
|
the Company engages in any other action or inaction that constitutes a material breach
|
c.
|
"Separation from Service" shall mean the date on which the Company and Officer reasonably anticipate that no further services will be performed after such date, or that the level of bona fide services Officer will perform after such date will permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately preceding 36-month period. Whether a Separation from Service occurs shall be interpreted consistent with Section 1.409A- l (h) of the U.S. Treasury Regulations.
|
Company:
|
|
|
|
|
|
ENVISION HEALTHCARE CORPORATION
|
|
|
|
||
|
|
|
|
|
|
By:
|
/s/ Christopher A. Holden
|
|
Date:
|
|
October 1, 2017
|
Name:
|
Christopher A. Holden
|
|
|
|
|
Title:
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
Employee:
|
|
|
|
|
|
|
/s/ Kevin D. Eastridge
|
|
Date:
|
|
October 1, 2017
|
|
Kevin D. Eastridge
|
|
|
|
|
4.
|
COMPENSATION.
|
a.
|
For all duties rendered by Executive, the Company shall pay Executive a minimum salary of $400,000 per year, payable in equal semi-monthly installments
.
In addition thereto, each year, beginning January 1, 2015, Executive's compensation will be reviewed by the Board of Directors of AMSURG, or the Compensation Committee thereof, or its/their designee, and after taking into consideration performance and any other factors deemed relevant, the Committee may increase Executive's salary. Executive will be eligible to receive an annual bonus on the terms and conditions approved by the Compensation Committee of AMSURG's Board of Directors. Executive shall also be eligible to receive equity incentive awards as approved from time to time by the Compensation Committee of AMSURG's Board of Directors.
|
b.
|
All compensation payable hereunder shall be subject to withholding for federal income taxes, FICA and all other applicable federal, state and local withholding requirements.
|
c.
|
The Company shall pay the reasonable expenses incurred by Executive in the performance of his duties under this Agreement (or shall reimburse Executive on account of such expenses paid directly by Executive) in accordance with the Company's policies and procedures. Any such reimbursement of expenses shall be made by the Company promptly upon or as soon as reasonably practicable following receipt of supporting documentation reasonably satisfactory to the Company (but in any event not later than the close of Executive's taxable year following the taxable year in which the expense is incurred by Executive); provided, however, that upon Executive's termination of employment with the Company, in no event shall any additional reimbursement be made prior to the Section 409A Payment Date (as such term is defined in
Section 22
) to the extent such payment delay is required under Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the
"Code").
In no event shall any reimbursement be made to Executive for such expenses after the later of (i) the first anniversary of the date of Executive's death or (ii) December 31 of the calendar year following the year of the Executive's termination of employment with the Company (other than by reason of Executive's death).
|
d.
|
Executive shall be eligible to receive such equity incentive awards under AMSURG's equity incentive plans as may be approved from time to time by the Compensation
|
a.
|
The Accrued Rights (as defined in
Section 7(a)
below);
|
b.
|
If Executive's employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in
Section 4(a)
. if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG's or the Company's actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in
Section 4(a)
. if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive's employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in
Section 4(a)
. if any, that Executive would have been entitled to receive for the fiscal year in which the Disability Payment Date (as defined below) occurs, based upon AMSURG's or the Company's actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have
|
c.
|
elapsed through the Disability Payment Date, payable to Executive pursuant to
Section 4(a
)
had Executive's employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program; and
|
d.
|
Through insurance or on its own account coverage for Executive that will provide payment of Executive's full salary and benefits for twelve (12) months, with (i) the payment of Executive's salary to commence within thirty (30) days (with the date of such initial payment(s) determined by the Company in its sole discretion) of the Disability Payment Date (as defined below) and (ii) such payments being paid on the same terms and with the same frequency as Executive's salary was paid prior to such incapacity or illness. For the period beyond twelve (12) months, the Company shall provide such coverage to Executive as is then available to Executive in accordance with Company policy. To the extent that payments are received from Worker's Compensation or other Company paid disability plans, the Company's obligations will be reduced by amounts so received.
|
7.
|
TERMINATION FOR CAUSE.
|
a.
|
The Company may terminate Executive's employment for Cause, without any further liability hereunder to Executive, except that Executive shall be entitled to (i) payment of all accrued but unpaid salary through the date of termination, (ii) reimbursement for all incurred but unreimbursed expenses for which Executive is entitled to reimbursement in accordance with
Section 4(g)
, and (iii) benefits to which the Executive is entitled as of the date of termination of employment under the terms of applicable benefit plans and programs (the "Accrued Rights").
|
b.
|
For the purposes of this Agreement, the Company shall have "Cause" to terminate Executive's employment based upon the following grounds (i) a felony conviction of Executive or the failure of Executive to contest prosecution for a felony, (ii)
conviction of a crime involving moral turpitude, or (iii) willful and continued misconduct or gross negligence by Executive in the performance of his duties as an Executive after written notice from the Company that reasonably identifies the manner in which the Company believes that he has committed gross negligence or willful misconduct and the failure by Executive to cure such failure within forty-five (45) days after delivery of such notice. For purposes of this Section 7, "willful" shall be determined by the Board of Directors of AMSURG. In making such determination, the Board of Directors of AMSURG shall not act unreasonably or arbitrarily and no act or omission by Executive shall be deemed willful if taken by Executive in a good faith belief that such act or omission to act was in the best interests of the Company or if done at the express direction of the Board.
|
c.
|
Prior to making a determination to terminate the Executive's employment for Cause, Executive shall have the opportunity, together with his counsel, to be heard before AMSURG's Board of Directors.
|
a.
|
The Accrued Rights;
|
b.
|
a lump sum payment equal to the sum of (i) the annual base salary payable to Executive as of the date of the Executive's Separation from Service and (ii) the target bonus established by the Compensation Committee of the AMSURG Board of Directors for the Executive pursuant to the annual cash bonus plan for the year in which the Separation of Service occurs;
|
c.
|
Executive shall also continue to be covered under health and life insurance plans of the Company for twelve (12) months, or the Company shall provide the economic equivalent thereof if such continuation is not permissible under the terms of the Company's insurance plans;
|
d.
|
If Executive's employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in
Section 4(a)
, if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG's or the Company's actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in
Section 4(a)
, if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive's employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in
Section 4(a)
, if any, that Executive would have been entitled to receive for the fiscal year in which the termination of employment occurs, based upon AMSURG's or the Company's actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have elapsed through the date of termination of employment, payable to Executive pursuant to
Section 4(a)
had Executive's employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program;
|
a.
|
a lump sum payment equal to two (2) times the sum of (i) the annual base salary payable to Executive as of the date of the Executive's Separation from Service and (ii) the target bonus established by the Compensation Committee of the AMSURG Board of Directors for the Executive pursuant to the annual cash bonus plan for the year in which the Separation of Service occurs;
|
b.
|
Executive shall also continue to be covered under health and life insurance plans of the Company for eighteen (18) months, or the Company shall provide the economic equivalent thereof if such continuation is not permissible under the terms of the Company's insurance plans; and
|
c.
|
If Executive's employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in
Section 4(a),
if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG's or the Company's actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in
Section 4(a),
if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive's employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in
Section 4(a)
, if any, that Executive would have been entitled to receive for the fiscal year in which the termination of employment occurs, based upon AMSURG's or the Company's actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have elapsed through the date of termination of employment, payable to Executive pursuant to
Section 4(a)
had Executive's employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program.
|
12.
|
RESTRI
CTIV
E COV
E
NAN
T
S
.
|
(a)
|
Confidential Information.
Executive agrees not to disclose, either during the time he is employed by the Company or following the termination of his employment at the Company, any confidential information concerning the Company or AMSURG
,
including, but not limited to, customer lists, business plans, contract terms, financial costs, sales data, or business opportunities whether for existing, new or developing businesses.
|
(b)
|
Non-Compete.
For a period of one (1) year following the date of the termination of Executive's employment with the Company other than in the event of a termination by the Executive for Good Reason, Executive agrees that he will not, either as an individual for his own account, as a partner or joint venturer, or as an employee, agent, Executive, director, consultant, owner or otherwise, without the written consent of the Company, own, finance, operate, manage, design, build, solicit prospects for or otherwise enter into or engage in any phase of:
|
(i)
|
the ambulatory surgery business,
|
(ii)
|
any business the products, services, or activities of which include the provision of anesthesia services, pain management services, emergency medicine services, neonatology services, perinatology services and/or radiology services (collectively the "Medical Services"),
|
(iii)
|
any business the products, services, or activities of which include the provision of administrative services for any of the Medical Services, including without limitation, quality assurance services, utilization management services, billing services, recruitment services and medical management information services, or
|
(iv)
|
any other line of business in which the Company is engaged on the date of termination of Executive's employment with the Company (for purposes of clarification of this Section 12(b)(iv), the Company shall not be deemed to be engaged in a line of business if the Company provides the goods or services that constitute such line of business solely to business units, segments or subsidiaries of the Company or facilities owned or operated by the Company),
|
(c)
|
Non-Solicitation.
Upon termination or expiration of his employment, whether voluntary or involuntary, Executive agrees not to directly or indirectly solicit business of the type described in Sections 12(b)(i), 12(b)(ii), 12(b)(iii), and 12(b)(iv) above from any entity, organization or person which has contracted with the Company, which has been doing business with the Company, or from which the Executive knew or had reason to know that the Company was soliciting or going to solicit business at the time of Executive's termination, for a one-year period from the date of Executive's termination of his employment with the Company. For purposes of this Section 12(c), references to the Company shall include all subsidiaries and affiliates of the Company, including but not limited to AMSURG.
|
(d)
|
Enforcement.
Executive and the Company acknowledge and agree that any of the covenants contained in this
Section 12
may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude Company from other remedies which may be available to it. In case any of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any respect, including without limitation geographic scope, duration or functional coverage, any such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had been limited or modified (consistent with its general intent) to the extent necessary to make it valid, legal and enforceable, or if it shall not be possible to so limit or modify such invalid, illegal or unenforceable provision or part of a provision, this Agreement shall be construed as if such invalid, illegal or unenforceable provision or part of a provision had never been contained in this Agreement.
|
(e)
|
Termination.
Notwithstanding any provision to the contrary otherwise contained in this Agreement, the agreements and covenants contained in this
|
21.
|
DEFINITIONS.
For purposes of this Agreement the following definitions shall apply:
|
a.
|
"Change in Control" shall mean the occurrence of any of the following:
|
(i)
|
the acquisition of at least a majority of the outstanding shares of Common Stock (or securities convertible into Common Stock) of AMSURG by any person, entity or group (as used in Section 13(d)(3) and Rule 13d-5(b)(l) under the Exchange Act);
|
(ii)
|
the merger or consolidation of AMSURG with or into another corporation or other entity, or any share exchange or similar transaction involving AMSURG and another corporation or other entity, if as a result of such merger, consolidation, share exchange or other transaction, the persons who owned at least a majority of the Common Stock of AMSURG prior to the consummation of such transaction do not own at least a majority of the Common Stock of the surviving entity after the consummation of such transaction;
|
(iii)
|
the sale of all, or substantially all, of the assets of AMSURG; or
|
(iv)
|
any change in the composition of the Board of Directors of AMSURG, such that persons who at the beginning of any period of up to two years constituted at least a majority of the Board of Directors of AMSURG, or persons whose nomination was approved by such majority, cease to constitute at least a majority of the Board of Directors of AMSURG at the end of such period.
|
b.
|
Unless otherwise stated, "Company" shall mean Sheridan Healthcare, Inc., any successor entity or their successors or assigns.
|
c.
|
"Good Reason" shall exist if:
|
(i)
|
there is a material diminution in the nature or the scope of Executive's authority and responsibilities;
|
(ii)
|
there is a material diminution in Executive's rate of base salary or overall compensation (for reasons other than AMSURG or Company performance or stock price);
|
d.
|
"Separation from Service" shall mean the date on which the Company and Executive reasonably anticipate that no further services will be performed after such date, or that the level of bona fide services Executive will perform after such date will permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately preceding 36- month period. Whether a Separation from Service occurs shall be interpreted consistent with Section 1.409A-l(h) of the U.S. Treasury Regulations.
|
e.
|
"Performance Termination" shall mean the termination of Executive's employment by the Company without Cause (as defined in Section 7) following the failure of AMSURG or the Company to achieve at least 85% of the budgeted level of earnings from continuing operations before income taxes (Corporate Pre-Tax Profits) or other similar budget measure approved by the Board of Directors of AMSURG (as such measure may be adjusted by the Board during any fiscal year) and designated by the Board of Directors as the budget measure for purposes of this definition of "Performance Termination," during any two fiscal years during a consecutive three fiscal year period
.
The determination whether AMSURG or the Company has failed to achieve any such budget measure for a fiscal year shall be based upon AMSURG's audited financial statements for such fiscal year. In making a determination whether AMSURG or the Company has failed to achieve any such budget measure for a fiscal year, the Board shall consider the impact of changes in general economic conditions
,
legal or regulatory changes generally affecting the industry in which AMSURG and/or the Company operates, and adverse weather incidents or other acts of God that are not within the control of AMSURG and the Company. In the event the Board of Directors determines that AMSURG or the Company has failed to achieve such budget measure in any fiscal year, the Board will give the Executive written notice of such fact within five (5) business days following the filing of the Annual Report on Form 10-K for AMSURG for such fiscal year. In the event the Board of Directors
|
25.
|
SECTION280G LIMITATION.
|
a.
|
Notwithstanding any other provision to the contrary, if any payments or benefits Executive would receive from the Company pursuant to this Agreement or otherwise (collectively, the "
Payments
") would, either separately or in the aggregate, (i) constitute "parachute payments" within the meaning of Section 2800 of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "
Excise Tax
"), then the Payments will be equal to the Reduced Amount (defined below). The "
Reduced Amount
" will be either (1) the entire amount of the Payments, or (2) an amount equal to the largest portion of the Payments that would result in no portion of any of the Payments (after reduction) being subject to the Excise Tax, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Executive's receipt, on an after-tax basis, of the greatest amount of the Payments. If a reduction in the Payments is to be made so that the amount of the Payments equals the Reduced Amount, the Payments will be paid only to the extent permitted under the Reduced Amount alternative;
provided
, that in the event the Reduced Amount is paid, the cash payments set forth in
Section 9
shall be reduced as required by the operation of this
Section 25
.
|
b.
|
The Company shall engage the accounting firm engaged by the Company for general audit purposes at least 20 business days prior to the effective date of the Change in Control to perform any calculation necessary to determine the amount, if any, payable to Executive pursuant to
Section 9
, as limited by this
Section 25
. If the accounting firm so engaged by the Company is also serving as accountant or auditor for the individual, entity or group that will control the Company following the Change in Control, the Company may appoint a nationally recognized accounting firm other than the accounting firm engaged by the Company for general audit purposes to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
|
c.
|
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within 20 days after the date on which such accounting firm has been engaged to make such determinations or within such other time period as agreed to by the Company and Executive. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
|
d.
|
Notwithstanding the foregoing, in determining the reduction, if any, that shall occur as a result of this
Section 25
, the amounts payable or benefits to be provided to Executive shall be reduced such that the economic loss to Executive as a result of the Excise Tax elimination is minimized. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A of the Code and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero.
|
e.
|
In the event that following the payment of any Payments pursuant to
Section 9
, as reduced, if applicable, as required by the operation of
Section 25(a)-(d)
, the Internal Revenue Service (the "IRS") determines that Executive is liable for the Excise Tax as a result of the receipt of such Payments or Reduced Amount, as applicable, then Executive shall be obligated to pay back to the Company, within 30 days after final IRS determination, an amount of the Payments or Reduced Amount, as applicable, equal to the "Repayment Amount." The Repayment Amount shall be the smallest such amount, if any, as shall be required to be paid to the Company so that the Executive's net proceeds with respect to the Payments or Reduced Amount, as applicable, (after taking into account the payment of the Excise Tax imposed on such Payments or Reduced Amount, as applicable) shall be maximized. Notwithstanding the foregoing, the Repayment Amount shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on the Payments or Reduced Amount. If the Excise Tax is not eliminated pursuant to this paragraph, Executive shall pay the Excise Tax.
|
|
|
|
/s/ Patrick Solomon
|
|
|
|
Patrick Solomon
|
|
|
|
Sheridan Healthcare, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Christopher A. Holden
|
|
Name:
|
|
Christopher A. Holden
|
|
Title:
|
|
Chief Executive Officer
|
|
|
|
AmSurg Corp.
|
1.
|
EMPLOYMENT
. The Company employs Officer and Officer hereby accepts employment under the terms and conditions hereinafter set forth.
|
2.
|
DUTIES
. Officer is engaged as the Senior Vice President and General Counsel of the Company. His powers and duties in that capacity shall be those normally associated with the position of Senior Vice President and General Counsel and as determined from time to time by the Chief Executive Officer and/or the Board of Directors of the Company. During the term of this Agreement, Officer shall also serve without additional compensation in such other offices of the Company and its subsidiaries to which he may be elected or appointed by the Board of Directors.
|
3.
|
TERM
. Subject to provisions of termination as hereinafter provided, the initial term of Officer's employment under this Agreement shall terminate on December 31, 2018. On each December 31 during the term of this Agreement, commencing on December 31, 2018, unless the Company notifies Officer, pursuant to the following paragraph, that his employment under this Agreement will not be extended, his employment under this Agreement shall automatically be extended for a one (1) year period on the same terms and conditions as are set forth herein.
|
4.
|
COMPENSATION
.
|
a.
|
For all duties rendered by Officer, the Company shall pay Officer a minimum base salary of $480,000 per year, payable in equal bi-weekly installments. In addition thereto, each year, beginning in January 2019, Officer's compensation will be reviewed by the Compensation Committee of the Board of Directors (the "Committee"), and after taking into consideration performance and any other factors deemed relevant, the Committee may, in its sole discretion, increase Officer's salary. Officer will be eligible to receive an annual short-term cash incentive payment on the terms and conditions approved by the
Committee.
|
b.
|
All compensation payable hereunder shall be subject to withholding for federal income taxes, FICA and all other applicable federal, state and local withholding requirements.
|
c.
|
The Company shall pay the reasonable expenses incurred by Officer in the performance of his duties under this Agreement (or shall reimburse Officer on account of such expenses paid directly by Officer) in accordance with the Company's policies and procedures. Any such reimbursement of expenses shall be made by the Company promptly upon or as soon
|
d.
|
Officer shall be eligible to receive such equity incentive awards under the Company's equity incentive plans as may be approved from time to time by the Committee. Any such awards shall be subject to such vesting and other terms and conditions as shall be approved by the Committee.
|
5.
|
EXTENT OF SERVICE
. Officer shall devote substantially his entire time, attention and energies to the business of the Company and shall not during the term of this Agreement take an active role in any other business activity without the prior written consent of the Company; but this shall not prevent Officer from making real estate or other investments of a passive nature or devoting time to charitable and non-profit activities, and service as a director on the board(s) of directors of companies other than the Company in a manner that does not interfere with the performance of his duties to the Company; provided, however, that Officer shall not serve on the board of directors of more than one public company other than the Company and shall not serve on the board of directors of any direct competitor of the Company.
|
6.
|
DISABILITY
. In the event Officer shall become disabled as defined in Treasury Regulation 1.409(A)-3(i)(4) ("Disability"), the Company shall provide the following payments and benefits:
|
a.
|
The Accrued Rights (as defined in Section 7(a) below);
|
b.
|
If Officer’s employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive with respect to such completed fiscal year, based upon the Company’s actual results, the Company shall pay to Officer, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program adopted by the Company, the amount of such bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive with respect to such completed fiscal year had Officer’s employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive for the fiscal year in which the Disability Payment Date (as defined below) occurs, based upon the Company’s actual results for the year of termination and the percentage of the fiscal year that shall have elapsed through the Disability Payment Date, payable to Officer pursuant to
Section 4(a)
had Officer’s employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program adopted by the Company; and
|
c.
|
Through insurance or on its own account coverage for Officer that will provide payment of Officer's full salary and benefits for six (6) months, with (i) the payment of Officer's salary to commence within thirty (30) days (with the date of such initial payment(s) determined by the Company in its sole discretion) of the Disability Payment Date (as
defined below) and
|
7.
|
TERMINATION FOR CAUSE
.
|
a.
|
The Company may terminate Officer's employment for Cause, without any further liability hereunder to Officer, except that Officer shall be entitled to (i) payment of all accrued but unpaid salary through the date of termination, (ii) reimbursement for all incurred but unreimbursed expenses for which Officer is entitled to reimbursement in accordance with Section
4(c),
and (iii) benefits to which the Officer is entitled as of the date of termination of employment under the terms of applicable benefit plans and programs (the "Accrued Rights").
|
b.
|
For the purposes of this Agreement, the Company shall have "Cause" to terminate Officer's employment based upon the following grounds (i) a felony conviction of Officer or the failure of Officer to contest prosecution for a felony, (i i) conviction of a crime involving moral turpitude, or (iii) willful and continued misconduct or gross negligence by Officer in the performance of his duties as an officer after written notice from the Company that reasonably identifies the manner in which the Company believes that he has committed gross negligence or willful misconduct and the failure by Officer to cure such failure with in forty-five (45) days after delivery of such notice. For purposes of this
Section 7
, "willful" shall be determined by the Board of Directors of the Company. In making such determination, the Board of Directors of the Company shall not act unreasonably or arbitrarily and no act or omission by Officer shall be deemed willful if taken by Officer in a good faith belief that such act or omission to act was in the best interests of the Company or if done at the express direction of the Board.
|
c.
|
Prior to making a determination to terminate the Officer's employment for Cause, Officer shall have the opportunity, together with his counsel, to be heard before the Board of Directors.
|
8.
|
TERMINATION WITHOUT CAUS
E
OR FOR GOOD
R
E
ASON
.
Officer's employment under this Agreement may be terminated by the Company at any time without Cause or by the Officer for Good Reason (as defined in
Section 18)
. In the event Officer's employment under this Agreement is terminated by the Company without Cause or by the Officer for Good Reason, the Company shall pay Officer the following payments and benefits:
|
a.
|
The Accrued Rights
.
|
b.
|
Two
years
of annual base salary
as of
the date of the Officer's Separation from Service payable to the Officer on a bi-weekly basis over two calendar
years.
|
c.
|
If Officer’s employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive with respect to such completed fiscal year, based upon the Company’s actual results, the Company shall pay to Officer, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program adopted by the Company, the amount of such bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive with respect to such completed fiscal year had Officer’s employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in
Section 4(a)
, if any, that Officer would have been entitled to receive for the fiscal year in which the termination of employment occurs, based upon the Company’s actual results for the year of termination and the percentage of the fiscal year that shall have elapsed through the date of termination of employment, payable to Officer pursuant to
Section 4(a)
had Officer’s employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program adopted by the Company.
|
d.
|
Officer shall also continue to be covered under health and life insurance plans of the Company for six (6) months; provided, that upon completion of each full calendar year of employment commencing January 1, 2018, Officer shall be entitled to one additional month of coverage under health and life insurance plans of the Company under this Section 8(c); provided, that in no event shall Officer be entitled to coverage under health and life insurance plans of the Company for a period in excess of twelve (12) months, or the Company shall provide the economic equivalent thereof if such continuation is not permissible under the terms of the Company's insurance plans.
|
9.
|
TERM
I
NATION
BY
OFFICER
WITHOUT
GOOD
R
E
ASON
.
Officer may terminate his employment under this Agreement at any time other than for Good Reason (as defined in
Section 18
herein) upon the provision of sixty (60) days prior written notice to the Company. In such event, the Company shall pay Officer the Accrued Rights, and officer shall not be entitled to any other benefits under this Agreement following the date of termination of this employment with the Company. In the
event
Officer gives notice of his intent to terminate his employment other than for Good Reason, the Company may elect to waive the period of notice or
any
portion thereof and accept Officer's resignation prior to the end of the notice period.
|
10.
|
COORDINATION
WITH REL
E
ASE
.
Notwithstanding any provision herein to the contrary, the provisions of this
Section 10
shall
apply to the payment of benefits under
Section 8
(the "Severance Payments"). The Severance Payments shall be made only if Officer
shall
have executed,
on
or prior to the Release Expiration Date (as defined below), a General Release in
|
11.
|
RESTRICTIVE COVENANTS
.
|
a.
|
Confidential
Information
. Officer agrees not to disclose, either during the time he is employed by the Company or following the termination of his employment at the Company, any confidential information concerning the Company, including, but not limited to,
strategies,
customer lists, business plans, contract terms, financial costs, sales data, or business opportunities whether for existing, new or developing businesses.
|
b.
|
Non-Compete
.
Officer and the Company acknowledge that generally attorneys cannot be bound by non-compete covenants with respect to performing legal services. However, the Company and Officer acknowledge that Officer has performed, and will continue to perform, non-legal services for the Company in the course of his employment.
For a period of two (2) years following the date of the termination of Officer's employment with the Company other than in the eve
nt
of a termination by the Officer for Good Reason, with respect to performing non-legal services, Officer agrees that he will not, either as an individual for his own account, as a partner or joint venturer, or as an employee, agent, officer, director, consultant, owner or otherwise, without the written consent of the Company, own, finance,
operate,
manage, design, build,
solicit prospects
for or otherwise
enter
into or
engage
in
any
phase
of:
|
i.
|
the ambulatory surgery business;
|
ii.
|
any business, the products,
services,
or activities of which include the provision of medical services, including without limitation, the provision of anesthesia services, pain management services, emergency medicine services, gynecological and obstetrical services, primary medical care services, hospitalist services, neonatology services, women's and children's services, pediatric services, perinatology services and radiology services;
|
iii.
|
any business, the products, services, or activities of which include the provision of medical services to patients, health maintenance organizations, preferred payer
|
iv.
|
any home health or hospice business or activities related thereto;
|
v.
|
any business the products, services, or activities of which include the provision of administrative services for medical services, including without limitation, quality assurance services, utilization management services, billing services, recruitment services and medical management information services;
|
vi.
|
any other activity, product, services or line of business which are competitive with the activities, products, services or lines of business of the Company or any of its subsidiaries or affiliates
on the date of termination of Officer's employment with the Company; in the case of each of (i) through (vi) above in any state within the United States or in any foreign country or territory in which the Company or any of its subsidiaries, parents, or affiliates conducts business as of the date of termination of Officer's employment with the Company. For purposes of Sections 11(b)(i) through (vi) above, references to the Company shall include all subsidiaries and affiliates of the Company.
|
c.
|
No-Solicitation
.
Upon termination or expiration of his employment, whether voluntary or involuntary, Officer agrees not to directly or indirectly solicit business of the type described in Sections 11(b)(i) through (vi) above from any entity, organization or person which has contracted with the Company, which has been doing business with the Company, or from which the Officer knew or had reason to know that the Company was soliciting or going to solicit business at the time of Officer's termination, for a one-year period from the date of Officer's termination of his employment with the Company.
|
d.
|
Enforcement
. Officer and the Company acknowledge and agree that any of the covenants contained in this
Section 11
may be specifically enforced through injunctive relief but such right to injunctive relief shall not preclude Company from other remedies which may be available to it.
|
e.
|
Termination
. Notwithstanding any provision to the contrary otherwise contained in this Agreement, the agreements and covenants contained in this Section 11 shall not terminate upon Officer's termination of his employment with the Company or upon the termination of this Agreement under any other provision of this Agreement.
|
12.
|
BENEFITS
. In addition to the benefits specifically provided for herein, Officer shall be entitled to participate in all benefit plans maintained by the Company for employees generally according to the terms of such plans
.
|
13.
|
NOTICES
. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing, and if sent by registered or certified mail to his residence in the case of Officer, or to its principal office in the case of the Company.
|
14.
|
WAIVER OF BREACH
. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by the other party.
|
15.
|
ASSIGNMENT
. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.
|
16.
|
ENTIRE AGREEMENT
.
This
instrument contains the
entire
agreement of the parties with respect to the matters addressed herein
.
It may not be
changed
orally but
only
by an agreement in writing
signed
by the party against whom
enforcement
of any waiver change modification
,
extension or
discharge is sought.
This
Agreement
shall
be
governed
by
the
laws
of the State of Tennessee.
|
17.
|
HEADINGS
. The sections, subjects and headings in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.
|
18.
|
DEFINITIONS
. For purposes of this Agreement the following definitions shall apply:
|
a.
|
"Company" shall mean Envision Healthcare Corporation, any successor entity or their successors or assigns.
|
b.
|
"Good Reason" shall exist if:
|
i.
|
there is a material diminution in the nature or the scope of Officer's authority and responsibilities;
|
ii.
|
there is a material diminution in Officer's rate of base salary or target overall compensation (for reasons other than Company performance or stock price), un less such diminution affects all similarly situated employees in a like manner;
|
iii.
|
the Company changes the principal location in which Officer is required to perform services outside a one-hundred (100) mile radius of such location without Officer's consent; or
|
iv.
|
the Company engages in any other action or inaction that constitutes a material breach of this Agreement by the Company.
|
c.
|
"Separation from Service" shall mean the date on which the Company and Officer reasonably anticipate that no further services will be performed after such date, or that the level of bona fide services Officer will perform after such date will permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately preceding 36-month period. Whether a Separation from Service occurs shall be interpreted consistent with Section 1.409A- l (h) of the U.S. Treasury Regulations.
|
19.
|
DELAY OF PAYMENTS
.
It is intended that (l) each installment of the payments provided under this Agreement is a separate "payment" for purposes of Section 409A of the Code, and (2) that the payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code, including those provided under Treasury Regulations l.409A- l (b)(4),
|
20.
|
HEALTH BENEFITS
. The costs of the Company's portion of any post termination health or life insurance premiums due under this Agreement shall be included in the Officer's gross income to the extent the provision of such benefits is deemed to be discriminatory under Section 105(h) of the Code.
|
21.
|
D
EE
M
E
D RESIGNATION
.
In the event Officer's employment under this Agreement is terminated for any reason, unless otherwise determined by the Board of Directors of the Company, Officer shall be deemed, without any further action on the part of Officer, to have automatically resigned as a director of the Company and as an officer and director
,
if applicable, o
f
all subsidiaries of the Company.
|
Company:
|
|
|
|
|
|
ENVISION HEALTHCARE CORPORATION
|
|
|
|
||
|
|
|
|
|
|
By:
|
/s/ Christopher A. Holden
|
|
Date:
|
|
February 27, 2018
|
Name:
|
Christopher A. Holden
|
|
|
|
|
Title:
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
Employee:
|
|
|
|
|
|
|
/s/ Craig A. Wilson
|
|
Date:
|
|
February 27, 2018
|
|
Craig A. Wilson
|
|
|
|
|
Director Compensation
|
|
Board Service
|
|
Committee Chair
|
|
Committee Member
|
Annual Cash Retainer
|
|
$90,000
|
|
|
|
|
Audit Committee
|
|
|
|
$35,000
|
|
$25,000
|
Compensation Committee
|
|
|
|
$35,000
|
|
$20,000
|
Nominating Committee
|
|
|
|
$25,000
|
|
$20,000
|
Compliance & Quality Committee
|
|
|
|
$25,000
|
|
$20,000
|
Annual RSU Award
|
|
$175,000
|
|
|
|
|
STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(In millions)
|
|||||||||||||||||||
|
Year Ended December 31,
|
||||||||||||||||||
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||
Computation of Earnings:
|
|
|
|
|
|
|
|
|
|
||||||||||
Pre-tax earnings (loss) from continuing operations, excluding equity in earnings of unconsolidated affiliates
|
$
|
300.0
|
|
|
$
|
287.2
|
|
|
$
|
479.8
|
|
|
$
|
174.5
|
|
|
$
|
(53.1
|
)
|
Plus: Fixed charges
|
32.5
|
|
|
87.0
|
|
|
125.8
|
|
|
147.0
|
|
|
237.4
|
|
|||||
Plus: Amortization of capitalized interest
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
|||||
Plus: Distributed earnings from equity investees
|
3.1
|
|
|
3.6
|
|
|
6.9
|
|
|
17.5
|
|
|
23.8
|
|
|||||
Earnings
|
$
|
335.7
|
|
|
$
|
377.9
|
|
|
$
|
612.6
|
|
|
$
|
339.1
|
|
|
$
|
208.2
|
|
Fixed Charges:
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense and amortization of deferred financing costs on all indebtedness
|
$
|
29.5
|
|
|
$
|
83.3
|
|
|
$
|
121.5
|
|
|
$
|
142.4
|
|
|
$
|
231.1
|
|
Estimate of interest component of rental expenses
|
3.0
|
|
|
3.7
|
|
|
4.3
|
|
|
4.6
|
|
|
6.3
|
|
|||||
Fixed charges
|
32.5
|
|
|
87.0
|
|
|
125.8
|
|
|
147.0
|
|
|
237.4
|
|
|||||
Preferred distributions
|
—
|
|
|
7.5
|
|
|
15.1
|
|
|
15.1
|
|
|
7.5
|
|
|||||
Total combined fixed charges and preferred distributions
|
$
|
32.5
|
|
|
$
|
94.5
|
|
|
$
|
140.9
|
|
|
$
|
162.1
|
|
|
$
|
244.9
|
|
Ratio of earnings to fixed charges
|
10.3x
|
|
|
4.0x
|
|
|
4.3x
|
|
|
2.1x
|
|
|
0.9x
|
|
Subsidiary List
|
||
Wholly Owned Subsidiaries
|
|
|
|
|
|
Name of Subsidiary
|
|
State of Organization
|
AmSurg KEC, Inc.
|
|
Tennessee
|
AmSurg EC Topeka, Inc.
|
|
Tennessee
|
AmSurg EC St. Thomas, Inc.
|
|
Tennessee
|
AmSurg EC Beaumont, Inc.
|
|
Tennessee
|
AmSurg EC Santa Fe, Inc.
|
|
Tennessee
|
AmSurg EC Washington, Inc.
|
|
Tennessee
|
AmSurg Torrance, Inc.
|
|
Tennessee
|
AmSurg Abilene, Inc.
|
|
Tennessee
|
AmSurg Maryville, Inc.
|
|
Tennessee
|
AmSurg Melbourne, Inc.
|
|
Tennessee
|
AmSurg Hillmont, Inc.
|
|
Tennessee
|
AmSurg Northwest Florida, Inc.
|
|
Tennessee
|
AmSurg Palmetto, Inc.
|
|
Tennessee
|
AmSurg Ocala, Inc.
|
|
Tennessee
|
AmSurg Crystal River, Inc.
|
|
Tennessee
|
AmSurg Abilene Eye, Inc.
|
|
Tennessee
|
AmSurg El Paso, Inc.
|
|
Tennessee
|
AmSurg La Jolla, Inc.
|
|
Tennessee
|
AmSurg Burbank, Inc.
|
|
Tennessee
|
AmSurg Inglewood, Inc.
|
|
Tennessee
|
AmSurg Suncoast, Inc.
|
|
Tennessee
|
AmSurg San Antonio TX, Inc.
|
|
Tennessee
|
AmSurg Temecula CA, Inc.
|
|
Tennessee
|
AmSurg Escondido CA, Inc.
|
|
Tennessee
|
AmSurg San Luis Obispo CA, Inc.
|
|
Tennessee
|
AmSurg Scranton PA, Inc.
|
|
Tennessee
|
AmSurg Arcadia CA, Inc.
|
|
Tennessee
|
AmSurg Main Line PA, LLC
|
|
Tennessee
|
AmSurg Oakland CA, Inc.
|
|
Tennessee
|
AmSurg Lancaster PA, LLC
|
|
Tennessee
|
AmSurg Pottsville PA, LLC
|
|
Tennessee
|
AmSurg Glendora CA, Inc.
|
|
Tennessee
|
AmSurg Holdings, Inc.
|
|
Delaware
|
AmSurg Anesthesia Management Services, LLC
|
|
Tennessee
|
AmSurg, LLC
|
|
Delaware
|
AmSurg HoldCo, LLC
|
|
Delaware
|
Long Beach NSC, LLC
|
|
Tennessee
|
Torrance NSC, LLC
|
|
Tennessee
|
Davis NSC, LLC
|
|
Tennessee
|
Fullerton NSC, LLC
|
|
Tennessee
|
San Antonio NSC, LLC
|
|
Tennessee
|
Austin NSC, LLC
|
|
Tennessee
|
Subsidiary List
|
||
Twin Falls NSC, LLC
|
|
Tennessee
|
Kenwood NSC, LLC
|
|
Tennessee
|
Towson NSC, LLC
|
|
Tennessee
|
Wilton NSC, LLC
|
|
Tennessee
|
NSC West Palm, LLC
|
|
Tennessee
|
Tampa Bay NSC, LLC
|
|
Tennessee
|
Coral Springs NSC, LLC
|
|
Tennessee
|
Weston NSC, LLC
|
|
Tennessee
|
NSC RBO East, LLC
|
|
Tennessee
|
Illinois NSC, Inc.
|
|
Tennessee
|
NSC Healthcare, Inc.
|
|
Tennessee
|
AmSurg Colton CA, Inc.
|
|
Tennessee
|
AmSurg Fresno Endoscopy, Inc.
|
|
Tennessee
|
AmSurg Temecula II, Inc.
|
|
Tennessee
|
AmSurg Santa Fe Anesthesia, LLC
|
|
Tennessee
|
All Women's Healthcare, Inc.
|
|
Florida
|
All Women's Healthcare Holdings, Inc.
|
|
Delaware
|
All Women's Healthcare of Dade, Inc.
|
|
Florida
|
All Women's Healthcare of Sawgrass, Inc.
|
|
Florida
|
All Women's Healthcare of West Broward, Inc.
|
|
Florida
|
All Women's Healthcare Services, Inc.
|
|
Florida
|
AllegiantMD, Inc.
|
|
Florida
|
Anesthesiologists of Greater Orlando, Inc.
|
|
Florida
|
Anesthesiology Associates of Tallahassee, Inc.
|
|
Florida
|
Arizona Perinatal Care Centers, LLC
|
|
Arizona
|
Bethesda Anesthesia Associates, Inc.
|
|
Florida
|
Boca Anesthesia Service, Inc.
|
|
Florida
|
Broad Midwest Anesthesia, LLC
|
|
Missouri
|
Brit Systems, LLC
|
|
Delaware
|
Desert Mountain Consultants in Anesthesia, Inc.
|
|
Arizona
|
Discovery Clinical Research, Inc.
|
|
Florida
|
Drs. Ellis, Rojas, Ross & Debs, Inc. d/b/a Kendall Anesthesia Associates
|
|
Florida
|
Flamingo Anesthesia Associates, Inc.
|
|
Florida
|
Envision Anesthesia Services of Sierra Vista, Inc.
|
|
Florida
|
Envision Children's Healthcare Services of North Mississippi, Inc.
|
|
Florida
|
Envision Anesthesia Services of Delaware, Inc.
|
|
Florida
|
Envision Healthcare Center for Quality and Patient Safety, LLC
|
|
Delaware
|
Envision Physician Services, LLC
|
|
Delaware
|
Imaging Advantage, LLC
|
|
Delaware
|
iSelect Healthcare, LLC
|
|
Delaware
|
Select Healthcare, PC
|
|
Arizona
|
FM Healthcare Services, Inc.
|
|
Florida
|
FMO Healthcare Holdings, Inc.
|
|
Delaware
|
FO Investments, Inc.
|
|
Florida
|
FO Investments II, Inc.
|
|
Florida
|
FO Investments III, Inc.
|
|
Florida
|
Global Surgical Partners, Inc.
|
|
Florida
|
Greater Florida Anesthesiologists, LLC
|
|
Florida
|
Subsidiary List
|
||
Gynecologic Oncology Associates, Inc.
|
|
Florida
|
Jacksonville Beaches Anesthesia Associates, Inc.
|
|
Florida
|
Jupiter Anesthesia Associates, LLC
|
|
Florida
|
Jupiter Healthcare, LLC
|
|
Florida
|
Medi-Bill of North Florida, Inc.
|
|
Florida
|
New Generations Babee Bag, Inc.
|
|
Florida
|
North Florida Anesthesia Consultants, Inc.
|
|
Florida
|
North Florida Perinatal Associates, Inc.
|
|
Florida
|
Resolute Florida Anesthesia, Inc.
|
|
Florida
|
Parity Healthcare, Inc.
|
|
Florida
|
Partners in Medical Billing, Inc.
|
|
Florida
|
Physician Office Partners, Inc.
|
|
Kansas
|
Sheridan Anesthesia Services of Alabama, Inc.
|
|
Florida
|
Sheridan Acquisition Associates of Georgia, PC
|
|
Georgia
|
SXR Medical, LLC
|
|
Delaware
|
The Physician Quality Registry, LLC
|
|
Delaware
|
Sheridan Anesthesia Services of Louisiana, Inc.
|
|
Florida
|
Sheridan Anesthesia Services of Mississippi, Inc.
|
|
Florida
|
Sheridan Anesthesia Services of Oklahoma, Inc.
|
|
Florida
|
Sheridan Anesthesia Services of Southwest Florida, Inc.
|
|
Florida
|
Sheridan Anesthesia Services of Virginia, Inc.
|
|
Florida
|
Sheridan CADR Solutions, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of Arizona, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of Kentucky, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of Louisiana, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of New Mexico, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of Ohio, Inc.
|
|
Florida
|
Sheridan Children's Healthcare Services of Virginia, Inc.
|
|
Florida
|
Sheridan Clinical Research, Inc. n/k/a Envision Physician Clinical Research, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of Alabama, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of Mississippi, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of Missouri, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of North Missouri, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of South Florida, Inc.
|
|
Florida
|
Sheridan Healthcare, Inc.
|
|
Delaware
|
Sheridan Healthcare of Louisiana, Inc.
|
|
Florida
|
Sheridan Healthcare of Missouri, Inc.
|
|
Florida
|
Sheridan Healthcare of Vermont, Inc.
|
|
Florida
|
Sheridan Healthcare of Virginia, Inc.
|
|
Florida
|
Sheridan Healthcare of West Virginia, Inc.
|
|
West Virginia
|
Sheridan Healthcorp, Inc.
|
|
Florida
|
Sheridan Healthcorp of California, Inc.
|
|
California
|
Sheridan Healthy Hearing Services, Inc.
|
|
Florida
|
Sheridan Holdings, Inc.
|
|
Delaware
|
Sheridan Hospitalist Services of Florida, Inc.
|
|
Florida
|
Sheridan InvestCo, LLC
|
|
Delaware
|
Subsidiary List
|
||
Sheridan Leadership Academy, Inc.
|
|
Florida
|
Sheridan Radiology Services, Inc.
|
|
Delaware
|
Sheridan Scientific Intelligence, Inc. n/k/a Envision Physician Scientific Intelligence, Inc.
|
|
Florida
|
Southeast Perinatal Associates, Inc.
|
|
Florida
|
St. Lucie Anesthesia Associated, LLC
|
|
Florida
|
Tennessee Valley Neonatology, Inc.
|
|
Florida
|
The Nova Health Group, LLC
|
|
Florida
|
Tiva Healthcare, Inc.
|
|
Florida
|
All Women's Healthcare of South Broward, Inc.
|
|
Florida
|
All Women's Healthcare of Southern Florida, Inc.
|
|
Florida
|
Pinecrest Anesthesia Associates, Inc.
|
|
Florida
|
Sheridan Emergency Physician Services of Virginia, Inc.
|
|
Florida
|
Sheridan Radiology Management Services, Inc.
|
|
Delaware
|
Sheridan Radiology Services of Virginia, Inc.
|
|
Florida
|
Surgery Specialists of Broward, Inc.
|
|
Florida
|
Medical Anesthesia Consultants Medical Group, Inc.
|
|
California
|
Comprehensive Teleradiology Solutions, Inc.
|
|
Florida
|
Florida United Radiology, LLC
|
|
Florida
|
Jupiter Imaging Associates, Inc.
|
|
Florida
|
Sheridan Radiology Services of Central Florida, Inc.
|
|
Florida
|
Sheridan Radiology Services of Kentucky, Inc.
|
|
Florida
|
Sheridan Radiology Services of Pinellas, Inc.
|
|
Florida
|
Sheridan Radiology Services of South Florida, Inc.
|
|
Florida
|
Anesthesia Associates of Pinellas County Division, LLC
|
|
Florida
|
Brandon Anesthesia Associates Division, LLC
|
|
Florida
|
Clearwater Pain Management Associates Division, LLC
|
|
Florida
|
Global Surgical Partners of Sarasota, LLC
|
|
Florida
|
Gulfcoast Anesthesia Partners Division, LLC
|
|
Florida
|
LA-NJ, LLC
|
|
New Jersey
|
PA Services, LLC
|
|
New Jersey
|
SAPM, LLC
|
|
New Jersey
|
SAS-NJ, LLC
|
|
New Jersey
|
South Florida Division of GFA, LLC
|
|
Florida
|
Sunbeam Asset LLC
|
|
Delaware
|
Unicom Anesthesia Associates Division, LLC
|
|
Florida
|
Radiology Associates of Hollywood, Inc.
|
|
Florida
|
Coastal Anesthesia Consultants, LLC
|
|
Florida
|
Bay Area Anesthesia, LLC
|
|
Florida
|
Sheridan ROP Services of Alabama, Inc.
|
|
Florida
|
Sheridan ROP Services of Florida, Inc.
|
|
Florida
|
Sheridan ROP Services of Virginia, Inc.
|
|
Florida
|
Emergency Physician Solutions of North Florida, LLC
|
|
Florida
|
Anesthesia Physician Solutions of North Florida, LLC
|
|
Florida
|
Sheridan Children's Services of Alabama, Inc.
|
|
Florida
|
Sheridan Perinatal Services of Arizona, Inc.
|
|
Florida
|
Valley Anesthesiology Consultants, Inc.
|
|
Arizona
|
Valley Clinical Research, Inc.
|
|
Florida
|
Medical Information Managements Solutions, LLC
|
|
Arizona
|
Subsidiary List
|
||
Chandler Emergency Medical Group, LLC d/b/a Premier Emergency Medical Specialists
|
|
Arizona
|
NAC Properties, LLC
|
|
Georgia
|
Sentinel Healthcare Services, LLC
|
|
Georgia
|
ASDH I, LLC
|
|
Tennessee
|
ASDH II, LLC
|
|
Tennessee
|
AmSurg EC Centennial, Inc.
|
|
Tennessee
|
AmSurg Miami, Inc.
|
|
Tennessee
|
AmSurg Naples, Inc.
|
|
Tennessee
|
AmSurg Kissimmee FL, Inc.
|
|
Tennessee
|
AmSurg Altamonte Springs FL, Inc.
|
|
Tennessee
|
AmSurg New Port Richey FL, Inc.
|
|
Tennessee
|
AmSurg Finance, Inc.
|
|
Tennessee
|
Ardmore NSC, LLC
|
|
Tennessee
|
SHI II, LLC
|
|
Tennessee
|
Ambridge Revenue Management Group, LLC
|
|
Tennessee
|
MidAtlantic Endoscopy. LLC
|
|
Tennessee
|
Direct Medical Supply, LLC
|
|
Tennessee
|
Kingsport Anesthesia Associates, LLC
|
|
Tennessee
|
USC Murrietta Anesthesia Associates, LP
|
|
Tennessee
|
USC Murrieta Holding GP, LLC
|
|
Tennessee
|
Port St. Lucie Anesthesia, LLC
|
|
Tennessee
|
Springfield OR Anesthesia Associates, LLC
|
|
Tennessee
|
USC Temecula Holding GP, LLC
|
|
Tennessee
|
Kingsport Anethesia Associates, LLC
|
|
Tennessee
|
USC Temecula Anesthesia Associates, LP
|
|
Tennessee
|
La Jolla Anesthesia Associates, LP
|
|
Tennessee
|
La Jolla Holding GP, LLC
|
|
Tennessee
|
AmSurg Santa Fe Anesthesia, LLC
|
|
Tennessee
|
Montgomery Anesthesia, LLC
|
|
Tennessee
|
Austin NSC, LP
|
|
Texas
|
Doctors Billing Service, Inc.
|
|
California
|
Emergency Medical Services LP Corporation
|
|
Delaware
|
EmCare HoldCo, Inc.
|
|
Delaware
|
EmCare Holdings, Inc.
|
|
Delaware
|
EmCare, Inc.
|
|
Delaware
|
EMCA Insurance Company, Ltd.
|
|
Cayman Islands
|
EmCare of California, Inc.
|
|
California
|
EmCare Physician Providers, Inc.
|
|
Missouri
|
EmCare Physician Services, Inc.
|
|
Delaware
|
Emergency Medicine Education Systems, Inc.
|
|
Texas
|
Healthcare Administrative Services, Inc.
|
|
Delaware
|
Reimbursement Technologies, Inc.
|
|
Pennsylvania
|
American Emergency Physicians Management, Inc.
|
|
California
|
Physician Account Management, Inc.
|
|
Florida
|
Provider Account Management, Inc.
|
|
Delaware
|
EMS Management, LLC
|
|
Delaware
|
American Medical Response, Inc.
|
|
Delaware
|
Hank's Acquisition Corp.
|
|
Alabama
|
Subsidiary List
|
||
Fountain Ambulance Service, Inc.
|
|
Alabama
|
MedLife Emergency Medical Service, Inc.
|
|
Alabama
|
Affilion, Inc.
|
|
Delaware
|
AMR HoldCo, Inc.
|
|
Delaware
|
Blythe Ambulance Service
|
|
California
|
Clinical Partners Management Company, LLC
|
|
Texas
|
EmCare Anesthesia Providers, Inc.
|
|
Delaware
|
American Medical Response Northwest, Inc.
|
|
Oregon
|
American Medical Response West
|
|
California
|
Metropolitan Ambulance Service
|
|
California
|
American Medical Response of Inland Empire
|
|
California
|
Desert Valley Medical Transport, Inc.
|
|
California
|
Springs Ambulance Service, Inc.
|
|
California
|
American Medical Response of Colorado, Inc.
|
|
Delaware
|
International Life Support, Inc.
|
|
Hawaii
|
Medevac MidAmerica, Inc.
|
|
Missouri
|
Medevac Medical Response, Inc.
|
|
Missouri
|
American Medical Response of Oklahoma, Inc.
|
|
Delaware
|
American Medical Response of Texas, Inc.
|
|
Delaware
|
Kutz Ambulance Service, Inc.
|
|
Wisconsin
|
American Medical Response Holdings, Inc.
|
|
Delaware
|
American Medical Response Management, Inc.
|
|
Delaware
|
Regional Emergency Services, LP
|
|
Delaware
|
Global Medical Response of India Limited
|
|
Mauritius
|
Gold Coast Ambulance Service
|
|
California
|
Northwood Anesthesia Associates, LLC
|
|
Florida
|
River Medical Incorporated
|
|
Arizona
|
A1 Leasing, Inc.
|
|
Florida
|
Florida Emergency Partners, Inc.
|
|
Texas
|
Mobile Medic Ambulance Service, Inc.
|
|
Delaware
|
Metro Ambulance Service, Inc.
|
|
Delaware
|
Metro Ambulance Service (Rural), Inc.
|
|
Delaware
|
Medic One Ambulance Services, Inc.
|
|
Delaware
|
American Medical Response of South Carolina, Inc.
|
|
Delaware
|
American Medical Response of North Carolina, Inc.
|
|
Delaware
|
American Medical Response of Georgia, Inc.
|
|
Delaware
|
Troup County Emergency Medical Services, Inc.
|
|
Georgia
|
Randle Eastern Ambulance Service, Inc.
|
|
Florida
|
Medi Car Systems, Inc.
|
|
Florida
|
Medi Car Ambulance Service, Inc.
|
|
Florida
|
American Medical Response of Tennessee, Inc.
|
|
Delaware
|
Physicians & Surgeons Ambulance Service, Inc.
|
|
Ohio
|
American Medical Response of Illinois, Inc.
|
|
Delaware
|
Midwest Ambulance Management Company
|
|
Delaware
|
Seawall Acquisition, LLC
|
|
Delaware
|
Sun Devil Acquisition, LLC
|
|
Delaware
|
V.I.P. Professional Services, Inc.
|
|
California
|
Paramed, Inc.
|
|
Michigan
|
Subsidiary List
|
||
Mercy Ambulance of Evansville, Inc.
|
|
Indiana
|
Tidewater Ambulance Service, Inc.
|
|
Virginia
|
American Medical Response of Connecticut, Inc.
|
|
Connecticut
|
American Medical Response of Massachusetts, Inc.
|
|
Massachusetts
|
Kurtz Special Event Services, Inc.
|
|
Illinois
|
Kurtz Industrial Fire Service, Inc.
|
|
Illinois
|
Kurtz Municipal Dispatching Services, Inc.
|
|
Illinois
|
Kurtz Paramedic Service, Inc.
|
|
Illinois
|
Guardian Critical Care services, LLC
|
|
Illinois
|
Kurtz Ambulance Service, Inc.
|
|
Illinois
|
AMR Brockton, LLC
|
|
Delaware
|
American Medical Response Mid Atlantic, Inc.
|
|
Pennsylvania
|
American Medical Response Delaware Valley, LLC
|
|
Delaware
|
Ambulance Acquisition, Inc.
|
|
Delaware
|
Metro Ambulance Services, Inc.
|
|
Georgia
|
Broward Ambulance, Inc.
|
|
Delaware
|
Atlantic Ambulance Services Acquisition, Inc.
|
|
Delaware
|
Atlantic/Key West Ambulance, Inc.
|
|
Delaware
|
Atlantic/Palm Beach Ambulance, Inc.
|
|
Delaware
|
Seminole County Ambulance, Inc.
|
|
Delaware
|
LifeFleet Southeast, Inc.
|
|
Florida
|
American Medical Pathways, Inc.
|
|
Delaware
|
ProvidaCare, LLC
|
|
Texas
|
Adam Transportation Service, Inc.
|
|
New York
|
Associated Ambulance Service, Inc.
|
|
New York
|
Park Ambulance Service Inc.
|
|
New York
|
Five Counties Ambulance Service, Inc.
|
|
New York
|
Sunrise Handicap Transport Corp.
|
|
New York
|
STAT Healthcare, Inc.
|
|
Delaware
|
American Medical Response Ambulance Service, Inc.
|
|
Delaware
|
Mercy, Inc.
|
|
Nevada
|
American Investment Enterprises, Inc.
|
|
Nevada
|
LifeCare Ambulance Service, Inc.
|
|
Illinois
|
TEK Ambulance, Inc.
|
|
Illinois
|
Mercy Life Care
|
|
California
|
Hemet Valley Ambulance Service, Inc.
|
|
California
|
American Medical Response of Southern California
|
|
California
|
Medic One of Cobb, Inc.
|
|
Georgia
|
Puckett Ambulance Service, Inc.
|
|
Georgia
|
Global Medical Response, Inc.
|
|
Delaware
|
Global Emergency Medical Services Limited
|
|
Trinidad
|
V.I.P. Professional Services, Inc.
|
|
California
|
Global Medical Response of Barbados Limited
|
|
Barbados
|
EHR Management Co.
|
|
Delaware
|
Air Ambulance Specialists, Inc.
|
|
Colorado
|
Radstaffing Management Solutions, Inc.
|
|
Delaware
|
Mission Care of Missouri, LLC
|
|
Missouri
|
Access2Care, LLC
|
|
Missouri
|
Subsidiary List
|
||
Abbott Ambulance, Inc.
|
|
Missouri
|
Nevada Red Rock Holdings, Inc.
|
|
Delaware
|
Nevada Red Rock Ambulance, Inc.
|
|
Delaware
|
MedicWest Holdings, Inc.
|
|
Delaware
|
MedicWest Ambulance, Inc.
|
|
Nevada
|
Radiology Staffing Solutions, Inc.
|
|
Delaware
|
Arizona Oasis Acquisition, Inc.
|
|
Delaware
|
Templeton Readings, LLC
|
|
Maryland
|
EMS Offshore Medical Services, LLC
|
|
Delaware
|
EverRad, LLC
|
|
Florida
|
Apex Acquisition, LLC
|
|
Delaware
|
MSO Newco, LLC
|
|
Delaware
|
Pinnacle Consultants Mid Atlantic, LLC
|
|
Texas
|
Holiday Acquisition Company, Inc.
|
|
Colorado
|
BestPractices, Inc.
|
|
Virginia
|
Medics Ambulance Service, Inc.
|
|
Florida
|
Medics Subscription Services, Inc.
|
|
Florida
|
Medics Emergency Services of Palm Beach County, Inc.
|
|
Florida
|
Medics Ambulance, Inc.
|
|
Florida
|
Medics Transport Services, Inc.
|
|
Florida
|
Medics Ambulance Service (Dade), Inc.
|
|
Florida
|
Hawkeye Holdco LLC
|
|
Delaware
|
Acute Management, LLC
|
|
Texas
|
Evolution Health, LLC
|
|
Delaware
|
APH Laboratory Services, Inc.
|
|
Texas
|
EMSC ServicesCo, LLC
|
|
Delaware
|
Spotlight HoldCo, LLC
|
|
Delaware
|
Rose Radiology, LLC
|
|
Texas
|
Guardian Healthcare Group, Inc.
|
|
Delaware
|
Guardian Healthcare Holdings, Inc.
|
|
Delaware
|
Agape Healthcare Agency, LLC
|
|
Ohio
|
OHERBST, Inc.
|
|
Texas
|
TKG, Inc.
|
|
Oklahoma
|
JLM Healthcare, Inc.
|
|
Texas
|
KMAC, Inc.
|
|
Texas
|
Care Connection of Cincinnati, LLC
|
|
Ohio
|
Gem City Home Care, LLC
|
|
Ohio
|
Guardian Health Care, Inc.
|
|
Texas
|
S. Fisher and S. Thomas, Inc.
|
|
Texas
|
Guardian Ohio Newco, LLC
|
|
Ohio
|
Health Priority Home Care, Inc.
|
|
Texas
|
Velita Smith Home Health, Inc.
|
|
Texas
|
Accent Home Health Care Inc.
|
|
Indiana
|
Evolution Mobile Imaging, LLC
|
|
Delaware
|
Greater Pinellas Transportation Management Services, Inc.
|
|
Florida
|
T.M.S. Management Group, Inc.
|
|
Florida
|
Transportation Management Services of Brevard, Inc.
|
|
Florida
|
CMORx, LLC
|
|
Texas
|
Subsidiary List
|
||
Life Line Ambulance Service, Inc.
|
|
Arizona
|
Herren Enterprises, Inc.
|
|
California
|
Emergency Medical Services LP Corporation
|
|
Delaware
|
EmCare HoldCo, Inc.
|
|
Delaware
|
EmCare Holdings, Inc.
|
|
Delaware
|
EmCare, Inc.
|
|
Delaware
|
Phoenix Physicians, LLC
|
|
Florida
|
Dan River Emergency Services, LLC
|
|
Virginia
|
Emergency Services of Central Ohio, LLC
|
|
Ohio
|
Phoenix Emergency Medicine of Broward, LLC
|
|
Florida
|
Phoenix Emergency Physicians of the Midwest, LLC
|
|
Florida
|
Phoenix Emergency Physicians of the Northeast, LLC
|
|
Florida
|
Phoenix Emergency Solutions of the Southeast, LLC
|
|
Florida
|
Phoenix Emergency Services of Inverness, LLC
|
|
Florida
|
Phoenix Emergency Services of Leesburg, LLC
|
|
Florida
|
Phoenix Obstetrics/Gynecology, LLC
|
|
Florida
|
Phoenix Pediatrics of Broward, LLC
|
|
Florida
|
Evergreen Emergency Services of Allentown, Inc.
|
|
Pennsylvania
|
Arkansas River Emergency Services, LLC
|
|
Arkansas
|
Vista Staffing Solutions, Inc.
|
|
Utah
|
Whitaker Physicians Services, LLC
|
|
Texas
|
EMX LP
|
|
New Jersey
|
Alpha Physician Resources, LLC
|
|
New Jersey
|
Bravo Reimbursement Specialists, LLC
|
|
New Jersey
|
ED Solutions, LLC
|
|
New Jersey
|
EDIMS, LLC
|
|
New Jersey
|
Proven Healthcare Solutions of New Jersey, LLC
|
|
New Jersey
|
WP Rocket Holdings, Inc.
|
|
Delaware
|
Community EMS, Inc.
|
|
Massachusetts
|
Vital Enterprises, Inc.
|
|
Massachusetts
|
Marlboro Hudson Ambulance & Wheelchair Service, Inc.
|
|
Massachusetts
|
MetroCare Services-Abilene, LP
|
|
Texas
|
Arizona EMS Holdings, Inc.
|
|
Arizona
|
Beacon Transportation, Inc.
|
|
New York
|
Bowers Companies, Inc.
|
|
California
|
ComTrans Ambulance Service, Inc.
|
|
Arizona
|
Corning Ambulance Service, Inc.
|
|
New York
|
Donlock, Inc.
|
|
Pennsylvania
|
Eastern Ambulance Service, Inc.
|
|
Nebraska
|
Eastern Paramedics, Inc.
|
|
Delaware
|
Emergency Medical Transport, Inc.
|
|
Massachusetts
|
EMS Ventures of South Carolina, Inc.
|
|
South Carolina
|
E.M.S. Ventures, Inc.
|
|
Georgia
|
Gold Cross Ambulance Services, Inc.
|
|
Ohio
|
Goldcross Ambulance Service of PA, Inc.
|
|
Ohio
|
LaSalle Ambulance, Inc.
|
|
New York
|
Mainstay Solutions, LLC
|
|
Arizona
|
Medical Emergency Devices and Services (MEDS), Inc.
|
|
Arizona
|
Subsidiary List
|
||
Metro Care Corp.
|
|
Ohio
|
National Ambulance and Oxygen Service, Inc.
|
|
New York
|
North Miss. Ambulance Service, Inc.
|
|
Mississippi
|
Pacific Ambulance, Inc.
|
|
California
|
Professional Medical Transport, Inc.
|
|
Arizona
|
R/M Arizona Holdings, Inc.
|
|
Arizona
|
R/M Management Co., Inc.
|
|
Arizona
|
R/M of Tennessee, GP, Inc.
|
|
Delaware
|
R/M of Tennessee, LP, Inc.
|
|
Delaware
|
RMC Corporate Center, LLC
|
|
Arizona
|
Rural Metro (Delaware), Inc.
|
|
Delaware
|
Rural Metro Corporation
|
|
Delaware
|
Rural Metro Corporation
|
|
Arizona
|
Rural/Metro Corporation of Florida
|
|
Florida
|
Rural Metro Corporation of Tennessee
|
|
Tennessee
|
Rural/Metro Fire Dept., Inc.
|
|
Arizona
|
Rural/Metro Mid-South, LP
|
|
Delaware
|
Rural/Metro of Brewerton, Inc.
|
|
New York
|
Rural/Metro of California, Inc.
|
|
California
|
Rural/Metro of Central Alabama, Inc.
|
|
Delaware
|
Rural/Metro of Central Colorado, Inc.
|
|
Delaware
|
Rural/Metro of Central Ohio, Inc.
|
|
Delaware
|
Rural/Metro of Greater Seattle, Inc.
|
|
Washington
|
Rural/Metro of Indiana, LP
|
|
Delaware
|
Rural/Metro of New York, Inc.
|
|
Delaware
|
Rural/Metro of Northern California, Inc.
|
|
Delaware
|
Rural/Metro of Northern Ohio, Inc.
|
|
Delaware
|
Rural/Metro of Ohio, Inc.
|
|
Delaware
|
Rural/Metro of Oregon, Inc.
|
|
Delaware
|
Rural/Metro of Rochester, Inc.
|
|
New York
|
Rural/Metro of San Diego, Inc.
|
|
California
|
Rural/Metro of Southern California, Inc.
|
|
Delaware
|
Rural/Metro of Southern Ohio, Inc.
|
|
Ohio
|
Rural/Metro of Tennessee, LP
|
|
Delaware
|
Rural/Metro Operating Company, LLC
|
|
Delaware
|
San Diego Medical Services Enterprise, LLC
|
|
California
|
Sioux Falls Ambulance, Inc.
|
|
South Dakota
|
Southwest Ambulance and Rescue of Arizona, Inc.
|
|
Arizona
|
Southwest Ambulance of Casa Grande, Inc.
|
|
Arizona
|
Southwest Ambulance of New Mexico, Inc.
|
|
New Mexico
|
Southwest Ambulance of Southeastern Arizona, Inc.
|
|
Arizona
|
Southwest Ambulance of Tucson, Inc.
|
|
Arizona
|
Southwest General Services, Inc.
|
|
Arizona
|
SW General, Inc.
|
|
Arizona
|
The Aid Ambulance Company, Inc.
|
|
Delaware
|
The Aid Company, Inc.
|
|
Indiana
|
Towns Ambulance Service, Inc.
|
|
New York
|
Valley Fire Service, Inc.
|
|
Delaware
|
Subsidiary List
|
||
W&W Leasing Company, Inc.
|
|
Arizona
|
QRx Medical Management, LLC
|
|
Delaware
|
ComTrans, Inc.
|
|
Delaware
|
Grace Behavioral Health, LLC
|
|
Delaware
|
Community Auto and Fleet, LLC
|
|
Delaware
|
SSAG, LLC
|
|
Delaware
|
Westmed Ambulance Service, Inc.
|
|
California
|
|
|
|
Majority-Owned or Consolidated Joint Venture Subsidiaries
|
|
|
|
|
|
Name of Subsidiary
|
|
State of Organization
|
Kenwood ASC, LLC
|
|
Ohio
|
Baptist Surgery and Endoscopy Centers, LLC
|
|
Florida
|
Mid-Atlantic Endoscopy, LLC
|
|
Tennessee
|
Spinal Diagnostics and Treatment Centers, LLC
|
|
California
|
Northeast Endoscopy Center, LLC
|
|
Tennessee
|
Maryland Surgery Center for Women, LLC
|
|
Tennessee
|
Towson Surgical Center, LLC
|
|
Maryland
|
Affiliated Endoscopy Services of Clifton, LLC
|
|
New Jersey
|
Davis Surgery Center, LP
|
|
California
|
North Jersey Gastroenterology & Endoscopy Center, PA
|
|
New Jersey
|
Baptist Surgery and Endoscopy Centers, LLC
|
|
Florida
|
Health Network Ambulatory Alliance, LLC
|
|
Florida
|
Torrance Memorial Surgical Center, LLC II
|
|
Delaware
|
Baltimore ASC Ventures, LLC
|
|
Delaware
|
Boston Out-Patient Surgical Suites, LLC
|
|
Tennessee
|
Middlesex Endoscopy Center, LLC
|
|
Tennessee
|
Fullerton Surgical Center, LP
|
|
California
|
Coral Springs Ambulatory Surgery Center, LLC
|
|
Delaware
|
Pioneer Valley Surgicenter, LLC
|
|
Tennessee
|
Surgery Center of Allentown, LLC
|
|
Tennessee
|
Eastern Massachusetts Surgery Center, LLC
|
|
Tennessee
|
Diagnostic Endoscopy Center, LLC
|
|
Tennessee
|
The Endoscopy Center of St. Thomas, LP
|
|
Tennessee
|
The Abilene ASC, LP
|
|
Tennessee
|
The Baltimore Endoscopy ASC, LLC
|
|
Tennessee
|
Boston Endoscopy Center, LLC
|
|
Tennessee
|
WB Surgery Center, LLC
|
|
Tennessee
|
Colton CA Multi ASC, LP
|
|
Tennessee
|
North Richland Hills Endoscopy Center, LLC
|
|
Tennessee
|
Old Town Endoscopy Center, LLC
|
|
Tennessee
|
Park Ventura Endoscopy Center, LLC
|
|
Tennessee
|
Redbird Square Endoscopy Center, LLC
|
|
Tennessee
|
32nd Street Surgery Center, LLC
|
|
Tennessee
|
Red River Surgery Center, LLC
|
|
Tennessee
|
South Austin Holdings, LLP
|
|
Delaware
|
Physicians' Eye Surgery Center, LLC
|
|
Tennessee
|
San Antonio ASC, LP
|
|
Texas
|
Subsidiary List
|
||
The San Diego CA Multi-Specialty ASC, LLC
|
|
Tennessee
|
Blaine MN Multi-Specialty ASC, LLC
|
|
Tennessee
|
Central Park Endoscopy Center, LLC
|
|
Tennessee
|
North Valley Orthopedic Surgery Center, LLC
|
|
Tennessee
|
Hillmoor Eye Surgery Center, LLC
|
|
Tennessee
|
Arizona Endoscopy Center, LLC
|
|
Tennessee
|
Hudson Crossing Surgery Center, LLC
|
|
Tennessee
|
Short Hills Surgery Center, LLC
|
|
Tennessee
|
Center for Ambulatory Surgery, LLC
|
|
Tennessee
|
Poway CA Multi-Specialty ASC, LLC
|
|
Tennessee
|
Mount Dora Ophthalmology ASC, LLC
|
|
Tennessee
|
Northeast Surgical Care of Newington, LLC
|
|
Tennessee
|
The Maryville ASC, LP
|
|
Tennessee
|
The Torrance CA Multi-Specialty ASC, LLC
|
|
Tennessee
|
West Palm Outpatient Surgery & Laser Center, LTD
|
|
Florida
|
MDSINE, LLC
|
|
Tennessee
|
Long Beach Surgery Center, LP
|
|
California
|
The Endoscopy Center of Knoxville, LP
|
|
Tennessee
|
The Endoscopy Center of Topeka, LP
|
|
Tennessee
|
The Endoscopy Center of Southeast Texas, LP
|
|
Tennessee
|
The Endoscopy Center of Santa Fe, LP
|
|
Tennessee
|
The Endoscopy Center of Washington D.C., LP
|
|
Tennessee
|
Endoscopy Center of the South Bay, LP
|
|
Tennessee
|
The Melbourne ASC, LP
|
|
Tennessee
|
The Hillmont ASC, LP
|
|
Tennessee
|
The Northwest Florida ASC, LP
|
|
Tennessee
|
The Palmetto ASC, LP
|
|
Tennessee
|
The Ocala Endoscopy ASC, LP
|
|
Tennessee
|
The Crystal River Endoscopy ASC, LP
|
|
Tennessee
|
The Abilene Eye ASC, LP
|
|
Tennessee
|
The El Paso ASC, LP
|
|
Tennessee
|
The La Jolla Endoscopy Center, LP
|
|
Tennessee
|
The Burbank Ophthalmology ASC, LP
|
|
Tennessee
|
Los Angeles/Inglewood Endoscopy ASC, LP
|
|
Tennessee
|
The Suncoast Endoscopy ASC, LP
|
|
Tennessee
|
The San Antonio TX Endoscopy ASC, LP
|
|
Tennessee
|
The Temecula CA Endoscopy ASC, LP
|
|
Tennessee
|
The Escondido CA Endoscopy ASC, LP
|
|
Tennessee
|
The San Luis Obispo CA Endoscopy ASC, LP
|
|
Tennessee
|
The Scranton PA Endoscopy ASC, LP
|
|
Tennessee
|
The Arcadia CA Endoscopy ASC, LP
|
|
Tennessee
|
The Main Line PA Endoscopy ASC, LP
|
|
Tennessee
|
The Oakland CA Endoscopy ASC, LP
|
|
Tennessee
|
The Pottsville PA Endoscopy ASC, LP
|
|
Tennessee
|
Glendora CA Endoscopy ASC, LP
|
|
Tennessee
|
The Knoxville Ophthalmology ASC, LLC
|
|
Tennessee
|
Montgomery Eye Surgery Center, LLC
|
|
Tennessee
|
EyeCare Consultants Surgery Center, LLC
|
|
Tennessee
|
Subsidiary List
|
||
The Columbia ASC, LLC
|
|
Tennessee
|
The Wichita Orthopaedic ASC, LLC
|
|
Tennessee
|
The Willoughby ASC, LLC
|
|
Tennessee
|
The Westglen Endoscopy Center, LLC
|
|
Tennessee
|
The Chevy Chase ASC, LLC
|
|
Tennessee
|
The Oklahoma City ASC, LLC
|
|
Tennessee
|
The Cincinnati ASC, LLC
|
|
Tennessee
|
The Fayetteville ASC, LLC
|
|
Tennessee
|
The Independence ASC, LLC
|
|
Tennessee
|
AmSurg Northern Kentucky GI, LLC
|
|
Tennessee
|
AmSurg Louisville GI, LLC
|
|
Tennessee
|
AmSurg Kentucky Ophthalmology, LLC
|
|
Tennessee
|
The Phoenix Ophthalmology ASC, LLC
|
|
Tennessee
|
The Toledo Endoscopy ASC, LLC
|
|
Tennessee
|
The Sun City Ophthalmology ASC, LLC
|
|
Tennessee
|
The Cape Coral/Ft. Myers Endoscopy ASC, LLC
|
|
Tennessee
|
The Boca Raton Ophthalmology ASC, LLC
|
|
Tennessee
|
The Minneapolis Ophthalmology ASC, LLC
|
|
Tennessee
|
Northside Gastroenterology Endoscopy Center, LLC
|
|
Indiana
|
The Waldorf Endoscopy ASC, LLC
|
|
Tennessee
|
The Sarasota Endoscopy ASC, LLC
|
|
Tennessee
|
The Middletown Endoscopy ASC, LLC
|
|
Tennessee
|
The Dover Ophthalmology ASC, LLC
|
|
Tennessee
|
The Surgery Center of Middle Tennessee, LLC
|
|
Tennessee
|
The Kingston Ophthalmology ASC, LLC
|
|
Tennessee
|
The Las Vegas East Ophthalmology ASC, LLC
|
|
Nevada
|
The Blue Ridge/Clemson Orthopaedic ASC, LLC
|
|
Tennessee
|
The Hutchinson Ophthalmology ASC, LLC
|
|
Tennessee
|
The Bel Air Endoscopy ASC, LLC
|
|
Tennessee
|
Bloomfield Eye Surgery Center, LLC
|
|
Tennessee
|
The Newark Endoscopy ASC, LLC
|
|
Tennessee
|
The Southfield Endoscopy ASC, LLC
|
|
Tennessee
|
The Alexandria Ophthalmology ASC, LLC
|
|
Tennessee
|
The Columbia ASC Northwest, LLC
|
|
Tennessee
|
St. George Endoscopy Center, LLC
|
|
Tennessee
|
The Paducah Ophthalmology ASC, LLC
|
|
Tennessee
|
The Greenville ASC, LLC
|
|
Tennessee
|
The Columbia TN Endoscopy ASC, LLC
|
|
Tennessee
|
The Rogers AR Ophthalmology ASC, LLC
|
|
Tennessee
|
The Tulsa OK Ophthalmology ASC, LLC
|
|
Tennessee
|
The Kingsport TN Ophthalmology ASC, LLC
|
|
Tennessee
|
The Lewes DE Endoscopy ASC, LLC
|
|
Tennessee
|
The Winter Haven/Sebring FL Ophthalmology ASC, LLC
|
|
Tennessee
|
The Rockledge FL Endoscopy ASC, LLC
|
|
Tennessee
|
The Tampa FL Endoscopy ASC, LLC
|
|
Tennessee
|
The Pueblo CO Ophthalmology ASC, LLC
|
|
Tennessee
|
Western Washington Endoscopy Centers, LLC
|
|
Tennessee
|
The Lakeland FL Endoscopy ASC, LLC
|
|
Tennessee
|
Subsidiary List
|
||
The Northern NV Endoscopy ASC, LLC
|
|
Tennessee
|
The Edina MN Ophthalmology ASC, LLC
|
|
Tennessee
|
The West Palm Beach FL Endoscopy ASC, LLC
|
|
Tennessee
|
Gainesville FL Orthopaedic ASC, LLC
|
|
Tennessee
|
The Raleigh NC Endoscopy ASC, LLC
|
|
Tennessee
|
The Lake Bluff IL Endoscopy ASC, LLC
|
|
Tennessee
|
The Sun City AZ Endoscopy ASC, LLC
|
|
Tennessee
|
The Overland Park KS Endoscopy ASC, LLC
|
|
Tennessee
|
The Casper WY Endoscopy ASC, LLC
|
|
Tennessee
|
The Rockville MD Endoscopy ASC, LLC
|
|
Tennessee
|
Blue Water ASC, LLC
|
|
Michigan
|
Greenspring Station Endoscopy ASC, LLC
|
|
Maryland
|
Maryland Endoscopy Center Limited Liability Company
|
|
Maryland
|
The Scranton PA GP, LLC
|
|
Tennessee
|
The Orlando FL Endoscopy ASC, LLC
|
|
Tennessee
|
The St. Louis MO Orthopaedic ASC, LLC
|
|
Tennessee
|
The Yuma AZ Endoscopy ASC, LLC
|
|
Tennessee
|
The Greensboro NC Endoscopy ASC, LLC
|
|
Tennessee
|
The Tulsa OK Endoscopy ASC, LLC
|
|
Tennessee
|
The St. Cloud MN Ophthalmology ASC, LLC
|
|
Tennessee
|
The Salem OR Ophthalmology ASC, LLC
|
|
Tennessee
|
The El Dorado Multi-Specialty ASC, LLC
|
|
Tennessee
|
The Nashville TN Ophthalmology ASC, LLC
|
|
Tennessee
|
The Laurel MD Endoscopy ASC, LLC
|
|
Tennessee
|
The Shenandoah TX Endoscopy ASC, LLC
|
|
Tennessee
|
The New Orleans LA Uptown/West Bank Endoscopy ASC, LLC
|
|
Tennessee
|
The Metairie LA Endoscopy ASC, LLC
|
|
Tennessee
|
The Rockville, ESC-North MD Endoscopy ASC, LLC
|
|
Tennessee
|
The Silver Spring MD Endoscopy ASC, LLC
|
|
Tennessee
|
Ocean Endosurgery Center, LLC
|
|
New Jersey
|
The South Bend IN Endoscopy ASC, LLC
|
|
Tennessee
|
The Mesquite TX Endoscopy ASC, LLC
|
|
Tennessee
|
The Conroe TX Endoscopy ASC, LLC
|
|
Tennessee
|
The Kissimmee FL Endoscopy ASC, LLC
|
|
Tennessee
|
The Altamonte Springs FL Endoscopy ASC, LLC
|
|
Tennessee
|
The Glendale AZ Endoscopy ASC, LLC
|
|
Tennessee
|
The Baton Rouge LA Endoscopy ASC, LLC
|
|
Tennessee
|
The Pikesville MD Endoscopy ASC, LLC
|
|
Tennessee
|
The Glen Burnie MD Endoscopy ASC, LLC
|
|
Tennessee
|
West Bridgewater MA Endoscopy ASC, LLC
|
|
Tennessee
|
The Orlando/Mills FL Endoscopy ASC, LLC
|
|
Tennessee
|
Miami Kendall FL Endoscopy ASC, LLC
|
|
Tennessee
|
St. Clair Shores MI Ophthalmology ASC, LLC
|
|
Tennessee
|
Marin Endoscopy Center, LLC
|
|
Tennessee
|
Casa Colina Surgery Center, LLC
|
|
Tennessee
|
Digestive Health Center, LLC
|
|
Tennessee
|
Digestive Endoscopy Center, LLC
|
|
Tennessee
|
Phoenix Orthopaedic Ambulatory Center, LLC
|
|
Tennessee
|
Subsidiary List
|
||
Gastroenterology Associates Endoscopy Center, LLC
|
|
Tennessee
|
Phoenix Endoscopy, LLC
|
|
Tennessee
|
Central Texas Endoscopy Center, LLC
|
|
Tennessee
|
Eye Surgery Center, LLC
|
|
Tennessee
|
Carroll County Digestive Disease Center, LLC
|
|
Tennessee
|
Elms Endoscopy Center, LLC
|
|
Tennessee
|
TEC North, LLC
|
|
Tennessee
|
Hermitage TN Endoscopy ASC, LLC
|
|
Tennessee
|
Waco Gastroenterology Endoscopy Center, LLC
|
|
Tennessee
|
Surgery Center of Volusia, LLC
|
|
Tennessee
|
COA ASC of Franklin County, LLC
|
|
Tennessee
|
North Valley Endoscopy Center, LLC
|
|
Tennessee
|
East Valley Endoscopy, LLC
|
|
Tennessee
|
Eagle Eye Surgery and Laser Center, LLC
|
|
Tennessee
|
Nashville Gastrointestinal Specialists, LLC
|
|
Tennessee
|
Connecticut Eye Anesthesia, LLC
|
|
Tennessee
|
Mississippi Coast Endoscopy and Ambulatory Surgery Center, LLC
|
|
Mississippi
|
Ocean Springs Surgical and Endoscopy Center, LLC
|
|
Mississippi
|
Eastern Shore Endoscopy Center, LLC
|
|
Tennessee
|
Center of Morehead City, LLC
|
|
Tennessee
|
Central Massachusetts Ambulatory Endoscopy Center, LLC
|
|
Tennessee
|
Doctors Park Surgery Center, LLC
|
|
Tennessee
|
AmSurg Tampa Bay Anesthesia, LLC
|
|
Tennessee
|
AmSurg North Valley Anesthesia, LLC
|
|
Tennessee
|
AmSurg Oakland Anesthesia, LP
|
|
Tennessee
|
AmSurg St. George Anesthesia, LLC
|
|
Tennessee
|
AmSurg Arcadia Anesthesia, LP
|
|
Tennessee
|
Mid-Atlantic Endoscopy Center, LLC
|
|
Tennessee
|
Sunrise Ambulatory Surgical Center, LLC
|
|
Tennessee
|
Glen Endoscopy Center, LLC
|
|
Tennessee
|
Cascade Endoscopy Center, LLC
|
|
Tennessee
|
Oak Lawn IL Endoscopy ASC, LLC
|
|
Tennessee
|
St. Charles-AmSurg ASC Partners, LLC
|
|
Delaware
|
Fresno CA Endoscopy ASC, LP
|
|
Tennessee
|
Temecula CA United Surgery Center, LP
|
|
Tennessee
|
Eye Surgery Center of Wichita, LLC
|
|
Tennessee
|
AmSurg Fresno CA Anesthesia, LP
|
|
Tennessee
|
Bend Surgery Center, LLC
|
|
Tennessee
|
Surgery Center of Northeast Texas, LLC
|
|
Tennessee
|
Louisville Eye Anesthesia, LLC
|
|
Tennessee
|
Manatee Surgical Center, LLC
|
|
Florida
|
Easton Anesthesia Associates, LLC
|
|
Tennessee
|
Forty Fort Anesthesia Associates, LLC
|
|
Tennessee
|
MSC Anesthesia, Inc.
|
|
Florida
|
Knoxville Eye Anesthesia, LLC
|
|
Tennessee
|
Meadows Surgery Center, LLC
|
|
New Jersey
|
South Palm Ambulatory Surgery Center, LLC
|
|
Florida
|
Glendora Anesthesia Associates, LP
|
|
Tennessee
|
Subsidiary List
|
||
Jupiter Medical Specialists, LLC
|
|
Florida
|
General Surgery of Jupiter Medical Specialists, LLC
|
|
Florida
|
Radiology Services of Jupiter Medical Specialists, LLC
|
|
Florida
|
Women's Health and Wellness of Jupiter Medical Specialists, LLC
|
|
Florida
|
HCA-Sheridan Holdings, LLC d/b/a Specialty Physician Solutions
|
|
Delaware
|
HCA-EmCare, LLC
|
|
Delaware
|
Integrated Health Ventures, LLC
|
|
Delaware
|
UHS-Evolution Home Care, LLC
|
|
Delaware
|
Ascension Health at Home, LLC
|
|
Delaware
|
Anesthesia Physician Solutions of South Florida, LLC
|
|
Florida
|
Emergency Physician Solutions of South Florida, LLC
|
|
Florida
|
Radiology Physician Solutions of Florida, LLC
|
|
Florida
|
Radiology Physician Solutions of West Florida, LLC
|
|
Florida
|
Anesthesia Physician Solutions of West Florida, LLC
|
|
Florida
|
Nephrology Services of Jupiter Medical Specialists, LLC
|
|
Florida
|
Campus Surgery Center, LLC
|
|
Tennessee
|
Waverly Surgery Center, LLC
|
|
Tennessee
|
College Heights Endoscopy Center, LLC
|
|
Tennessee
|
Ocala FL Orthopaedic ASC, LLC
|
|
Tennessee
|
Surgical Center at Millburn, LLC
|
|
Tennessee
|
AmSurg San Luis Obispo Anesthesia, LLC
|
|
Tennessee
|
AmSurg Willoughby Anesthesia, LLC
|
|
Tennessee
|
AmSurg Westminster Anesthesia, LLC
|
|
Tennessee
|
AmSurg Lewes Anesthesia, LLC
|
|
Tennessee
|
AmSurg Rockledge FL Anesthesia, LLC
|
|
Tennessee
|
AmSurg Altamonte Springs Anesthesia, LLC
|
|
Tennessee
|
AmSurg Citrus Anesthesia, LLC
|
|
Tennessee
|
AmSurg Port Orange Anesthesia, LLC
|
|
Tennessee
|
AmSurg South Bay Anesthesia, LP
|
|
Tennessee
|
AmSurg Marin Anesthesia, LP
|
|
Tennessee
|
AmSurg Abilene Anesthesia, LLC
|
|
Tennessee
|
AmSurg Hermitage Anesthesia, LLC
|
|
Tennessee
|
AmSurg Oak Lawn IL Anesthesia, LLC
|
|
Tennessee
|
Anesthesia Associates of Ocala, LLC
|
|
Tennessee
|
AmSurg Melbourne Anesthesia, LLC
|
|
Tennessee
|
AmSurg MDSINE Anesthesia, LLC
|
|
Tennessee
|
AmSurg Stamford Anesthesia, LLC
|
|
Tennessee
|
AmSurg Indianapolis Anesthesia, LLC
|
|
Tennessee
|
AmSurg Cincinnati Anesthesia, LLC
|
|
Tennessee
|
Surgical Specialty Center of Northeastern Pennsylvania, LLC
|
|
Tennessee
|
Maryland Endoscopy Anesthesia, LLC
|
|
Tennessee
|
Eye Surgery Center of Western Ohio, LLC
|
|
Tennessee
|
AmSurg Springfield Anesthesia, LLC
|
|
Tennessee
|
Anesthesia Associates of Columbia TN, LLC
|
|
Tennessee
|
Anesthesia Associates of Joplin, LLC
|
|
Tennessee
|
South Portland Surgical Center, LLC
|
|
Tennessee
|
Anesthesia Associates of Bryan, LLC
|
|
Tennessee
|
River Drive Surgery Center, LLC
|
|
Tennessee
|
Subsidiary List
|
||
Connecticut Eye Surgery Center South, LLC
|
|
Tennessee
|
Eastern Connecticut Endoscopy Center, LLC
|
|
Tennessee
|
Redding Anesthesia Associates, LP
|
|
Tennessee
|
AmSurg Columbia Anesthesia, LLC
|
|
Tennessee
|
AmSurg Toledo Anesthesia, LLC
|
|
Tennessee
|
The El Paso ASC, LP
|
|
Tennessee
|
AmSurg Greenville Anesthesia, LLC
|
|
Tennessee
|
AmSurg Greensboro Anesthesia, LLC
|
|
Tennessee
|
Associated Eye Surgical Center, LLC
|
|
Tennessee
|
Orlando Mills Anesthesia Associates, LLC
|
|
Tennessee
|
Pottsville Anesthesia Associates, LLC
|
|
Tennessee
|
1.
|
I have reviewed this annual report on Form 10-K of Envision Healthcare Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
|
By:
|
/s/ Christopher A. Holden
|
|
Name:
|
Christopher A. Holden
|
|
Title:
|
President and Chief Executive Officer
|
1.
|
I have reviewed this annual report on Form 10-K of Envision Healthcare Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
|
By:
|
/s/ Kevin D. Eastridge
|
|
Name:
|
Kevin D. Eastridge
|
|
Title:
|
Executive Vice President and
|
|
|
Chief Financial Officer
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
/s/ Christopher A. Holden
|
|
|
Christopher A. Holden
|
|
|
President and Chief Executive
|
|
|
Officer of the Company
|
|
|
|
|
|
March 1, 2018
|
|
|
/s/ Kevin D. Eastridge
|
|
|
Kevin D. Eastridge
|
|
|
Executive Vice President and
|
|
|
Chief Financial Officer of the Company
|
|
|
|
|
|
March 1, 2018
|